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Introduction
This issue of the MEDICAL COLLEGE OF
VIRGINIA QUARTERLY is devoted to the publication of the proceedings of the Cardiac Arrhythmias Symposium held at the Cavalier Hotel
in Virginia Beach, Virginia from June 8-10, 1972.
The meeting was co-sponsored by the Council on
Clinical Cardiology of the American Heart Association and the Tidewater Heart Association. This was
the second cardiovascular program to be held within
a year in which Medical College of Virginia faculty
members, teamed with a guest faculty of national
recognition, provided a review of basic and clinical
aspects in the field of cardiac arrhythmias. Approximately three hundred persons, including physicians and nurses, attended the meeting which
utilized a format of formal presentations, panel discussions, and evening workshops. The first meeting,
a Cardiac Pacing Symposium, was held in Williamsburg, Virginia on April 16 and 17, 1971. The proceedings of this program were published by the
MEDICAL COLLEGE OF VIRGINIA QUARTERLY in Volume Seven, Number Four, 1971.
The reason for such emphasis upon the field
of cardiac arrhythmias is primarily due to the fact
that there has been an awakened interest in recent
years in the problem of sudden death. It is now
being appreciated that a significant number of
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deaths attributed to cardiovascular disease are due
to cardiac arrhythmias, a potentially correctable
disorder.
The success of the meeting would not have
been possible without the able support of Mr. Melvin
Shaffer and his Audio-Visual Department. I would
also like to express my appreciation to the co-directors, Dr. Eugene M. Wyso, Dr. William A. Dickinson, Jr., and Dr. Robley D. Bates, for their assistance
in the development of the program. The electrocardiographic materials were provided by cardiovascular fellows of the Cardiovascular Division of
the Department of Medicine and the coronary care
unit nursing staffs of both the Medical College of
Virginia Hospital and St. Mary's Hospital. In addition, I would like to thank the editorial staff of the
MEDICAL COLLEGE OF VIRGINIA QUARTERLY, which included Miss Mary Parke Johnson,
Mrs. Nancy Varmette, and Miss Stuart Gravatt, as
well as my own secretaries, Mrs. Barbara Hendrick
and Mrs. Marty Eagle, whose efforts will never be
forgotten.
CHARLES L. BAIRD, JR., M.D.

Director, Virginia Heart Institute
102 Berrington Street
Richmond, Virginia

Conducting Pathways of the Human Heart*
FERGUS O'M. SHIEL, M.D.
Associate Professor of Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University,
Richmond, Virginia

FABIO GUTIERREZ, M.D.
Resident in Department of Pathology, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University,
Richmond, Virginia

For over a century the cardiac beat has been
experimentally observed and analyzed. To a surprising degree the relevancy of the early researches
persists, and the views of the 19th century investigators though modified, have not been eclipsed by
time. It may, therefore, be appropriate to preface
this clinicopharmacological seminar on arrhythmias
by a brief review of the cardiac conducting pathways whose existence is generally accepted today
and to retrace the concepts which led to their discovery.
The phenomenon was already so familiar that
by 1882 the Cambridge physiologist W. H. Gaskell
(fig. 1) could neglect specific citations in his reference to the ease with which cardiac contractions
in cold blooded animals are seen to commence in
the sinus venosus and with distinct pauses, sequentially pass to the auricles and ventricles (3). From
his writings and those of several contemporaries, it is
clear that basic questions regarding cardiac conduction were not only well defined but could already be
physiologically explored against a formidable background of embryology, comparative anatomy, and
histology. The continuous tubal structure of the primitive heart permitting a wave of contracture was
well known. In contrast were the obstacles to be
circumvented when hearts evolved with interposing
rings of fibrous (fig. 3) tissue which appeared to

* Presented by Dr. Shiel at the Symposium on Cardiac
Arrhythmias, June 8, 1972, at Virginia Beach, Virginia.
MCV QUARTERLY 9(1): 7-10, 1973

separate the muscular continuity of the atria and
ventricles.
Simple notions that contractions resulted from
"direct stimulation of the blood on cardiac muscle"
had long since been abandoned. In particular, the
discovery of both cardiac nerves and the ganglionic
masses of Remak (23), Bidder (2), and Ludwig
(21) introduced the possibility of a much more
plausible neurological explanation for the transmission of cardiac impulses. It was inferred that
cardiac muscle contracted in response to a stimulus
initiated at central nervous system or peripheral
ganglionic level. Since neural connections between
atria and ventricles could be demonstrated, the apparent muscular dissociation between these chambers could be disregarded.
The attraction of a neurological mechanism in
explaining cardiac rhythm and contraction waves
was further enhanced by the earlier experiments
which purported to show that isolated portions
of heart would contract only if they contained
elements of neural ganglia. This comfortable situation was soon to be disturbed by Gaskell's instinct
to challenge the accepted. Though his meager illustrations are poor quality woodcuts and his argument sometimes diffuse, two essential advances
emerge from his research : 1) a recognition of
inherent excitability in cardiac muscle independent of
ganglia and 2) demonstration in a tortoise heart that
a bridge of muscle tissue exists between the atria
and ventricles (3).
7
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Fig. 1-Walter H. Gaskell . 1847-1914.

Fig. 2-Wilhelm His, Jr. 1863- 1934.

With the identification of the fasciculus atrioventricularis, or "Gaskell's Bridge,'' the myogenic
concept of cardiac conduction was established. It
remained to show that the structure observed in
poikilothermic animals had an analogous counterpart in mammals. This was accomplished by W. His,
Jr. (fig. 2) in 1893 (7, 8, 9), and almost simultaneously by the independently working A. F. Stanley Kent ( 16). Predictably, the ensuing years were
occupied in successful search and survey of alternate
pathways. These major systems are depicted in
the diagrams and discussed in the order of their
discovery (figs. 3, 4, 5, and 6).
Following the identification of the atrioventricular fasciculus, the attached A-V node and the bundle branches curiously remained undescribed until
the appearance of Tawara's monograph in 1906
(24). In this year also, the sinoatrial node was dis-

covered by Keith and Flack (13, 14, 15), an event
which stimulated search for internodal tracts. Three
bundles of Purkinje-like tissue associated with the
names of Wenckebach, Thorel, and Bachmann (27,
25, 1) have been described. They are represented
in figures 3, 4, and 5, and have been reidentified
by James (11) as the middle, posterior, and anterior internodal tracts.
Though the bundle of His is apparently the sole
atrioventricular muscular connection in normal
human hearts, a number of accessory pathways
have been found in fetal, infant, and pathological
hearts. They are of particular interest and significance in explaining arrhythmias associated with the
Wolff-Parkinson-White syndrome. Notably these
tracts include the connections described by Kent
( 18, 19, 20) between the_ lateral walls of the right
atrium ventricle, the paraspecific fibers of Mahaim

SHIEL AND GUTIERREZ: CONDUCTING PATHWAYS OF THE HUMAN HEART
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Fibrous ring of - - - - , ;pulmonary artery
Left fibrous trlgone

Conu1 llgam•nt
Fibrous ring of aorta
Bachmann's

Septum membranaceum

Left atrlov•ntrlcular
ring

bundle

Right atrloventrlcular
ring

.Right fibrous trlgon•

Fig. 3-The interatrio.ventricular fibrous skeleton : Note
A-V bundle penetrating right fibrous trigone.

Fig. 5-Scheme of the conducting pathways viewed from
the left atrioventricular aspect.

(22) which run from the left bundle branch to the
upper interventricular septum, and fhe accessory fibers described by James (10). The vast and fastidious labors on the conducting system have even in
modern times not deterred some investigators, notably, though not uniquely, Glomset and his associates (4, 5, 6) from denying the existence in man
of a myogenic conduction system and attempting to
reincarnate the supremacy of the neurogenic theory. Perusal of their papers will reassure the reader
that, however he receives them, their views are
not unsupported by much careful investigation.
There are indeed many reasons for the doubts and
discrepancies of various investigations. Anatomic
certainty comes only from meticulous serial sectioning, and the tedium and labor involved have perhaps tempted some conclusions whose validity has
been impaired by faulty techniques. On physiological grounds alone, the presence of conducting systems is incontrovertible, and there is abundant
anatomical data testifying not only to specialized
muscle paths but also to their intimate association
with neural elements. Whether the situation of nerve
and muscle indicates mere anatomic proximity or
bespeaks a close functional connection, is, however,

a question still unsettled. Though the long and current ascendancy of the myogenic theory reflects the
accumulated evidence in its favor, this review of
the discovery of the conducting system may bear
witness to the dangers of facile acceptance. The
myogenic theory was conceived in dissatisfaction
with the heurogenic explanation and born in the
labors of Gaskell, His, and Kent. Not all discoveries
have survived attempts at confirmation, and in particular, the existence of the lateral A-V fibers described by Kent (fig. 3) have been successively accepted, rejected, and later reinstated as present in
fetal and certain pathological hearts. Again, so far
from excluding the possible contribution of neural
elements to conduction, modern ultrastructural and
histochemical studies of the S-A and A-V nodes have
strengthened the evidence of autonomic nerves
(26) and cholinesterase activity at these sites (12).
Clearly, therefore, the identification of both neural
and muscular components in no way abates the
potential importance of either. On the contrary,
continued exploration of the neuromuscular relationships is required, and it remains the task to
solve the contribution of each before today's discordant views can harmonize.

Bachmann'S

bundle -

-1----J"/

BACHMANN

Anterior

internodal tract

""''·~--V~-

Right
bundle branch
Common

A ~

V

bundle (His )
Posterior
in ternodal tract

Moderator band
""-',~'----

Purkinje fibers

(WINDOW
CUT-OUT )

..C~,.,,,__-- SINOATRIAL

NODE

.-'----+-+- WENCKEBACH

THOR EL
'CllL__- - J --f--- ATRIOVENTRICULAR
NODE

Accessory fibers of James
Bypass fibers of Kent

Fig. 4-Scheme of the conducting pathways viewed from
the right atrioventricular aspect.

Fig. 6-Heart viewed from above showing the Wenckebach,
Thorel, and Bachmann bundles (middle, posterior, and
anterior internodal tracts of I ames).
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Neural Effects on Cardiac Rate and Rhythm*

H. PAGE MAUCK, JR., M.D.
Professor of Medicine and Professor of Pediatrics,
Medica l College of Virginia, Health Sciences Division
of Virginia Commonwealth University, Richmond, Virginia

The importance of autonomic discharge emanating from high neural regions rostral to the medulla oblongata on heart rhythm was first recognized in the classical studies by Schiff ( 5) and
Danilewsky ( 1) during the late nineteenth century.
Only in the last two decades, however, has a precise
description of these neural effects on heart rhythm
become possible. Crucial to these more recent
advances have been improvements in technology
which have permitted application of discrete electrical stimuli to various regions of the brain as well
as continuous monitoring of heart rate and arterial
pressure. These studies, reported here, represent a
portion of a broader research project carried out
in the neurophysiological laboratory of the Medical
College of Virginia for a number of years and
aimed at clarification of the role of autonomic discharge from higher neural centers on organ function (2, 4).
Briefly, the experiments were performed in
anesthetized dogs, cats, and monkeys. Steel electrodes were guided under stereotaxic control into
regions of the cortex and subcortex of the brain,
and stimulation was delivered at a constant electrical current. H eart rate and arterial pressure were
monitored continuously throughout the procedures.
In one series of experiments, stimulation of
an area of the cerebral cortex within the cingular
gyrus consistently produced severe disturbances of
h.eart rhythm consisting of sinus bradycardia,
smus and ventricular arrest and frequently atrial
flutter and fibrillation (fig. '1). Section of the vagi
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bilaterally abolished these arrhythmias. Thus, it was
clearly demonstrated that certain regions of the
brain were capable of exerting considerable control
on parasympathetic function.
In a second group of experiments, electrodes
were similarly placed more deeply into the subcortex in a region within the mesencephalic reticular
formation. Stimulation of this region evoked striking
increases in sympathetic efferent discharge which
produced all of the ventricular arrhythmias observed
in the clinical ECG. Furthermore, the arrhythmias
were always evoked in a sequence; for example,
sinus tachycardia was followed by ventricular fusion
contractions, ventricular premature contractions,
ventricular tachycardia, and rarely, ventricular fibrillation (3) . It is particularly noteworthy that
a graded incre ase in stimulus intensity was also
capable of producing this spectrum of ventricular
rhythm disturbances (fig. 2). If we sectioned the
vagus nerves bilaterally, no change occurred in
the responses observed. Administration of propranolol in small doses totally abolished all of the
effects. Although alterations in arterial pressure
occurred in many experiments, the changes were not
closely correlated with the rhythm disturbances.
Thus, stimulation of regions in the subcortex in the
first series of experiments produced marked changes
deeper within the brain than those observed in
cardiac rhythm as a result of enhanced sympathetic
discharge.
These experimental studies demonstrate that
higher regions of the brain superior to the medulla
may produce significant changes in cardiac rhythm
as a result of alterations in autonomic discharge.
Furthermore, in various regions of the brain, either
11
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Fig. 1- The effect of stimulation of the cingulat e gyms on heart rhythm.

dominantly parasympathetic or sympathetic responses are produced. It is possible through these
alterations in neural discharge to produce essen-

tially all of the arrhythmias observed by electrocardiography in the clinical setting.
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Introduction to the Phasic Effects of the Vagus on
Sinoatrial and Atrioventricular Nodes*

GORDON MOE, M.D., Ph.D.

Director of Research, Masonic Medical Research Laboratory,
Utica, New York

I want to emphasize that the vagus has effects
upon both the sinus node and the A-V node . It
slows sinus discharge, and it depresses, delays, or
blocks atrioventricular transmission . It is also known
that under certain conditions the discharge of vagal
fibers to the heart may be phasic. From the physiological standpoint, it ought to be phasic, particularly at slow heart rates. The reason it should be
phasic is that when the systolic pulse wave arrives
at the baroreceptor regions of the aorta and of the
carotid sinuses, it elicits a discharge of afferent fibers
in those regions which goes to the central nervous
system and leads to enhancement of vagal activity.
By enhancement I mean an increase in the frequency
of discharge. An increase in pressure in the pressuresensitive regions of the arterial tree leads to an increase of vagal impulses to the heart. Since the
systolic pulse rate is phasic, the changes in pressure
in these baroreceptor areas are also phasic. One
might reasonably expect that this is a closely coupled
reflex arc; the discharge from the vagus nerve fibers
would also be phasic and more or less locked to
the systolic pressure cycle.
This has been recognized for a long time,
particularly in one of the clinical situations that has
aroused the curiosity of electrocardiographers
through the years. When there is atrioventricular
block so that the atria and the ventricles respond
separately and independently, the condition known
as ventriculophasic sinus arrhythmia has been ob-
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served. That is, if the basic rate of the ventricle
following the development of A-V block is very
slow, perhaps 30 beats per minute, and if the sinus
rate is considerably faster, then it can be observed
that the sinus discharge which follows a ventricular
contraction is somewhat delayed. When the ventricle
is beating once every two seconds, it will eject a
large stroke volume with a wide pulse pressure,
and there will be a sharp rise in systolic pressure.
Thus, there will be a discrete stimulation to the
baroreceptors, a resulting reflex discharge of vagus
fibers to the heart, and a decrease in sinoatrial
frequency. There are many possible ways of explaining ventriculophasic sinus arrhythmia, but the
reflex vagal explanation makes the most sense and
almost certainly is responsible. It has not been
generally recognized that there might also be timelocked phasic changes in vagal activity to the atrioventricular conduction system; yet, this is also a
possibility. Changes in conduction time or intermittent block, as in Wenckebach periodicity, could
be reflexively induced through this baroreceptive
mechanism, but the possibility of vagal activity has
been rejected because there is often not a corresponding change in the sinoatrial cycle. In the process of another investigation, we discovered that the
time course of vagal effects upon the sinus node
and upon the A-V node are distinctly and discretely
separate. These effects occur out of phase with one
another, depending upon the heart rate. If the
baroreceptor reflex produces alterations in sinus
nodal activity which are out of phase with effects
on A-V nodal activity, then one might expect that
at one heart rate effects upon one system would
13
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predominate, and that at another heart rate effects
upon the other might predominate. This is precisely what happens. Therefore, in the analysis of
complex arrhythmias it is necessary to consider the
time intervals between the possible phasic discharge
in the vagus and the next event in the cardiac cycle.
Experimentally, the overall time from a QRS complex to the expected effect upon sinus discharge is
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approximately 600 msec; the latency for effects on
A-V transmission is approximately 400 msec.
Analysis of complex arrhythmias could very often
be made much simpler if the electrocardiograms
were recorded with a simultaneous record of arterial
pressure, so that it would be possible to time the
electrical events relative to the time and amplitude
of the systolic pulse wave.

The Critical Use of the His Bundle Electrogram*
BENJAMIN J. SCHERLAG, Ph.D.
From the Division of Cardiology, Department of Internal Medicine,
Mount Sinai Medical Center, Miami Beach, Florida, and the
Department of Medicine, University of Miami School of Medicine,
Coral Gables, Florida

The technique for electrode catheter recording
of consistent and stable His bundle activity presently
used in the clinical laboratory was initially developed
as an investigational tool ( 10, 11). In the clinical
laboratory, the His bundle electrogram, in conjunction with the surface electrocardiogram-a technique
that h.as been termed His bundle-electrocardiography
by Castellanos ( :2 )-has provided a more accurate
means of localizing the site of conduction abnormality in patients with various forms of heart block. In
addition, this technique has been utilized to study
various physiological and pharmacological interventions (6, 12), arrhythmias (7), and the Wolff-Parkinson-White syndrome (3, 4).
Unfortunately, published reports have contained a variety of terms applied to the various
intervals representing conduction through the atrioventricular transmission system. Moreover, the
procedures for quantitating critical conduction measurements made with the use of His bundle-electrocardiography have relied heavily upon the shape of
a recorded deflection during the P-R segment and
its temporal relationships to atrial or ventricular
activity. In view of the numerous reports using His
bun~le recordings that are presentiy appearing in
the literature, a critical evaluation of the His bundle
electrogram and some of its applications seems
appropriate.
Figure 1 shows an anterior-posterior view of
the heart and the position of an electrode catheter
during the recording of His bundle electrograms.
. *Presented by Dr. Scherlag at the Symposium on Cardiac Arrhythmias, June 8, 1972, at Virginia Beach, Virginia.
~!ea~e send requests for reprints to: Dr. B. Scherlag, Mount
. 1na1 Medical Center, 4300 Alton Road, Miami Beach, Florida 33140.
Mc v QUARTERLY 9 (1): 15-2 1. 1973

In general, the His bundle electrogram is recorded
by the use of a standard bipolar pacing catheter
with ring electrodes 5 mm or 10 mm apart. The
catheter is introduced from the femoral vein into
the right heart and stabilized at the A-V ring at
the base of the posterior tricuspid leaflet.
In figure 2A, electrograms from the high right
atrium and from the His bundle area are shown with
simultaneously recorded ECG leads. As opposed
to standard electrocardiographic recordings which
are usually made with relatively wide frequency
response settings, that is, 0.1 to 200 Hz, the His
bundle electrogram is commonly recorded with narrower band width limits to accentuate rapid deflections and attenuate slower waves, that is, 40 to
200 or 40 to 500 Hz. For this illustration, another
bipolar catheter in the right atrium near the sinus
node recorded atrial activity at the onset of the P
Wave. The His bundle electrogram, in conjunction
with the three standard ECG leads, allows a division
of the P-R interval into three components. The
first is the P-A interval. This is the time from the
earliest onset of the P wave (atrial activation in the
area of the sinus node), as seen in any of the surface
electrocardiograms, to the onset of atrial activity
in the area of the A-V junction, as seen in the His
bundle electrogram. This interval is taken as a measure of a representative portion of intra-atrial conduction, specifically the conduction time from the
area of the sinus node to the area of the A-V node
during normal sinus rhythm.
The A-H interval is the time from the beginning of the A wave to the onset of His bundie activity. This interval is taken as a measure of A-V nodal
conduction. In our initial study, the term P-H interval was used as a measure of A-V nodal con15
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tion time (P-A = 35 msec); A-V nodal conduction time (A-H = 53 msec); and His-Purkinje system conduction time (H-V = 32 msec).
B. Pacing at a faster rate than the sinus rate, from the recording electrodes (stimulus, Hb), produces an unchanged QRS complex in
all leads with a pacer impulse (Pl) to R wave interval (PT-R) of 31 msec, directly comparable to the previously measured H-V time,
32 msec (panel A). Pacing the His bundle from the aortic root allowed retrograde activation of the atrium (PI-SA = 132 msec). The
interval between time lines equals I second. (Reproduced by permission of The American Heart Association, Inc., from B. J. Scherlag,
et al., "His Bundle Electrogram," Circulation 46:602, 1972.)

atrial activity in the immediate vicinity of the A-V
node and therefore, eliminates the intra-atrial conduction between the sinus node and the low right
atrium. In addition, the A-H interval allows a comparison of A-V nodal conduction during both sinus

duction. Unfortunately, this term has persisted
although we now use the term A-H interval since
it represents a more accur(!te measure of transmission through the A-V node. Ordinarily, the A
wave of the His bundle electrogram represents local
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F ig. 2- The ef1ect of atrial pacing on intra-atrial (P-A or Pl-A), A-V nodal (A-H), and His-Purkinje (H-V) intervals in the dog.
A. During sinus rhythm at a heart rate of 94 beats per minute, the P-A, A-H, and H-V time measured from the His bundle electrogram (Hb) and the simultaneously recorded ECG leads I, AVR, and A VF, are 10, 50, and 30 msec respectively. Band C. Atrial pacing
up to a rate of 201 beats per minute produces a progressive increase in the A-H interval to 95 msec while the H-V interval remains
constant at 30 msec. The pacer impulse to atrial activity (PI-A) is essentially the same at 23 to 25 msec during atrial pacing. D. At a
heart rate of 208 beats per minute, a 5:4 Wenckebach cycle is seen with A-H variation from 75 to 150 msec. Pl-A and H-V remain
the same at 24 and 50 msec, respectively. Note that in the blocked beat the H and V deflections do not appear after the stimulus
and atrial activity.
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Fig. 3- Case W.A. Twelve standard ECG leads (top) show first degree block with right bundle branch block and left axis deviation.
A. Simultaneous recordings of bipolar electrogram (BE) from the area of the A-V junction and stand~rd ECG leads L-1, L-2, and
AVF, during normal sinus rhythm. The A-H time varies between 150 and 175 msec, with variations in P-P interval. The H-V time
of 95 msec remained constant. B. Simultaneous recordings of bipolar electrogram (BE) from the right atrium (RA) with standard
ECG leads L-1, L-2, and AVF, during BH pacing at a rate of 100 per minute (Pl-PI = 600 msec). Pl-R interval of 95 msec is the
same as the H-V time during normal sinus rhythm and the shape of the QRS complex remained unaltered throughout. (Reproduced
by permission of The American Heart Association, Inc. from 0. S. Narula, ef al. "Pervenous Pacing of the Specialized Cori.ducting
System in Man: His Bundle and A-V Nodal Stimulatioµ." Circulation 41 :77, 1970.)

rhythm and atrial pacing because the atrial deflection
used in the measurement is not ordinarily altered
by the pacing site (fig. 3). This is in contrast to
the P-H measurement which cannot be accurately

compared during spontaneous rhythm and atrial
pacing since the pacer impulse is not usually applied
in the area of the sinus node (compare figs. 3A and
2B,C,D).
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The H-V interval is the time required for the
impulse to traverse the His-Purkinje system, that
is, from the onset of His bundle activity to the
earliest onset of regular ventricular muscle activity
as seen on any of the ECG leads or the His bundle
electrogram. The term H-Q interval has been used
to describe the conduction time through the HisPurkinje system in several reports. We prefer the
term H-V on the basis of the fact that a Q wave
may not be present in the ventricular deflection
utilized for the measurement. In addition, we have
stressed the use of at least three standard ECG
leads to accurately determine the time of earliest
ventricular activation. The use of only one ECG
lead allows the possibility that the onset of ventricular activation is isoelectric in that lead. This
would indicate an H-V measurement which is
falsely prolonged.
Since the precise anatomic location of the recording electrodes on a catheter cannot be ascertained by fluoroscopy, a recorded deflection within
the P-R segment must be verified as truly representing His bundle activity. Several criteria must be met
to validate the recording as emanating from the
His bundle and not from the atrium, A-V node, or
the proximal bundle branches. The independence of
a presumed His bundle deflection from atrial activity
can be most easily obtained by right atrial pacing
or induced premature atrial beats. This procedure
uniformly produces a prolongation of the interval
from atrial activity to the His bundle deflection (fig.
3). At rapid atrial paced rates, Wenckebach cycles
can be elicited with progressive prolongation of the
A-H interval and dropped beats indicating block
proximal to the site of the recorded His bundle
deflection.
Perhaps the most direct means of demonstrating the specificity of the His bundle deflection is
the use of stimulation from the recording electrode
catheter. In our clinical laboratories, standard safeguard procedures routinely utilized during temporary transvenous ventricular pacing are employed
during His bundle pacing. Under these circumstances, we have found His bundle pacing no more
difficult or hazardous than pacing in any other
portion of the right or left ventricle. Pacing of the
His bundle produces capture of the ventricles with
the same QRS morphology in all ECG leads as that
seen during sinus rhythm or atrial pacing (fig. 2B).
This indicates that the point of stimulation was
proximal to the right or left bundle branch and must
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therefore be located in the His bundle or A-V
node. Note also that the interval from the pacer
impulse to the onset of ventricular activity is the
same as the interval from the recorded His bundle
potential to ventricular activation during sinus
rhythm or paced atrial rhythm . If this interval is
constant over a wide range of heart rates, a pacing
site in the A-V node can be eliminated since conduction velocity in any part of the A-V node decreases with increasing rate . On the other hand,
conduction in the His-Purkinje system is virtually
unaffected by heart rate . We have found that these
criteria for validating the His bundle potential by
His hundle pacing apply equally as well in patients
with normal A-V conduction as in those patients
exhibiting severe disease of the His-Purkinje system (9) .
Figure 4 shows tracings from a patient exhibiting right bundle branch block with left axis deviation, and an H-V time which was markedly prolonged, 95 msec. An abnormal QRS complex was
simultaneously recorded in leads I, II, and A VF.
His bundle pacing reproduced the H-V time of
95 msec as well as the same QRS configuration
seen in all three ECG leads during sinus rhythm.
In figure 5, this same patient showed alternating bilateral bundle branch block during the
study, but there were periods of left bundle branch
block again with the characteristic QRS complex
in all three leads, and now an H-V time of 90 msec.
Pacing from the His bundle at this time reproduced
the same QRS configuration and duration in all
three leads as seen during sinus rhythm . Note also
that the time from the stimulus to the onset of the
earliest ventricular activity is the same with this
bundle branch block pattern as the measured H-V
time seen during sinus rhythm .
At this point, the matter of normal and abnormal H-V time should be mentioned. Normal
values for A-V conduction have been battered
about somewhat in the recent literature; therefore,
we have scrutinized three published studies in which
recordings from the His bundle have been obtained
from 51 adult patients with so-called normal A-V
conduction, that is, a P-R interval of 200 msec or
less. Table I is a statistical analysis of the values
from these various studies. It can be seen that the
values in the study by N arula et al. ( 8) as well as
from the study of Bekheit et al. ( 1) from Great
Britain are closely comparable. In addition, if one
assumes an average P-A time of 40 msec, the data
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Fig. 4- Case W.A. Twelve standard ECG leads (top) from the same patient as in figure 3, whose pattern changed during study from
right bundle branch block to left bundle branch block. A. Simultaneous bipolar eleetrograms (BE) recorded from the area of the
A-V junction and standard ECG leads L-1 , L-2, and AVF. The A-H time at P-P interval of 850 msec was 180 msec. The induced
(Pl) premature atrial systole (A) at P-P interval of 640 msec either blocked and was followed by an A-V junctional escape beat or
conducted with an extremely prolonged A-H time. The H-V time of 90 msec was constant throughout. B. Bundle of His pacing at a
rate of 100 per minute (PI-PI = 600 msec). The Pl-R interval of 90 msec is equal to the H-V time during normal sinus rhythm. The
shape of the QRS complex remains unaltered throughout. (Reproduced by permission. of The American Heart Association, Inc.
from 0. S. Narula, et al. "Pervenous Pacing of the Specialized Conducting System in Man : His Bundle and A-V Nodal Stimulation."
Circulation 41 :77, 1970.)

for heart rate P-R, P-A, A-H intervals in all three
studies show good agreement. The lower and upper
limits for the H-V interval, that is ± 2 standard
deviations, in the last two studies are also in close
accord, giving a range of 33 to 49 msec and 27
to 4 7 msec, respectively. In the study by Damato

et al. (5), the H-V intervals averaged 51 ± 12 with
a range of 39 to 63 msec. Other laboratories have
reported normal values of 35 to 55 msec, and in a
more recent report, Damato and his group have indicated an average value of 45 msec for the normal
H-V time in patients. Unfortunately, no tabulated
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"Normal" Values of A-V Conduction Intervals in Man
(mean and standard deviation)
CONDUCTION TIME (msec)

BASAL HR
(beats / min)

P-R

P-A

A-H

H-V

Narula et al. (8)

67 ± 10

172 ± 11

43 ± 14

88 ± 21

41 ± 4

Damato et al. (5)

71 ± 8

167 ± 16

Bekheit et al. (I)

64 ± 15

154 ± 19

REFERENCE

116 ± 14*

37 ± 11

51 ± 6
78 ± 18

37 ± 5

Basal HR = normal sinus rate; P-R = intra-atrial, A-V nodal and
His-Purkinje conduction time; P-A, A-H, H-V. See text for discussion.

* This value represents the

P-H interval consisting of P-A

+ A-H. See text for discussion.

(Reproduced by permission of The American Heart Association, Inc. from B. J. Scherlag, et al., "His Bundle Electrogram," Circula-

tion 46 :606, 1972.)

data have been published to substantiate these ranges
and average values. It should be emphasized that
the determination of normal limits is of more than
academic interest. Basic studies as well as recent
clinical reports indicate a close association between
prolongation of the H-V time and the existence of
partial or complete bilateral bundle branch block.
Other reports have shown a correspondence between
an abbreviated A-H or H-V interval and anomalous
A-V conduction.
It is generally considered that His bundle-electrocardiography has provided a more direct means
for electrophysiological and diagnostic study of
various clinical problems. However, these interpretations and diagnoses based on His bundle recordings must stand up to critical quantitative verification
of the presumed His bundle deflection. Quantitative
determinations of the interpretations based on His
bundle-electrocardiographic measurements are critical, and in order to facilitate such determinations,
greater standardization of measurements and terminology is required.

Author's note: We thank Mrs. Marie Ellis for
her dedicated assistance in the preparation of this
manuscript.
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Electrophysiology of Concealed Conduction*
E. NEIL MOORE, D.V.M., Ph.D., F.A.C.C.
Professor of Physiology, the School of Veterinary Medicine, University
of Pennsylvania, and Professor of Physiology in Medicine,
Department of Medicine, Hospital of the University of Pennsylvania,
Philadelphia, Pennsylvania

The phenomenon of cardiac excitation penetrating conducting tissue but failing to traverse it
completely was called "concealed conduction" by
Langendorf in 1948 ( 1). Earlier electrocardiographers had cl early demonstrated its occurrence.
Since the introduction of this term in 1948, the concept of concealed atrioventricular (A-V) conduction has been invoked to explain many complex
arrhythmias and has found wide application in
clinical electrocardiography. In the clinical electrocardiogram, penetration of impulses that do not
emerge from the A-V conduction system (concealed
conduction) can be inferred from their influence
on subsequent events such as 1) delay of conduction of a succeeding propagated response, 2) block
of a succeeding atrial impulse which occurs at a
time when the transmission system should have
been excitable, 3) delay of the expected discharge
of a junctional pacemaker, or 4) in some cases,
facilitation or acceleration of a succeeding impulse.
In many early experimental, and most clinical
investigations, the A-V node was thought to be the
location in which antegrade as well as retrograde
incomplete penetration of an impulse resulted in
an effect on subsequent events. This was largely
based upon the fact that the ECG only permits
analysis of atrial and ventricular activity; electrocardiographers, therefore, considered the A-V node
as the location where the atrial input was modulated
to produce the resultant ventricular response pattern. Further refinements in microelectrode tech-

* These studies were supported in part by grants from
the American Heart Association (71-787) and USPHS
(HE-04885-13). Presented by Dr. Moore at the Symposium
on Cardiac Arrhythmias, June 8, 1972, at Virginia Beach,
Virginia.
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niqu es have allowed more precise localization of
the area of concealed conduction as well as some
insight into the mechanisms by which a nonpropagated impulse can block, delay, or accelerate subsequent conduction within the A-V node or HisPurkinje conduction systems, or both.
Several figures are presented here to demonstrate the different mechanisms of concealed conduction in which microelectrodes were used to
record from the A-V node and His-Purkinje system
together with simultaneously recorded atrial and
ventricular electrograms. Of course, in a standard
ECG, one would not be able to determine what
was occurring within the specialized A-V conduction system, since only the information provided by
the atrial and ventricular electrograms (P wave
and QRS complex) would be available for interpretation.
Delays and block of antegrade conduction by
premature beats are the most common examples of
concealed conduction in man. The first illustration,
recorded in an isolated rabbit atrioventricular preparation, shows an example of a premature ventricular contraction (PVC) causing complete A-V block
of the subsequent sinus beat. This is due to the
PVC partially penetrating the A-V conduction system. In figure 1, the upper trace is an electrogram
recorded from the right atrium (RA), and the
lower trace (RV) is an electrogram recorded from
the right ventricular muscle. Simultaneously, transmembrane action potentials were recorded from a
single A-V nodal fiber (AVN, second trace) and
a single right bundle branch fiber (RBB, third
trace). Time dots denote 100 msec intervals. The
first atrial response was propagated from the atrium,
through the A-V node, bundle of His (not recorded
from), right bundle branch fibers and then to the
MCV QUARTERLY 9(1): 22-25, 1973
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Fig. 1-A concealed ventricular premature response causing
block of a normally conducted atrial activation. Bipolar
electrograms were recorded in the isolated rabbit heart
from the right atrium (RA) and right ventricles (RV),
together with transmembrane potentials from the A-V node
(AYN) and right bundle branch (RBB). The timing pulses
(T) denote 100 msec. At the arrow, the preparation was
prematurely activated by electrical stimulation through
electrodes placed over the region of the right bundle branch.
The third sinus response was blocked as a result of the
premature ventricular response prematurely invading the
A-V node. (Reproduced, with modifications, by permission
of the American Journal of Cardiology, 28:409, 1971.)

ventricular myocardium. Following the first two
normally conducted atrial beats, a premature ventricular contraction develops (third ventricular electrogram in the RV tracing). Retrograde conduction
of this PVC is blocked as clearly shown by the
failure of the third atrial response resulting in a
ventricular response at the expected time. In this
instance, the PVC was conducted retrograde and
excited the A-V nodal fiber earlier than conduction
from the atrium would have been expected to excite
the impaled A-V nodal fiber. Note that the time
between the third atrial to A-V nodal response is
clearly shorter than either the normally conducted
first or second beats.
Another important and commonly observed
clinical example of the role that atrial rate plays
in determining the occurrence and frequency of concealment is the fact that the ventricular response
is more rapid during atrial flutter than during atrial
fibrillation. In figure 2, extracel~ular atrial (RA)
and ventricular electrograms (RV) were recorded
simultaneously with transmembrane action potentials
from a bundle of His fiber (BH) and right bundle
branch fiber (RBB) in an isolated rabbit atrioventricular preparation during atrial flutter (fig. 2A)
and during atrial fibrillation (fig. 2B). During atrial
flutter, every other atrial response is blocked within
the A-V node, as demonstrated by the absence of
all-or-none bundle of His, right bundle branch, and

R:~:~~~~~
RV~-~-'---~~~~~___,r~~~~~-~~

T

--------~-----------------------------------------~----- -

Fig. 2-Atrioventricular conduction during atrial flutter
and fibrillation in the isolated rabbit heart . Bipolar electrograms were recorded from the right atrium (RA) and right
ventrjcle (RV) together with transmembrane potentials
from the bundle of His ( BH) and right bundle branch
(RBB). The timing pulses (T) denote 100 msec. A : the
isolated atrioventricular preparation is driven from the
atria at a cycle length of 300 msec. B: the atria are stimulated rapidly to simulate atrial fibrillation . (Reproduced, with
modifications, by permission of the American Journal of
Cardiology, 28 :408, 1971.)

ventricular responses. During atrial fibrillation provoked by very rapid electrical stimulation of the
atria, the ventricular response interval in the RV
electrogram is slower and more irregular than during
atrial flutter. During the Jong interval between the
second and third ventricular responses (RV-RV),
5 atrial responses occur in the atrial electrogram
which are not conducted to the bundle of His and
the right bundle branch. All of the ventricular responses are delayed to various degrees within the
A-V node. The degree of consecutive concealment
governs the irregularity of the ventricular rate during
atrial fibrillation.
Occasionally during atrial fibrillation, aberrant
QRS complexes are recorded. This has been thought
to result in some instances from escape of subsidiary
pacemaker. However, we have observed that aberrant QRS complexes may result from block or
concealed conduction within the right bundle branch.
Similar findings have been reported in man during
His bundle recordings. We believe, therefore, that
variation in degree of concealed conduction within
the A-V node is the most common cause of the irregular, slow R-R periods observed during atrial
fibrillation .
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A third manifestation of concealed conduction
is that a partially conducted impulse may not only
affect subsequent conduction, but may also disturb
impulse formation in a subsidiary pacemaker. In
figure 3, a subsidiary pacemaker was present either
in the lower A-V node or bundle of His fiber (BH,
second trace) . Pacemaker activity, also referred to
as diastolic depolarization or phase 4 depolarization,
can be noted in the pacemaker fiber labelled BH
by the fact that upon repolarization, the membrane
potential progressively depolarizes until the threshold
potential is reached and an action potential develops.
The fact that the BH fiber drives both the atrium
and ventricles can be noted by the evocation of its
action potential prior to atrial, right bundle branch,
or ventricular activity. Thus retrograde conduction
to the atria and antegrade conduction to the ventricles occurs in the first two beats. Following the
second atrial response, a premature atrial beat develops (third RA electrograms). This atrial response
is conducted antegrade to the impaled BH fiber and
prematurely fires a subsidiary pacemaker. Concealment is complete since the premature atrial beat
fails to be propagated beyond the subsidiary pacemaker, that is, no action potentials occur at either
the RBB or RV recording sites. In this instance,
the development of the next expected discharge
of the subsidiary BH pacemaker was delayed by
58 msec due to the premature discharge of the BH
pacemaker.
The fourth example of concealed conduction
is one where partial penetration of the A-V con-

duction system by a cardiac impulse results in the
facilitation or acceleration of a succeeding impulse.
Figure 4 is an example, also recorded in the isolated rabbit atrioventricular preparation, in which
facilitation of conduction occurs; this figure could
also be considered an example of supernormal conduction. Electrograms were recorded from the right
atrium and ventricles (RA and RV) simultaneously
with transmembrane action potentials recorded from
the A-V node (AVN) and right bundle branch
(RBB). In figure 4A, the atria were driven at a
constant rate, and basic atrial responses were conducted antegrade to the ventricles as shown by the
first 2 atrial beats. The third atrial response was
evoked prematurely, and it can be seen that the
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Fig. 3-Premature atrial activation causing "resetting" of
a junctional pacemaker. Bipolar electrograms were recorded
in the isolated rabbit h~art from the right atrium (RA)
and right ventricle (RV), together with transmembrane
potentials from the bundle of His (BH) and right bundle
branch (RBB). The timing pulses (T) denote 10 msec. At
the arrow, the preparatio11 was prematurely activated by
electrical stimulation through electrodes placed on the
right atrium. (Reproduced, with modifications, by permission of the American Journal of Cardiology, 28:410,
l 971.)

T -.-.-.-.- .- .-.-.-.-.-.-.- .-.-.-.-.-.

t
Fig. 4-A concealed ventricular premature activation causing conduction of a previously blocked atrial activation.
Bipolar electrograrns were recorded in the isolated rabbit
heart from the right atrium (RA) and right ventricle (RV),
together with transmembrane potentials from the A-V node
(AYN) and right bundle branch (RBB). The timing
pulses (T) denote JOO msec. The sequence of atrial
activation was identical in A and B. In A, note that the
third atrial response was not conducted to the ventricles
but was blocked within the A-V node with only a local
nonpropagated response occurring (unpublished data, Moore
and Spear). At the arrow in B, the preparation was prematurely activated by electrical stimulation through electrodes placed over the region of the right bundle branch.
(Reproduced, with modifications, by permission of the
American Journal of Cardiology, 28 :412, 1971.)
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impulse caused a nonpropagated local response in
the impaled A-V nodal cell which failed to be
conducted to the bundle branch and ventricles.
Therefore, it was concealed somewhere within the
A-V node. In figure 4B, the atria were driven at
the identical cycle lengths as those in figure 4A,
but a premature ventricular response (at the arrow)
was evoked prior to the expected arrival of the
ventricular response which would have resulted from
antegrade conduction of the second atrial response.
This ectopic ventricular response was conducted
retrograde to the impaled A-V nodal cell. The
second atrial complex was evoked at precisely the
same time as in figure 4A; however, conduction of
this atrial response to the impaled A-V nodal cell
was blocked since the impaled A-V nodal fiber was
excited by the premature ventricular response.
Therefore, bidirectional collision occurred somewhere above the impaled A-V nodal fiber. The premature atrial response (third atrial RA response)
occurred at identical times in panels A and B.
However, the response in figure 4B, unlike that in
4A, was conducted to the ventricles because the
concealed premature ventricular response facilitated
conduction of the premature atrial response by
peeling back a refractory barrier within the A-V
node. Figure 4B, then, is an example of concealed
conduction which resulted in the development of
facilitated or "supernormal" conduction.
In summary, I have tried to present examples
and mechanisms for concealed conduction. Illustrations recorded in the isolated rabbit A-V preparation
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were selected since this preparation permits one to
obtain not only the information available in the
ECG (atrial and ventricular activity), but also to
see what the A-V node, bundle of His, bundle
branches, and Purkinje system are doing during
concealment. The development of the catheter electrode technique for recording from the bundle of
His now permits validation of phenomena occurring within different regions of the A-V conduction
system in man.
Thus, concealed conduction of atrial, jimctional, and ventricular impulses can result in delay
or block in the conduction of a subsequent impulse,
delay in the expected discharge of a junctional pacemaker or, occasionally, facilitation or acceleration
in conduction of a subsequent impulse. Concealed
conduction is also involved in producing the irregular
ventricular response during atrial fibrillation.
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Clinical Significance of Exit Block*
IRANY M. DE AZEVEDO, M.D.
YOSHIO WATANABE, M.D.
LEONARD S. DREIFUS, M.D.
From the Departments of Medicine, Physiology, and Biophysics,
Hahnemann Medical College, Philadelphia, Pennsylvania

The confinement of an ectopic discharge to its
focus, and its consequent inability to invade the adjacent myocardium when falling outside of the refractory period of the heart, is a well established
phenomenon called "exit block." This cardiac arrhythmia was originally described by Kaufmann
and Rothberger ( 8) to explain the failure of a parasystolic focus to activate the heart. All pacemakers
are subject to exit block (9, 13, 15, 14, 11, 16, 12,
3, 10, 7, 1), however, by convention, conduction
disturbances involving the sinus node (S-A block)
are usually excluded from this concept, and the term
is reserved for ectopic pacemakers. Recent electrophysiological and clinical studies have shown that
exit block may complicate reentrant arrhythmias and
may be of either Wenckebach type I or II (2, 5).
Several examples of exit block will be discussed in an
attempt to show some different clinical aspects of this
mechanism.
Sinoatrial Block. In figure 1, precordial leads,
Vl-3 demonstrate a sinus rhythm at a rate of approximately 65 per minute. The P-R interval measures 0.13 seconds, and the QRS complexes are of
normal contour and duration. The first P-P interval in V3 measures 0.84 seconds; the second, 1.76
seconds, the third P-P, 0.96 seconds, the fourth,
0.86 seconds, and the fifth P-P interval, 1.84 seconds.
This is an instance of sinoatrial block. The
second and fifth P-P intervals are longer than twice
the shorter P-P intervals. Such variation of P-P intervals could be explained by Wenckebach conduction from the sinus node to the atria. Sinoatrial block
is a true form of exit block, but the term is ordinar-

* Presented by Dr. Dreifus at the Symposium on
Cardiac Arrhythmias, June 8, 1972, at Virginia Beach,
Virginia.
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ily reserved for ectopic pacemakers, rather than the
sinus node.
High Grade Atrioventricular Block. In virtually all instances, exit block occurs in the presence
of higher degrees of A-V block. Failure of the
impulse to propagate from the subsidiary ectopic
focus to either the ventricles, atria, or both is characteristic of this form of exit block. Several examples are illustrated. In figure 2, there is high grade
A-V block causing A-V dissociation. The atria are
under the control of the sinus node at a rate of 71
per minute, and the ventricles are controiled by a
subsidiary ectopic pacemaker, probably originating
in the right bundle branch at a rate of approximately
40 per minute. Jn A VL the two first R-R intervals
measure 1.46 seconds after the third QRS complex; a
long pause of 2.74 seconds occurs, probably due to
exit block from the Purkinje pacemaker, and only
atriai activation is seen. In another instance of
high-grade A-V block (fig. 3), sinus tachycardia is
present at a rate of 105 per minute. There is complete A-V dissociation, and the ventricles are under the control of a sub-junctional pacemaker, probably located in the right bundle branch system, at
a rate approximately of 25 per minute. In aVF and
Vl, the R-R intervals are almost the same with a
duration of 2.40 seconds. However, the first R-R interval in V2 is 2.64 seconds and suggests concealed
conduction to the level of the subsidiary pacemaker.
The second R-R interval in V2 measures 5.72 seconds and is longer than twice the R-R intervals in
aVF and V1, probably due to a combination of
both exit block and concealed conduction as is shown
by the diagram. In figure 4, three records are taken
from a patient with an inferior myocardial infarction. A high degree of A-V block is present. The
MCV QUARTERLY 9(1): 26-3 2, 1973
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Fig. 1- Sinoatrial block. Three sinus beats are seen followed by a pause. The fourth P wave is not visible as 4 : 3 block occurs between
the sinus node and atria as seen in diagram.

atria are under the control of the sinus node at a
rate of 91 per minute, and the ventricles are under
a control of a junctional pacemaker at a rate of 66
per minute. In B, longer pauses are observed, but
the atrial rate is decreased to 83 per minute, and
the ventricular rate is 63 per minute. In C, the atrial
rate is 97 per minute, and the ventricular rate is
32
.
per mmute. T he R-R interval s measure 1.87
seconds, _twice the R-R interval seen in B, probably
due to exit block of the junctional pacemaker.
b
In ~any instances, high-grade A-V block may
e associated with atrial fib rillation. Exit block from

the subsidiary pacemaker can be easily identified
if the block occurs with a precise conduction ratio
as seen in figure 5. In this example, there is atrial
fibrillation, and the ventricles are under the control of a junctional pacemaker at a rate of 64 per
minute. In V2, the R-R intervals become more prolonged and measure 1.83 seconds, almost twice
that seen in I and II, and are probably due to exit
block from the subsidiary junctional pacemaker. Another example of this problem is illustrated in figure
6. Junctional tachycardia is present at a rate of
approximately 125 per minute. Th e atrial activity is
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v
Fig. 2- High-grade A-V block is present. rn strip AYL a long pause is seen, indicating exit block from a subsidiary Purkinje pacemaker, probably located in the right bundle branch system.

hardly seen, and atrial fibrillation is present. After the
third, ninth, and twelfth QRS complexes, long
pauses of 0.86 seconds, sometimes twice the R-R
interval of the basic rhythm, are present. These
pauses are engendered by exit block from the subsidiary junctional pacemaker. In sharp contrast to
these last two examples, an irregular ventricular
response in the presence of atrial fibrillation can
cause some diagnostic confusion unless W enckebach conduction from the subsidiary pacemaker is
considered. In figure 7, atrial fibrillation is present.
The ventricles are under the control of a junctional
pacemaker at a rate of approximately 136 per minute. The R-R intervals as seen by the diagram vary
slightly. After the seventh QRS complex, right carotid
sinus pressure was applied, and the R-R intervals
became prolonged from 0.44-0.46 to 0.88 seconds,
twice the R-R intervals seen previously. This is due
to exit block from a subsidiary junctional pacemaker. At the end of record B, 2 : I, 3: 2, and 4: 3
ratios are seen. This variation of R-R intervals in
B is caused by Wenckebach conduction from the
subsidiary junctional pacemaker.
Ventricular Parasystole. In figure 8, two differ-

ent types of QRS complexes are seen in the upper
record, the first one upright and the other one
predominantly downward. There are two independent rhythms, sinus rhythm and ventricular parasystole, as shown in the diagram. The parasystolic
pacemaker has a cycle length of 580 per msec, and
the variation of R-R intervals during the parasystole
is due to Wenckebach phenomenon in the transmission of the impulse from the ectopic parasystolic
pacemaker to the ventricles. When exit block of the
parasystolic pacemaker occurs with a ratio of 4: 3,
sinus impulses are transmitted to the ventricles.
The coupling intervals show slight variation beats in
2, 6, 10, 14, 18.
Among the clinical examples, figure 1 was presented to demonstrate a similar mechanism between sinoatrial block and exit block. Hence, only
the failure of an ectopic pacemaker to activate adjacent myocardium is considered exit block. However, other authors admit that exit block can occur
in all excitable tissues of the heart with pacemaker
or latent pacemaker properties (2, 6). Thus, if the
latter assumption is accepted, it would be very hard
to differentiate sinoatrial block from exit block of
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Fig. 3- High-grade A-V block is present and in lead V2, a long diastolic interval is seen which is greater than twice the subsidiary
junctional pacemaker rate. Two possibilities may be considered : (I) exit block from the subsidiary pacemaker and (2) concealed
penetration into the subsidiary pacemaker by one of the sinus beats, delaying the rhythmicity of the subsidiary pacemaker.

sinus impulse origin. It is true that fibers possessing
high degrees of automaticity such as those in the
sinoatrial node generally show a lower level of
resting membrane potential, a smaller action potential amplitude, and a markedly slower rate of depolarization than other cardiac fibers. These factors
engender a slower conduction velocity and may
even cause decremental conduction and precipitate exit block (4, 6). In fact, loss of resting membrane potential due to phase 4 depolarization in
fibers surrounding the actual pacemaker may produce slow conduction, fractionation of the wave
front, decrement, and finally, exit block.
Exit block at a level of the junctional pace-

maker, the Purkinje tissue, and the ventricular parasystolic pacemaker focus were shown above. However, exit block is most commonly observed in
junctional rhythms with accelerated impulse formation due to digitalis excess ( 13, 17).
In figure 3, a combination of concealed conduction and exit block is shown in the ladder diagram.
The differentiation between these two rhythm disturbances by electrocardiographic techniques is
made by the identification of concealed conduction.
Note that the R-R interval is shorter than two basic
R-R intervals in the presence of exit block. Since
Wenckebach conduction from the junctional pace-
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maker is not present, the R-R interval is a precise
multiple of the basic R-R interval.
In junctional rhythm with exit block, the cause
of block is attributed mainly to a small action potential amplitude with a slow rate of depolarization,
a mechanism favoring decremental conduction (17).
The last tracing shown illustrates exit block from a
ventricular parasystolic focus as indicated by the
diagram. Wenckebach structure is postulated to
account for the progressive shortening of the R-R
interval. The increased automaticity in a group of
specialized fibers may create an ectopic pacemaker,
but at the same time, because the propagation of
the impulses through this region becomes more difficult, both entrance and exit block may coexist.
However, in this particular case, in which the parasystolic focus is rapid, unidirectional block engendered by rapid discharge of the pacemaker might
play a greater role in causing exit block rather than
in protecting the parasystolic focu s.
It is impossible on the basis of surface electro-

B

(,
Fig. 4- Tn A, an inferior wall infarction is present with hi ghgrade A-V block ; In B, the subsidiary pacemaker rate is
slowed to 60 / min ; In C, the subsidiary pacemaker rate is now
30, hence, 2: 1 exit block from thi s pacemaker is considered.
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Fig. 5- Tn the upper two strips, atrial fibrillation is present, although the ventricular rate is quite regular at 60 / min. In the lower two
strips, the rate is 30 / min, hence, exit block fr om the subsidiary pacemaker is present in the face of atri al fibrillation .
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Fig. 6-Atrial fibrillation is pr~sent with group beating. The l?nge~ d.iastolic pauses are equaUo two of the. basic junctional beats. In
this instance, atrial fibrilla tion is present with complete A-V d1ssociat10n due to A-V block, with escape of Junct10nal pacemaker and
exit block from the junctional pacemaker.
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Fig. 7-A. At the left-hand portion of the strip, a rapid regular rhythm is present at 140 / min. Following right carotid sinus pressure,
the rate in the right portion of the strip is slowed to 75 / min, and 2: 1 exit block from the subsidiary junctional pacemaker is present .
B. Here the rhythm is irregular although group beating is seen, particularly bigeminy. Wenckebach conduction from the subsidiary
pacemaker is present.

cardiograms to be certain if the exit block is due to
alte~ation in phase 4 of the pacemaker action potential or to failure of conduction once the impulse
leaves the pacemaker cell (5). However, electrophysiological studies and in vivo experiments have
shown that exit block is a result of conduction depression surrounding the site of impulse formation
and can be a feature of both an automatic and
reentrant rhythm (2, 4, l ?).
Summary. Clinical features of exit block were
sh~wn and its probable electrophysiological mech~m~ms dis~ussed. Based on recent electrophysioogical studies, it is emphasized that exit block is a
result of de
d
.
t .
presse conduction surrounding the ecopic pacemaker.
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Fig. 8- Basically a sinus rhythm is present. Note narrow QRS complexes which are preceded by P waves (see diagram). However, a
rapid ventricular rhythm is seen showing periods of Wenckebach periodicity as the R-R interval of the ectopic beats becomes shorter
before the pauses and the reemergence of the sinus rhythm. H ence, exit block from an accelerated, ventricular parasystolic tachycardia
is present with exit block showing Wenckebach periodicity.
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Reentry*
GORDON MOE, M.D., Ph.D.
Director of Research, Masonic Medical Research Laboratory,
Utica, New York
There are two ways in which impulses can be
generated: one is by the spontaneous discharge
of a pacemaker cell in either the normal site or
a subsidiary site, and the other is by reentry. The
concept of reentry is a very old one postulated
by clinical cardiologists many years before its
demonstration.
The conditions that are necessary to permit
this to happen have been known for at least 75
years. First of all, the conduction pathway must be
blocked at some site; thus, an impulse arrives at
a junction which is refractory or poorly excitable,
and the margin of safety for continued propagation
falls below the magic figure of 1. Second, there must
be slow conduction over an alternate route to the
tissue beyond the site of block. Since the cardiac
tissue is largely syncytial in nature, there are always alternate routes around a localized area of
block. Third, delayed excitation must occur beyond
the site of the block. If that excitation is sufficiently
delayed and if the tissue proximal to the site of the
block is by that time recovered, it can then be excited
from the opposite direction, and this would complete
the circuit. Reentry can and probably does commonly happen. Reentry may be concealed; in other
words, there may be localized reentrant activity
which never escapes from that site because of refractoriness in the conduction pathway.
Therefore, it does not appear on the surface
electrocardiogram, and it may not even appear in
records from localized electrodes. So I repeat: of
the four conditions necessary, the sine qua non is
block. There has to be block for reentry to occur.
Second, there is slow conduction over an alternate
route to the tissue beyond the block; and third, there
is delayed activation of that tissue beyond the block,
and finally, reentry occurs.
*This is a transcription, edited by Dr. Charles L. Baird,
Jr., of a lecture presented by Dr. Moe at the Symposium
o~ <?a.rdiac Arrhythmias, June 8, J 972, at Virginia Beach,
Virginia.
MCV QUARTERLY 9(1): 33, 1973

PANEL DISCUSSION

Dr. Baird: Is it possible to differentiate from the
scalar electrocardiogram whether the mechanism
of ectopic beats is due to reentry or automaticity?
Dr. Moe: I do not think it is possible. The termination of supraventricular tachycardia or ventricular
tachycardia by a single stimulus only suggests that
reentry is the mechanism rather than automaticity.
I am not nearly as comfortable as I was several
years ago.
Dr. Hoffman: I feel at least as insecure as Dr. Moe.
Dr. Dreifus: Ventricular tachycardia due to digitalis
toxicity is probably on an ectopic basis.
Dr. Moe: I agree, however, ectopic activity initiated
by digitalis can also be the stimulus which generates
circus movement. What starts something is not necessarily what continues it.
Dr. Baird: Can one differentiate the origin of ectopic
beats from the scalar electrocardiogram?
Dr. Dreifus: I do not believe that this is possible.
Dr. Hoffman: Digitalis affects the cells of the specialized conduction system, and ectopic rhythms arise
because of the depression of these specialized fibers
which are more sensitive to the digitalis effects
than ventricular muscle. Evidence is also accumulating that the internodal tracts of the atrium are more
sensitive to the effects of digitalis than the atrial
muscle fibers.
Dr. Moore: We have produced unifocal ventricular
tachycardia experimentally in dogs, and mapping
studies demonstrated that the left ventricle was
the origin of the ectopic rhythm . Isolated studies
of the Purkinje fibers from both the right and left
ventricles also demonstrated that the left side was
more sensitive.
Dr. Dreifus: Clinically, the ectopic beats occur at the
site of the preexisting conduction block. However, it
is very difficult to determine from where ventricle
ectopic beats are arising, since the scalar electro~ardiogram only provides the axis deviation.
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The Gouaux-Ashman Phenomenon:
His Bundle Recordings*
BENJAMIN J. SCHERLAG, Ph.D.
From the Division of Cardiovascular Disease, Department of Internal
Medicine, Mount Sinai Medical Center, Miami Beach, Florida,
and the Department of Medicine, University of Mif;1mi School of
Medicine, Coral Gables, Florida

The differentiation of ventricular premature
beats from supraventricular beats with aberrant
ventricular conduction is often difficult on the basis
of the surface electrocardiogram. The diagnosis of
aberrant conduction has been based largely on the
presence of a right bundle branch block pattern appearing in a short cycle subsequent to a longer cycle
(2). Several other criteria for diagnosing aberrant
conduction of a supraventricular beat such as variable coupling time have been used to differentiate
these abnormal ventricular complexes from ventricular premature beats which are most commonly followed by a full compensatory pause. This differentiation is often inexact and under some critical clinical
circl)mstances cannot be accomplished with any
degree of reliability. In 1947, Gouaux and Ashman
wrote a report entitled: "Auricular Fibrillation with
Aberration Simulating Ventricular Paroxysmal
Tachycardia" (2). It is thus in the clinical context
of atrial fibrillation that the diagnosis of abemmt
conduction of supraventricular beats as opposed to
ventricular tachycardia becomes particularly difficult.
Recent reports in the literature have emphasized
the use of the His bundle-electrocardiographic
technique as a means of differentiating between
aberrant conduction and ventricular ectopic complexes (3, 4, and 6). In order to evaluate this method
of differentiation, it is important to note the physio-

* Presented by Dr. Scherlag at the Symposium on
Cardiac Arrhythmias, June 8, 1972, at Virginia Beach,
Virginia. Please send reprint requests to: Dr. B. Scherlag,
Mount Sinai Medical Center, 4300 Alton Road, Miami
Beach, Florida 33140.
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logical behavior of A-V nodal and His bundle conduction under these two circumstances.
Figure I, taken from a study by Damato et al.
(1), shows the response of the His-Purkinje system
to atrial prematl)re beats delivered at varying intervals after the previous cardiac cycle. A slight
degree of aberration can be seen even with no prolongation of the H-V or H-0 time. However, more
marked aberration occurs with the prolongation of
His-Purkinje conduction time from 45 to 65 msec.
Finally, block is showrl distal to the recorded His
bundle deflection, and these properties of the HisPurkinje system during premature activation have
been confirmed in other clinical laboratories. Therefore, the normal response to atrial premature or His
premature beats which result in aberrant ventricular
conduction is either an unchanged or prolonged
H-V time.
In contrast to the constancy or prolongation of
the fl-V interval during supraventricular beats
conducted with aberration, ventricular ectopic beats
or fusion beats show either no His potential preceding the aberrant ORS complex or a shortened
H-V time. In figure 2, the His bundle-ECG
tracings reveal an H-V time of 50 msec with a
wide ORS complex. Note that the P-R interval is
190 msec during sinus rhythm. In the second beat in
panel A, a shortening of the P-R interval from 190
to 175 msec with a narrowing of the ORS complex
is observed. Also, a shortening of the H-V time to 35
msec occurred. That this beat represents in fact a
fusion of a normally conducted atrial impulse and a
ventricular ectopic peat is indicated in panels B and
C. Here the P-R shortens to 135 rns~c in the secMCV QUARTERLY 9(1): 34-38, 1973
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ond beat of each panel with a negative H-V time,
that is, ventricular activity precedes His bundle activity by 5 msec and 20 msec, respectively. It can
be seen that the change in H-V time from normal
is appropriately matched by the change in the P-R
interval.
Unfortunately, these quantitative aspects of the
His bundle recording in regard to ventricular ectopic
beats and supraventricular beats conducted with aberration have been essentially ignored in several
recent publications . In a, report by Lau et al. (3),
the authors were the first to note that the recording
of His bundle activity represents a valid method for
diagnosing aberrant conduction, particularly in differentiating supraventricular beats and ventricular
premature contractions of ventricular tachycardia.
However, in illustrating this point, a case of atrial
fibrillation was examined with simultaneous recordings of H is bundle electrogram and a standard ECG
lead (fig. 3). The authors state that the second complex in this figure is a supraventricular beat conducted from above with aberrant ventricular activation. However, the H-V time is clearly shorter in
this beat than in the normally conducted beats, 1,
4, and 6. Note that the H-V time is measured from
the H deflection to the earliest ventricular activation
which in this case is the standard ECG lead. In the
normally conducted beats, the earliest ventricular
activation occurs in the His bundle electrogram.
In another recent report by Massumi, a case
was presented (fig. 4) in which the first two beats
shown are sinus beats showing atrial, His bundle,
and ventricular activity. The third beat shows a
QRS complex which the author describes as a pattern of "incomplete right bundle branch block and
left axis deviation suggesting impaired conduction
through the right bundle branch and superior division of the left bundle branch." Massumi localizes
the extrasystolic focus as occurring within the His
bundle and bases this conclusion on the observation
that this extrasystole is preceded by a His bundle
potential. However, it should be noted that the Hy time of this third beat is markedly shortened compared to the H -V time seen during sinus beats. Both
of the previous records can be interpreted as ventricular beats arising in the proximal portion of the
right or left bundle branch which are simultaneously
conducted antegrade to the ventricular myocardium
and retrograde to the His bundle. Under these
circumstances the QRS would be aberrant and if one
were only recording His bundle activity, this poten-
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Fig. I-In panels A through D , the top tracin g is a lead
V1 and the bottom tracing a His bundle electro gram (HBE ).
When the atrium was prem aturely stimulated at a coupling
interval of 380 msec (panel A) , a delay in A-V conduction
occurred as manifested by an increase in th e P-H interval
to 132 m sec. The H-Q interval remained constant, and
ventricular depolarization was only slightly altered. Shortening the coupling interval to 370 msec (p anel B) and 365
msec (panel C) resulted in aberrant ventricular depolarization (RBBB and LBBB) with an associated prolongation of
the H-Q interval. At a coupling interval of 355 msec (panel
D), complete block below the His bundle resulted. (Reproduced by permission of the American H eart Association,
Inc. from Damato, A. N . et al. "A Study of Atrioventricular
Conduction in Man U sing Premature Atrial Stimul ation and
His Bundle Recordings. " Circ11/atio11 40:64, 1969) .

tial would appear before the QRS with a shortened
H-V time.
Just such recordings have been made in our
clinical laboratory by N arula et al. ( 5). Figure 5
shows a simultaneous recording of His bundle and
left bundle activity during sinus rhythm in a patient
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Fig. 2- The effect of fusion beats on the H-V interval in a patient with intermittent ventricular ectop ic beats. Traces from above:
Bipolar His bundle electrogram (BE, Hb) a nd 3 simultaneously recorded ECG leads I, A VF, a nd V1. A. During si nus beats, the P-R
of 190 msec was composed of intra-atrial conduction time (P-A = 50 msec). A-V nodal conduction (A-H) = 90 msec and His-Purkinje
conduction (H-V) = 50 msec. A fu sion bea t (F) caused a shortening of the "P-R" to 175 msec entirely due to H-V diminution of
15 msec (50-35 msec). The vertical dotted line indicates the earliest ventricular activation in all leads. B. Another fu sion beat (2nd
complex marked F) causes a further shortening of the P-R to 135 msec and a reversal of the H -V with the onset of ventricular activation preceding His bundle activation by 5 msec. C. Another fu sion beat (F) produced " normalization" of the QRS complex as compared to other beats. Note that the shortening of the P-R in each case is matched exactly by the alteration in H-V or V-H time; the
P-A and A-H interval remain constant throughout. The interval between time lines equals 100 msec.

with a normal ORS complex. The second beat in
panel A shows left bundle activity preceding His
bundle activity during ventricular premature contractions which probably arose in the area of the
proximal left bundle. In panel B, a series of beats
arising in the same region of left bundle activity
preceding His bundle activity is seen . Without the
left bundle recording, one could interpret the aberrant beats with a shortened H-V time as arising in
the His bundle and conducting through the ventricles aberrantly.

In conclusion, it is important to state that the
use of His bundle-electrocardiography in differentiating supraventricular beats with aberration from
ventricular beats requires a critical approach to the
interpretations of deflections appearing in the P-R
segment. The use of quantitative rather than qualitative tests is essential when only the His bundle
recording is used as opposed to the simultaneously
recorded activity from the proximal bundle branches.
In some cases, His bundle pacing may be helpful in
reproducing spontaneously occurring aberrant pat-
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Fig. 3- In this clinical case of atrial fibrillation, the first, fourth , and sixth complexes represent the normally conducted beats, each of
which is preceded by a His deflection. The second complex, which is also preceded by a His deflection, represents an aberrant beat.
The third complex is a premature ventricular contraction. No His potential precedes this beat. (Reproduced by permission of the
American Heart Association, Inc. from Lau, S. H. et al. "A Study of Atrioventricular Conduction in Atrial Fibrillation and Flutter in
Man Using His Bundle Recordings." Circulation 40:73, 1969).
thereafter is explainable on the basis of the well-known
effect of the long preceding cycle, in this case, cycle 1-2.
(Reproduced by permission of the American Journal of
Medicine 49 :267, 1970, and R. A. Massumi) .

Ill W.

DCU NltOI

Fig. 4-Simultaneous recording of leads I, II, and V, together with His bundle potentials recorded from the main
His bundle. The sinus P waves before beats 1, 2, 4, 6, are
clearly visible in leads I and II and also in the His bundle
recording just before the atrioventricular node potentials
marked N. Note that the His bundle potentials, marked by
arrows, precede not only the QRS of the sinus beats 1, 2,
4, 6, but also the interpolated extrasystoles 3, 5, and 7.
The aberrant intraventricular conduction of the first interpolated extrasystole No. 3, is of the incomplete right
bundle branch block and left axis deviation type, suggesting impaired conduction through the right bundle
branch and the superior division of the left bundle
branch. Our localization of the extrasystolic focus within the
His bundle is based on the observation that the extrasystoles
3, 5, and 7 are preceded by His bundle potentials but not by
atrioventricular node potentials like the sinus beats. Had
they arisen from the atrioventricular node, the atrioventricular node potentials would have also been recorded just
before the His potentials of the extrasystoles. This indicates
that the extrasystoles originate below the atrioventricular
node. The low frequency, low amplitude distortion of the
baseline seen before the His potential of the extrasystoles
represents the T wave of the preceding beat, two of which
are marked with T. Finally, the reason for aberration of the
first beat of the run of tachycardia with normal conduction

terns. Although one should expect a normal or prolonged H-V time in supraventricular or His bundle
beats conducted with aberration, one must rule out
the theoretical possibilities of a shortened H-V time
due to "super-normality," or a constant or prolonged
H-V time due to a beat arising in the bundle
branches which is conducted with delay to the ventricular musculature but with normal retrograde
conduction to the His bundle.

Author's note: We thank Mrs. Marie Ellis for
her dedicated assistance in the preparation of this
manuscript.

REFERENCES
1. DAMATO, A. N., LAU, S. H., PATTON, R. D ., et al. A study
of atrioventricular conduction in man using premature
atrial stimulation and His bundle recordings. Circulation
40:61-70, 1969.

2. GOUAUX, J. L. AND ASHMAN, R. Auricular fibrillation with
aberration simulating ventricular paroxysmal tachycardia.
Amer. Heart ! . 34 : 366- 373, 1947.
3. LAU, S. H., DAMATO, A. N., BERKOWITZ, w. D ., et al.
A study of atrioventricular conduction in atrial fibrillation
and flutter in man using His bundle recordings. Circulation 40:71- 78, 1969.

SCHERLAG: GOUAUX- ASHMAN PHENOMENON

38

'I

>.i v;

I

BEPJ

:

I

A

I

,.

v

11
::
II
11
, :'.-------i'-V'j'1----~o°'li'-'T-----------------1~;I

V

:... !

111:

l

. ::

-------:·""'~ :~\~1·,, ,

-+ l I·

:V

____..,

A

A,

IM

,,------------~
K.V JO -.ec

I

11-V 2 5 -

H

A
a VF

BEil!

----.. . .II-·;.~,·;..·,.______~,.._,,.;.~:.
"{

B

BE"

1

,·
V
" '+
' ..... ~ ~'

11
'i,;..
------~.:

I

: ;.

-----..T-~;.+. . _____:..-:...~Vr
I, ;

11

,. i·

; ~ :.

\ •

~-----'". . . . l'f :\...~.-----.'."-'/..,

A

11-V 2 5 -

aVR---~

l-2
a VF
C. Woo.

117~

llO/f/111

I/OUN

Fig. 5- Case 5: Retrograde activation of the BH by premature "ventricular" beats (probably left bundle beats). (Reproduced by
permission of the American Heart Association, Inc. from N arula, 0 . S. et al. "Significance of His and Left Bundle Recordings from
the Left Heart in Man. " Circulation 42:395, 1970).

4. MAssuMr, R. A. Interpolated His bundle extrasystoles.
Amer. J. Med. 49:265- 270, 1970.

5. NARULA, 0. S., JAVIER, P. J ., SAMET, P., et al. Significance
of His and left bundle recordings from the left hea rt in
man. Circulation 42: 3 85- 396, 1970.

6. PUECH, P., GROLLEAU, R., FIJAC, E., et al. The diagnosis
of supraventricular arrhythmias and the differentiation
between supraventricular tachycardias with aberrant conduction a nd ventricul a r tachycardias. In: Symposium on
Cardiac Arrhythmias. (eds.) E. Sandoe, E. FlinstedJensen, and J. A. B. Ol ese n. Astra, Sodertalje, Sweden,
1970. Chapt. 11 .

Mechanisms of Supraventricular Tachycardia*
BENJAMIN J. SCHERLAG, Ph.D.
RALPH LAZZARA, M.D.
From the Division of Cardiology, Department of Internal Medicine,
Mount Sinai Medical Center, Miami Beach, Florida, and the
Department of Medicine, University of Miami School of Medicine,
Coral Gables, Florida

"Circus movement" or continuous cyclic conduction along a closed pathway was proposed by
Mines (6) in 1913 to explain paroxysmal tachycardia. In 1943, Barker et al. (1) suggested that
the S-A node or the A-V node, on the basis of their
properties of slow conduction, were the turn around
sites of such a circus or reentry arrhythmia. Insofar
as the A-V node was concerned, this postulation
was confirmed and expanded by the investigations
of Moe et al. (7) who showed that under conditions
of slowed conduction the A-V nodal pathways could
dissociate functionally. More recently, Mendez and
Moe ( 5) using microelectrode recording techniques
have found that areas within the A-V node can be
identified as the sites of rebound or echo beats
which returned to the atrium. Wit et al. ( 13) were
able to induce paroxysmal tachycardias in isolated
portions of rabbit atria containing the A-V node.
Clinically, Goldreyer and Bigger (2), induced and
terminated, in patients with a predisposition to
paroxysmal supraventricular tachycardia, periods
of supraventricular tachycardia with appropriately
placed atrial premature beats. Their evidence from
His bundle recordings pointed to the A-V node as
a site of reentry for these paroxysmal supraventricular tachycardias in man.
In figure 1, a schematic representation is shown
of the series of events that might occur in the course
of an induced period of supraventricular tachycardia.
After ;i normally conducted sim.is beat (SB), an

* Presented by Dr. Scherlag at the Symposium on Cardiac Arrhythmias, June 9, 1972, at Virginia Beach, Virginia.
Please send requests for reprints to: Dr. B. Scherlag, Mount
Sinai Medical Center, 4300 Alton Road, Miami Beach,
Florida 33140.
MCV QUARTERLY 9(1): 39-45, 1973

atrial premature beat (APB) occurring spontaneously or electrically induced is conducted slowly
through the A-V node. If the A-V nodal delay is
great enough to produce functional longitudinal dissociation, a reentrant pathway can be set up either
giving rise to one rebounding beat into the atrium,
an echo beat (EB) , or a continuous circuit may
ensue within the A-V node with atrial and ventricular responses being thrown out of the node with
each intra-nodal circuit. The interruption of the
circuit can occur due to another atrial premature
beat thus terminating the paroxysm and reinstituting
sinus activity. There is both clinical and experimental evidence supporting the intra-A-V nodal
circuit as the prime mechanism involved in reentry
arrhythmias such as paroxysmal atrial tachycardias
or in reciprocal beating. On the other hand, there
are studies which clearly indicate that the atrium
participates in the reentry pathway. For example,
in the study of Wit et al. ( 13), these authors
found that excision of a large portion of atrial
muscle prevented the induction of paroxysmal
tachycardia in the isolated rabbit preparation, and
Golc\reyer and Bigger ( 3) also indicated on the
basis of A-V nodal conduction times during paroxysmal supraventricular tachycardia in patients that
the atrium was involved in the reentry path. Thus,
in our schematic representation, we have indicated
by the dotted lines the possibility that activity echoing back from the A-V node, the first site of reentry, can enter the atrium, which serves as the
second site of reentry, to continue the paroxysmal
tachycardia. It is at this point, where intra-atrial
reentry is implicated that one encounters a controversy that has occupied a great deal of journal space
39
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Fig. 1-A schematized version of impulse conduction during
induced atrial tachyarrhythmias. The modified ladder diagram depicts three major cardiac compartments: the atrium
(A); the A-V junction (A-VJ) composed of the A-V node
(avn) and the His-Purkinje system (hps); and the ventricle
(V). The electrocardiogram is depicted below (ECG).
Other abbreviations are : sb = sinus beats; apb = atrial premature beats; eb = echo beats; pat = paroxysmal atria
tachycardia. See text for discussion.

recently. In looking at the schematic, particularly
the atrial bridge, one notices that at the point at
which atrial activation must reverse itself atrial refractoriness must be infinitely rapid or another area
of slow conduction must be postulated to account
for the atrial bridge. In a recent issue of Chest,
Surawicz ( 11) has concisely addressed himself to
this point and indicates that the electrophysiologist
must return to the drawing board, so to speak, in
order to elucidate mechanisms by which the atrial
bridge hypothesis can be substantiated. Below, we
would like to present evidence for perhaps one
mechanism by which an intra-atrial bridge or a
second reentry site may be involved in paroxysmal
supraventricular tachycardias.
Our investigations were based on an interesting
observation and clever postulation made by Vassalle,
Greenspan, and Hoffman in 1963 (12). They observed that a ventricular escape beat which terminated a vagal arrest of the heart often initiated atrial
fibrillation. They postulated that in some way the
retrograde impulse entering the atrium proceeded
in a heterogeneous fashion so that the dissociated
atrial wave front could establish a return pathway(s)
within the atrium thereby initiating atrial flutter or
fibrillation.
We were able to reproduce this phenomenon
and analyze atrial activation patterns (fig. 2). In
panel A, close bipolar electrograms were recorded
in various parts of the dog atria in order to find the
earliest and latest epicardial areas of activation.

These corresponded to the high right atrium in
the area of the sinus node and the inferior-posterior
left atrium, respectively. The total antegrade atrial
activation time, that is the time from the beginning
of the earliest activation to the end of the latest
activation or total atrial activation time (AA), was
100 msec. In contrast, during ventricular pacing
with retrograde atrial activation, AA was only 65
msec. Note that the sequence of activation during
retrograde conduction showed low atrial activity
occurring first and sinus activity as well as posterior
left atrial activation occurring last.
In panel C, an asystolic interval with a ventricular escape time equal to 12 seconds due to vagal
stimulation was terminated by a ventricular escape
beat which produced a normal retrograde atrial
activation pattern. Note that the sequence of activation as well as the total atrial activation is the
same during this retrograde atrial activation as that
seen with ventricular pacing in panel B. No arrhythmia occurred subsequent to this ventricular
and atrial beat. In the same animal, panel D, with
a 13-second asystolic period, a ventricular escape
beat was associated with activation of the atria
which differs markedly from the normal retrograde
atrial activation pattern. Although the first area to
be activated in the low right atrium is in the area
of the coronary sinus ostium, the other low right
atrial region approximately 3-5 mm away is activated later. Note that in panel C, both areas were
activated almost simultaneously. Total duration of
retrograde atrial activation now occupies 100 msec
instead of the normal 65 msec. Subsequent to this
initial aberrant atrial activation pattern atrial fibrillation ensued. In those animals in which ventricular
escape beats often produced runs of atrial fibrillation, this phenomenon of dispersion of atrial activation was regularly seen and was clearly related
to the occurrence of atrial arrhythmias.
We found that the dispersion of atrial activation was not limited to ventricular escape beats
with retrograde atrial activation. It also occurred
commonly with retrograde Wenckebach cycles (fig.
3). During ventricular pacing at 120 beats per
minute there was regular 1 : 1 retrograde atrial activation. The total atrial activation time was 55 msec.
When the ventricular rate was increased to 145 per
minute, the Wenckebach phenomenon was seen with
a reciprocal beat. The retrograde atrial activation
interposed between the ventricular and normal sinus
beat shows a total activation time of 65 msec com-
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Fig. 2- The phenomenon of atrial fibrillation associated with a ventricular escape beat during vagal induced cardiac arrest. Traces
from top down: Lead II (L-2) ECG; bipolar plunge wire electrograms from the high right atrium (HRA): Bachmann's bundle (Bb);
low right atrium (LRA); His bundle region (Hb) showing atrial (A), His bundle (H), and ventricular (V) activation; coronary sinus
ostium (CS); posterior left atrium (PLA) showing left atrium muscle (LAM), and left atrial tract (LAT) potentials (13); and from
the inferior left atrium (ILA). A. Total atrial activation time (AA) measured from the beginning of the earliest activation in the
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high right atrium to the end of the latest activation, LAT in the posterior left atrium, is 100 msec. B. During the ventricular pacing
(VP) with retrograde atrial activation the total atrial activation time equals 65 msec. C. With vagal stimulation induced cardiac
asystole and a ventricular escape time (VET) of 12 secs, the ventricular escape beat produces normal retrograde atrial activation
with a total atrial activation time of 65 msec. No atrial arrhythmia ensues. D. With a ventricular escape time of 13 secs, a ventricular
escape beat with the same configuration as seen in C produces a dispersion of retrograde atrial activation. Compare the first sequence
of atrial activation in panel D (within the dotted rectangle) with the first sequence of atrial activation seen in panel C. Total atrial
activation equals 100 msec in panel D for the first atrial sequence as compared to the normal 65 msec seen in panels B and C. Note
the occurrence of atrial fibrillation subsequent to the dispersion of atrial activation in panel D. Interval between time lines equals
1 second.

pared to normal retrograde activation time of 55
msec, probably indicative of some dispersion of
atrial activation associated with the stress of A-V
nodal conduction. When the rate was increased to
150 per minute a short Wenckebach cycle was
seen with a reciprocal beat. Only the last beat of
the Wenckebach cycle shows dispersion of atrial
activation with a total time of 75 msec compared to
the normal 55 msec. Also note that there is a direct
relationship between the degree of dispersion and
the degree df retrograde A-V nodal delay. When
the H-A time was 165 msec, AA was 65 msec,
whereas when the H-A time was 195 msec, the AA
was 75 msec. With 2: 1 conduction no dispersion of
atrial activation was seen.
In figure 4, we have presented a schematized
version of what may be taking place during retro-

grade atrial activation when dispersion of atrial activation occurs. In panel A, the normal pattern of
retrograde atrial activation is shown as recently
demonstrated by Spach et al. (10) in the dog and
rabbit A-V nodal preparation. These authors found
that activation coming out of the A-V node rather
uniformly excited atrial musculature at the A-V
nodal-atrial border. In panel B, on the other hand,
we have postulated that during stress of A-V nodal
conduction during which there is "functional longitudinal dissociation" of activation through the A-V
node, impulses may asynchronously exit from one
portion of the A-V node into adjacent atrial tissue;
whereas at other sites within the A-V node, marked
slowing or block of retrograde impulses occur. Due to
this asynchronous exit from the A-V node, atrial
activation may proceed either back into the A-V
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Fig. 3-The occurrence of atrial dispersion during retrograde Wenckebach cycles. Traces from above: Lead JI (L-2) ECG: bipolar
plunge wire electrograms from the sinus node area (SA); the low right atrium (LRA); the area of the His bundle showing only His
bundle activity (H) and ventricular activation (V); coronary sinus ostium (CS); the inferior left atrium (ILA); and the posterior left
atrium (PLA). During ventricular pacing at 120 per minute with 1: 1 retrograde conduction, atrial activation time (AA) equals 55
msec. As the rate is increased to 145 per minute, a Wenckebach cycle occurs ending in a reciprocal beat (Rec. B). Note that the
total atrial activation time increases from 60 to 65 msec just prior to the reciprocal beat and coincident with the retrograde Wenckebach
cycle. With a ventricular pacing rate of 150 per minute, another Wenckebach cycle occurs and now the beat prior to the reciprocal
beat shows dispersion of atrial activation, 75 msec. With ventricular pacing at 165 per minute there is 2: 1 retrograde conduction
with no change in the atrial activation pattern or total atrial activation time from the normal.
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B

Fig. 4-A schematic version of retrograde atrial activation. A. Indicates activation proceeding from the His bundle retrograde through
the various regions of the A-V node : nh, n, an. (After Spach et al.) (10). Activation spreads uniformly into the atrium. B. Retrograde
activation with asynchronous exit of impulses from the A-V node leading to the possibility of reentry into the node or the atrium.
See text for discussion.

node and then to the ventricle to produce a reciprocal beat, or activation may proceed in an asynchronous manner so that local reentry circuits may
develop at one or more sites to produce atrial
arrhythmias. In any event, dispersion of atrial activation would be a consequence of this asynchronous
exit from the A-V node.
In order to relate this phenomenon of dispersion of atrial activation with the occurrence of reentry atrial tachycardias, we attempted to induce
echo beats in the dog atrium with the delivery of
premature stimuli to the atrium during sinus rhythm
(fig. 5). To enhance the occurrence of echo beats,
we also delivered local subthreshold epicardial stimulation to a site in the low right atrium near the
coronary sinus ostium so that parasympathetic nerve
elements supplying the A-V node were preferentially affected ( 8). In this way, exacerbation of
A-V conduction delay was obtained. In panel A,
normal retrograde atrial activation time was 55
msec; in panel B, a premature atrial stimulus was
delivered to the high right atrium during sinus
rhythm and induced an echo beat. Note the stimulus
artifacts seen on the coronary sinus (CS) trace.
These are due to the subthreshold stimuli applied
to epicardial parasympathetic nerve elements (local
vagal stimulation). The echo beat has a general
appearance of retrograde atrial activation with activity in the low right atrium occurring before activa-

tion of the high right atrium or the posterior left
atrium. Note also that the total atrial activation is
slightly prolonged during this echo beat as compared
to the normal retrograde atrial activation pattern,
85 msec as compared to 55 msec. In panel C,
with the same coupling interval, an atrial echo beat
was induced by an atrial premature systole, however, it was followed by another reentry beat. Note
that there was a greater degree of dispersion of
atrial activation, 95 msec, in the echo beat seen
in panel C as compared to the echo beat in panel B,
85 msec. The reentrant beat also showed the general appearance of retrograde activation; however,
the degree of atrial dispersion is now only 85 msec
and reentrant rhythm spontaneously terminated.
Also note that the degree of dispersion of atrial
activation can appear on the surface ECG as well
although the interposition of P wave, ST, and T
waves may obscure this aspect. Thus, it can be seen
that with a high degree of dispersion, the P wave
is broadened with 95 msec of atrial dispersion as
compared to 85 msec. The P wave polarity remains
the same.
Dr. Alfred Pick was kind enough to bring to
our attention some suggestive evidence that atrial
dispersion does occur in patients under conditions
of compromised A-V conduction. In figure 6, taken
from Katz and Pick ( 4), it can be seen that during
retrograde Wenckebach cycles not only does the
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Fig. 5- Comparison between normal retrograde activation in the atrium and dispersion of atrial activation. Traces from above:
Lead II (L-2) of the ECG ; bipolar plunge wire electrograms from the high right atrium (HRA); the low right atrium (LRA) ; the His
bundle region (Hb) ; the coronary sinus ostium (CS); the inferior left atrium (ILA) ; and the posterior left atrium (PLA). A. During
ventricular pacing at 105 beats per minute retrograde conduction to the atrium indicates early activation of the low right atrium
and coronary sinus regions with activity proceeding to the high right atrium and posterior left atrium. The total atrial activation time
(AA) in each beat is 55 msec. PI = pacer impulse. B. Atrial premature stimuli (AP Stirn.) was applied to the heart after two simultaneous sinus beats (SB). The atrial premature beat (APB) is fo llowed by an echo beat (EB). Note the inverted P wave in lead II as
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well as the sequence of atrial activation (within the dotted rectangle) conforming to the general retrograde atrial activation pattern
as seen in panel A. However, atrial activation time was 85 msec, a 30 msec increase from that seen during normal retrograde atrial
activation. The small stimulus artifacts seen on the coronary sinus trace indicate the application of subthreshold epicardial stimulation
to parasympathetic nerve elements supplying the A-V node (Loc.Vag. Stirn.) (5). C. A short burst of reentrant rhythm is shown with
the introduction of an atrial premature stimulus which induces an atrial premature beat followed by an echo beat and another
spontaneous beat labelled REB or reentrant beat. The last two beats of this short run both show characteristics of retrograde atrial
activation; however, the echo beat now shows an atrial activation time of 95 msec followed by a reentrant beat with atrial activation
time of 85 msec. See text for discussion.

R-P interval lengthen, but also with this lengthening
there is a slight but appreciable broadening and
deeping of the retrograde P wave with the greatest
effect occurring prior to the reciprocal beat.
In summary, we have found a close association
between the stress of A-V nodal conduction and
the occurrence of atrial dispersion or aberration.
We could not explain atrial dispersion on the basis
of incomplete recovery of atrial activity, slowing
of atrial conduction, or the occurrence of atrial
fusion. We postulate that the phenomenon of dispersion of atrial activation is related to the functional dissociation within the A-V node seen during

situations which stress A-V conduction. This phenomenon may represent a mechanism whereby a
second area of "turnaround" other than the A-V
node is involved in reentry atrial tachyarrhythmias.
Indeed, such a mechanism could provide a physiological basis for the concept of the atrial bridge
being involved in supraventricular tachycardias and
reciprocal beating.

Authors' note: We thank Mrs. Marie Ellis for
her dedicated assistance in the preparation of this
manuscript.

B

Fig. 6-An electrocardiograph tracing taken from a patient showing a retrograde Wenckebach cycle ending in a reciprocal beat.
Note that with the progressive lengthening of the R-P interval, there is a broadening and deepening of the P wave (Reproduced with
permission from Katz, L. N. and Pick, A. Clinical Electrocardiography, Part I. " The Arrhythmias." Lea and Febiger, Philadelphia,
19 58, Chapt. 9, fig. 67).
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Some Mechanisms of Supraventricular Tachycardia*
GORDON MOE, M.D., Ph.D.
Director of Research, Masonic Medical Research Laboratory,
Utica, New York

Reciprocal rhythm was proposed about 30
years ago by Barker, Wilson, and Johnston as a
probable mechanism for the explanation of supraventricular tachycardia. They proposed, on the basis
of approximately 100 clinical records at the University of Michigan Hospital, that reentry through
the A-V node, better known as reciprocal tachycardia, would account for approximately 40% of
their cases. They also postulated that reentry
through the S-A node might account for another
40%, and that 20% were probably due to ectopic
foci. Ectopic focal activity is demonstrable in the
laboratory, and it probably happens in man. Reentry or reciprocal activity through the A-V node
can also be demonstrated, and it probably occurs in
man.
Wilson and collaborators based their conclusions upon the termination of supraventricular
tachycardia by brief periods of vagal stimulation
induced by carotid sinus pressure. The postulate
was that the effect of the vagus was to depress
transmission or even block it within one part of
the reentrant pathway. In those cases of reciprocal
tachycardia in which the P waves were inverted,
the postulate was that this was through the A-V
node, and, therefore, the effect of the vagus terminating the episode was due to depressed conductivity or block within the A-V node. In another 40%
in which the P waves were upright, the postulate
was that the sinus node was the site of reentry
and that the effect of vagal stimulation was to depress the conductivity in the sinus node. In others
who had bizarre P waves and were unresponsive

* This is a transcription, edited by Dr. Charles L.
Baird, Jr., of a lecture presented by Dr. Moe at the Symposium on Cardiac Arrhythmias, June 9, 1972, at Virginia
Beach, Virginia.
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to vagal stimulation, it was postulated that these
were in fact ectopic rhythms.
We have performed experiments through the
years and arrived at the conclusion (much later
than the clinical cardiologists) that dissociation can
occur in the node. Reciprocation could conceivably
be induced by premature stimulation of the atrium,
which Dr. Scherlag has already shown you, or it
could be induced by premature activity within the
ventricle. Dr. Scherlag and I have both emphasized
the use of a premature beat to initiate this kind
of activity. That is not as artificial as it might seem;
the only reason for introducing a premature beat, let
us say to induce atrial reciprocation or an atrial
echo, is to take advantage of the fact that during
the relatively refractory period potentially dissociable pathways will be dissociated.
It is also conceivable, as Dr. Moore told you,
to have concealed conduction. It is perfectly possible to have block below the site of the junction
of two dissociated pathways, so that an impulse
initiated in the atrium and returning to it fails to
reach the ventricle because of the depressed conductivity below that junction. A premature atrial
response which activates one pathway within the
node returns to the atrium over an alternate route,
reengages the first path within the node, and only
then reaches the ventricle. Thus, we can have an
impulse initiated within the atrium which takes, let
us say, the alpha pathway down to the junction of
the final common pathway which is still refractory
and therefore fails to conduct to the ventricle. It
nevertheless returns over the beta pathway of this
y-shaped structure, activates the atrium, and
reactivates the alpha pathway. By that time, the
lower nodal pathway has recovered, and it is perfectly possible to have a 2: 1 A-V block on the
basis of circus movement within the node. Thus,
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paroxysmal atrial tachycardia with block does not
exclude the possibility of circus activity.
I mentioned that Barker, Wilson, and Johnston proposed that some of these paroxysmal atrial
tachycardias may be due to reentry within the
sinus node. Dr. Han, in our laboratory, tackled this
rather difficult problem seeking to demonstrate
whether or not this was indeed possible. He explored the sinus node, rather laboriously, since this
is a relatively difficult area to study over an extended period of time. It is easy to get responses
from pacemaker cells within the sinus node, but
it is difficult to hold them for a long enough period
to get satisfactory evidence. At any rate, the technique here was to record an electrogram from atrial
tissue within an excised scrap of muscle and to
drive it for a time at a regular frequency, followed
by a premature stimulus. Obviously, if this premature
impulse is going to enter the sinus node and return,
it had to fail to activate some elements of the sinus
node; in other words, the one prime requisite for
reentrant activity is that there has to be block somewhere. In Dr. Han's experiments, entry into the
sinus node from the atrium and exit from the sinus
node to the atrium were clearly not at the same
sites . In other words, a loop was inscribed, and
this accounts for the reentry. This is a possibility
which was suggested by Dr. Hoffman about 15
years ago.
Atrial flutter has also been thought to be on the
basis of a self-sustained reentrant circuit. The experimental technique for inducing flutter in dogs
is first to crush an area of atrium in order to provide
a circuit of suitable dimensions. The most convenient
area lies between the superior vena cava and inferior vena cava. Thus, an obstacle is created which
includes the crushed, nonconducting atrial tissue,
plus the openings of the vena cava. Flutter can
then be induced by stimulating the atrium at a
rate more rapid than it can follow; in other words,
to induce by electrical stimulation a brief period
of atrial fibrillation. Upon terminating the stimulation, one of two things can happen-either the atria
will stop momentarily until the sinus node resumes

47
control of the activity or the atrial fibrillation will
be replaced by flutter movement.
One of the characteristics of flutter is that sometimes it appears to drift into a state of fibrillation
and back out. This has been taken as evidence that
the same fundamental mechanism is involved both
in flutter and in fibrillation, with the only difference
being the rate of discharge of an ectopic focus .
I think that one can · understand that if the rate
of discharge of an ectopic focus is sufficiently slow
so that adequate time for recovery (and adequate
does not need to be more than a few milliseconds)
from the refractory state occurs between events,
then the activation pattern of the atrium would be
relatively uniform, abnormal but uniform. If, however, that pacemaker were to accelerate to a point
where it impinged upon ihe refractory period of
some elements within the atrium and not ort others
(and we call upon biological nonhomogeneity of the
tissue to say that some elements may recover before others), then the activation pattern would
become grossly irregular. Let us suppose that you
have an impulse circulating around an obstacle,
and that the dimensions of the obstacle and the refractory period of the tissue are such that the
impulse is struggling to make it each time; that
is, it just barely clears the refractory period. Now
let us suppose we stimulate the vagus by carotid
sinus massage. We will abbreviate the refractory
period of atrial tissue which ought to inake it easier
for the circulating impulse to continue; it ought to
accelerate. But when the vagus is stimulated there
is hot a uniform abbreviation of refractory period.
The response is a spotty one because some fibers
are closer to vagal endings than others; the effect
of the vagus would be to abbreviate the refractory
period and facilitate conduction in some areas of
the circus loop, and to fail to affect it in others.
Transmission will accelerate in those parts of the
loop in which conduction is facilitated but will infringe upon fibers that are still totally refractory
and cannot participate. This will fractionate the
wave front and will generate fibrillation. This is the
textbook picture of conversion of atrial flutter to
fibillation by digitalis.

Ventricular Tachyarrhythmias*
BORYS SURAWICZ, M.D.
Professor of Medicine, Director of Cardiovascular Division,
University of Kentucky College of Medicine, Lexington, Kentucky

The mechanisms of ventricular tachyarrhythmias fall into two broad categories of increased
automaticity and reentry. It is usually difficult to
differentiate clinically between the two mechanisms; however, I plan to discuss certain approaches
that may be helpful in this regard.
Experimental evidence of increased automaticity in the isolated Purkinje fibers can be obtained
by placing cardiac tissue in a bath and adding epinephrine, isoproterenol, digitalis, or lowering the
potassium concentration in the bath. This suggests
that ventricular tachycardias precipitated by infusion of isoproterenol, excessive doses of digitalis,
or hypokalemia may be ascribed to increased automaticity. On the other hand, quinidine or hyperkalemia suppresses automaticity in isolated preparations, and therefore ventricular arrhythmias occurring in patients treated with excessive doses of quinidine or potassium are probably due to reentry rather
than to increased automaticity. This type of extrapolation from an experimental setup to a clinical
situation does not prove the mechanism but the
data may be used in support of a reasonably sound
working hypothesis.
The experimental evidence for reentry presented by Drs. Hoffman, Cranefield, Moe and others
in the isolated preparation appears soundly documented. Similar conclusions can be drawn from
experimental studies in the entire heart following
production of myocardial infarction in dogs (fig. 1).
Figure 1 shows the result of an experiment in which
electrograms are recorded from right atrium (AD),
right ventricle (VD), and left ventricle (VS) after
experimental occlusion of the left coronary artery
in a dog. In the infarcted area (VS) the conduction
is slow as evidenced by delayed onset and long

* Presented by Dr. Surawicz at the Symposium on Cardiac Arrhythmias, June 9, 1972, Virginia Beach, Virginia.
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duration of the QRS complex. This QRS complex is inscribed at the time when the recovery of
the noninfarcted area (QT interval in the right ventricle) is completed. Therefore, the extrasystole (Ex)
can be ascribed with reasonable certainty to the
reentry of the slowly propagating impulse from the
infarcted into the noninfarcted area.
Since most of our patients have closed chests,
we have no access to local electrograms, and we
must limit our analysis to the surface electrocardiogram. This may occasionally provide information concerning the mechanism of ectopic
beats which initiate ventricular tachycardias. There
are two types of ectopic beats-dependent and
independent. The dependent requires the presence of a preceding dominant pacemaker. Features that support a dependent mechanism are: 1)
fixed coupling; that is, the beats are coupled in a
fixed way to the preceding sinus beat, and 2)
predictable response to change in the rate of the
sinus pacemaker. For instance, when the cardiac
rate slows, the ectopic beats become less frequent
in response to carotid sinus stimulation (fig. 2),
but when the sinus rhythm accelerates, the number
of ectopic beats increases. Figure 3 illustrates
some of the possible explanations for the dependent
mechanism. The propagated impulse disturbs a
quiescent Purkinje fiber and induces diastolic depolarization (3B). Such a fiber would acquire pacemaker properties, and by firing before the next sinus
impulse, would produce a ventricular extrasystole
with a fixed coupling interval due to repetitive
firing. Another possibility of a repetitive firing is
shown in figure 3C. In this case the fiber has a
short refractory period as evidenced by short
duration of action potential. This fiber can be depolarized again by a current generated during repolarization. In this case reentry preceding a
closely coupled extrasystole is ascribed to nonMCV QUARTERLY 9(1): 48-5 2, 1973
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vs
100 ms
~

VD

Ex

AD

Fig. 1-Electrograms of a dog with experimental occlusion
of left coronary artery. (Reproduced by permission of L.
Baschieri, L. Palagi, and M. Puletti. "Experimental Study of
the Pathogenesis of Ventricular Extrasystolia." Cardiologia,
50:371, 1967. Explanation in text.)

homogeneous refractoriness. The third mechanism
which supports the dependent type, and which is
most commonly illustrated in textbooks, is the
mechanism whereby a particular fiber is bypassed
on the way to the ventricle (3D). In such a case
of a so-called unidirectional block, the bypassed
fiber does not fire during normal propagation of
an impulse but becomes depolarized when the impulse returns from another side and causes an ex-
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CAROTID

SINUS

trasystole. These are the three possibilities whose
occurrence may produce a ventricular extrasystole
of a dependent type.
An example of an independent mechanism
is a parasystole. How does one diagnose parasystole? Obviously, we look for evidence of variable
coupling, fusion beats, and a common denominator
indicating the assumed rate of firing of the independent, or "protected" pacemaker. When the
parasystolic impulses do not appear at the expected time, we postulate an exit block, or intermittence due to temporary loss of protection. When
application of carotid sinus stimulation suppresses the dominant pacemaker, the so-called
parasystolic focus will emerge undisturbed and fire
at the same rate as prior to the carotid sinus stimulation (fig. 4) .
In clinical practice, automaticity and reentry
can be occasionally distinguished on the basis of
response to treatment. For instance, treatment of
digitalis induced ectopic atrial tachycardia with
potassium demonstrates that the rate ,o f the ectopic
pacemaker gradually decreases. This would suggest
that the rate of diastolic depolarization is slowed
and that this type of arrhythmia is based upon
automaticity rather than reentry. We believe that
reentry would be more likely to cease rather abruptly and not by gradual slowing of the rate. This
is shown in figure 5. In this patient severe hyperkalemia produced ventricular flutter which did not
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Fig. 2-Continuous tracing of lead II of a 48-year-old man with rheumatic heart disease. Ventricular ectopic beats with fixed coupling
interval. After carotid sinus stimulation (lower tracing), the sinus rate is slower but the coupling interval remains unchanged and no
ventricular ectopic beats appear during long P-P intervals. (Reproduced by permission of B. Surawicz and M. G. MacDonald and the
American Journal of Cardiology, 13:199, 1964.)
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A.No ES

B. ES DUE TO DIASTOLIC DEPOL.
(REPETITIVE)

C.ES DUE TO RE-ENTRY (REPETITIVE)

D. ES DUE TO RE-ENTRY (UNIDIRECTIONAL BLOCK)

Fig. 3-Diagram representing 3 different mechanisms of dependent ventricular extrasystole originating in a Purkinje fiber marked by
asterisk. In A, the fiber is depolarized by the impulse spreading from the sinus node (black dot) and no extrasystole ensues. In B, the
sinus impulse enhances diastolic depolarization which causes repetitive firing. In C, the refractory period of the depolarized Purkinje
fibers is short, and the repolariz;ition is completed during ventricular repolarization (dashed action potential). In this case, reentry
may be due to potential difference between the ventricular fiber and the prematurely repolarized Purkinje fiber if these two fibers are
in close proximity to each other. In D, reentry is due to unidirectional block (see text).

C:S. STIMULATION

Fig. 4- Lead II of a 64-year-old laborer admitted to the hospital after an episode of syncope suffered on the street. Continuous strip
of a tracing recorded on admission. The range of R-R intervals in the entire tracing was 0.52 to 0.68 sec and of coupling intervals,
0.42 to 0.56 sec. The interectopic intervals are multiplicants of an interval ranging from 0.82 to 0.98 sec. After carotid sinus stimulation
(lower tracing), the sinus pacemaker is inhibited and the first and second ventricular ectopic beats appear before the first atrial deflection is recorded. The intervals between ventricular ectopic beats measure 0.98 sec and are constant. The P waves are apparent on
the descending limb of the T wave from the 2nd to the 8th ventricular ectopic beats but the corresponding atrial impulses are not
conducted to the ventricles. Note a fusion beat at the end of the lower strip. (Reproduced by permission of B. Surawicz and M. G.
MacDonald and the American Journal of Cardiology, 13:199, 1964.)
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There have been other methods for managing refractory ventricular tachycardia, such as aortocoronary bypass and resection of a ventricular
aneurysm. It is reasonable to conclude that the removal of dead myocardium with resultant disappearance of the arrhythmia suggests a reentry mechanism rather than increased automaticity. Finally, it
is conceivable that certain tachyarrhythmias may be
due to combinations of increased automaticity and
reentry, for example, repetitive reentry into a partially, or intermittently protected parasystolic focus.
In summary, there is well documented experimental evidence of both increased automaticity and
reentry in the experimental preparations. However,
in the clinical setup, the distinction between these
two mechanisms of ventricular tachyarrhythmia is
usually very difficult to determine. Certain diagnostic
clues can be obtained from the observations of the
dependence of the ectopic beats upon the preceding dominant impulses and from the responses to
therapeutic interventions.

respond to conventional treatment of hyperkalemia.
The administration of lidocaine terminated the flutter abruptly, and this would suggest that the origin
of arrhythmias is on the basis of reentry. Another
interesting clinical situation was that of a 42-yearold man with ventricular tachycardia complicated by
syncope and requiring repeated electrical defibrillation. This patient's particular tachyarrhythmia was
resistant to all forms of therapy with the exception
of fairly large amounts of procainamide. Thus,
it was decided to introduce a temporary ventricular
pacemaker catheter in order to convert his arrhythmia. When the patient developed ventricular
tachycardia, the first pacemaker stimulus fell upon
the refractory period, and the second one fell upon
the T wave and produced a fusion beat that resulted
in prompt reversion to sinus rhythm (fig. 6). It
is interesting to observe that the pacemaker rate
was slower than the rate of the ventricular tachycardia. This type of response suggests a reentry
mechanism rather than one based upon automaticity.
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Fig. 5- Abrupt termination of ventricular flutter after administration of lidocaine in a 15-year-old patient with hyperkalemia and
atrial flutter. Note the characteristic peaked T wave after termination of ventricular tachyarrhythmia. Lidocaine was administered
after the failure of conventional therapy with sodium bicarbonate, glucose and insulin.
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Fig. 6-Monitor lead of a 42-year-old man with ventricular tachycardia terminated by transvenous right ventricular pacing (see text).

Pharmacology of Antiarrhythmics: Quinidine,
Beta-Blockers, Diphenylhydantoin, Bretylium *
ALBERT J WASSERMAN, M.D.
Professor of Medicine, Chairman, Division of Clinical Pharmacology,
Medical College of Virginia, Health Sciences Division of Virginia
Commonwealth University, Richmond, Virginia

JACK D. PROCTOR, M.D.
Assistant Professor of Medicine, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University,
Richmond, Virginia

The electrophysiologic effects of the antiarrhythmic drugs, presented elsewhere in this symposium, form only one of the bases for the selection of a therapeutic agent in any given clinical
situation. The final choice depends at least on the
following factors:
1. The specific arrhythmia
2. Underlying heart disease, if any
3. The degree of compromise of the circulation, if any
4. The etiology of the arrhythmia
5. The efficacy of the drug for that arrhythmia
due to that etiology
6. The toxicity of the drug, especially in the
given patient with possible alterations in
volume of distribution, biotransformation,
and excretion
7. The electrophysiologic effects of the drug
8. The routes and frequency of administration
available for that drug
As no one drug meets, or even approaches,
the criteria for the ideal antiarrhythmic, a knowledge of several drugs is essential. Unfortunately,

* Presented by Dr. Wasserman at the Symposium on
Cardiac Arrhythmias, June 9, 1972, at Virginia Beach,
Virginia.
MCV QUARTERLY 9(1): 53- 64, 1973

adequate, controlled clinical comparisons are virtually nonexistent.
A complete presentation of the non-electrophysiologic pharmacology would include the following considerations:
1.
2.
3.
4.
5.
6.
7.
8.

Absorption and peak effect times
Biotransformation
Rate of elimination or half-life
Drug interactions
Toxicity
Clinical usefulness
Therapeutic drug levels
Dosage schedules

(t 1 1 ~ )

As all of the above data cannot be presented in
the limited space available, only selected items will
be discussed. Much of the preceding information
is available, however, in standard texts (17, 10).
(See Addendum 1)
Quinidine. Quinidine is principally transformed in the liver by hydroxylation, but some 1050% is excreted unchanged in the urine. This variation in the quantity excreted in the urine is of
considerable importance, and it is influenced by
both glomerular filtration and by urine pH.
Bellet et al. ( 3) measured the serum levels
of quinidine in three groups of ten subjects after
600 mg of oral quinidine. Normal subjects had, af53
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ter two hours, significantly lower serum quinidine
levels than the subjects with congestive heart failure
( creatinine clearances of 35-80 ml per minute), or
the subjects with renal disease and azotemia. While
this study does not consider alterations in the volume
of distribution, liver function, and so forth, the correlation between the peak level of quinidine and
the rate of fall of the serum levels with glomerular
filtration is evident. Thus, we must consider renal
function much in the same way as when we use
digoxin.
In addition to renal function, the pH of the
urine is important in the excretion of quinidine. As
urine pH rises, more of the urinary tubular quinidine
is nonionized and, hence, more readily passes across
the tubular epithelium, thus decreasing the quantity
of filtered quinidine excreted in the urine.
Figure 1 is taken from the study of Gerhardt et al.
(9). In normal subjects, urine pH was raised
by administering acetazolamide and sodium bicarbonate. As shown, serum quinidine levels rise as urine pH increases and, furthermore, the pharmacologic significance of the higher serum quinidine
levels is indicated by progressive increase in the QT interval.
Molar sodium lactate has been recommended as

a means of treating the arrhythmic abnormalities associated with quinidine toxicity. While such alkalizing therapy may improve the arrhythmias, it surely
will also delay the excretion of quinidine and
might prolong the duration of the toxicity. Also a
large segment of the population has been consuming a very effective urinary acidifier, ascorbic acid, in
a huge dose. The doses of quinidine needed to establish an antiarrhythmic effect might be titrated
in such an individual, who then discontinues the
ascorbic acid. A considerable increase in serum
quinidine could occur with a significant chance of
serious toxicity.
Thus the physician must consider glomerular
filtration rate and urine pH when prescribing quinidine. Alterations in liver function and the apparent
volume of distribution are probably also important
but less quantifiable.
The serum half-life (t 112 ) is known for all of
the available antiarrhythmic drugs, and this simplified concept is useful in understanding the necessity
for loading doses, the frequency of dosing, the duration of toxicity, and the timing of clinical observations of the patient.
The serum half-life is defined as the time required to reduce the serum level of a drug to one-
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heart rate (expression of quinidine effect), plotted relative to urine pH, for two subjects. (Reproduced by permission of Annals of
Internal Medicine, 71 :929, 1969, and R. E. Gerhardt).
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half its initial level. As the great majority of drugs
follow first-order kinetics (the amount eliminated
is proportional to the qµantity pres~nt), the following "rules" of half-life are widely applicable:
1. The serum half-life is independent of the

quantity of drug present. In figure 2, the
disappearance curve declines 50% each
half-life, decreasing from 100% to 50%
the first half-life, from 50% to 25% the
second half-life, and so forth.
2. The half-life concept is independent of the
mechanism of elimination; urinary or intestinal excretion, hepatic transformation, and
so forth.
3. The dosing interval must be shorter than
the half-life to avoid wide fluctuations in
serum levels and body stores of a drug.
4. Essentially complete elimination of a drug
is achieved after five half-lives and conversely, with regular dosing, at frequencies
of the half-life, or more often, equilibrium
levels are achieved after five half-lives (see
accumulation curve) . After 3.3 half-lives,
90% of equilibrium levels are achieved. This
would then be an appropriate time to make
clinical observations on the pharmacologic
effects of the drµg.
For quinidine, the half-life is about 4-6 hours.
Doctors Richardson, Zee, and Wyso (21) from our
institution reported on studies in which quinidine
was given at 9 A.M., 1, 5, and 9 P.M. While the serum
levels before the next day's dose were still adequate,
they were achieved at the expense of excessive
levels one and one-half hours after the 9 P.M. dose.
A six-hour schedule would have avoided the potentially toxic levels at bedtime.
In a study to be described further , below,
Bloomfield et al. (7) gave patients quinidine 300
mg at 0, 3, and 6 hours, as a loading attempt and
then gave 300 mg every 6 hours thereafter. Fig-
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ure 3 shows that the serum concentrations did not
reach equilibrium levels until after 24 hours, in
keeping with the principles noted above.
In summary, application of the rules of t 112
to quinidine suggests that where prompt action is
needed, a loading dose should be given and that
quinidine should be given every six hours to avoid
peaks and troughs of serum levels and associated
toxicity and subtherapeutic concentrations.
"Quinidine Syncope" is the name employed
by Selzer and Wray (23) to describe recurrent
ventricular fibrillation, usually self-terminating, seen
in patients treated with quinidine. It usually occurs
after the first few doses, and it may be noted in
patients with normal or even low serum quinidine
levels. While tachyarrhythmias and ventricular fibrillation are well-known toxic effects of quinidine, these
individuals seem to be unusually susceptible to this
serious adverse effect. While most patients receiving
quinidine have underlying heart disease, quinidine
syncope can occur in patients with no detectable
organic heart disorder.
Some clinicians are attempting close monitoring
of patients during the initiation of quinidine therapy.
The effectiveness of such monitoring will be difficult to assess because of the infrequency of this syndrome. Selzer and Wray estimated that 3-5% of
patients treated with quinidine may develop this
idiosyncratic toxicity, but Bjerkelund (6) reported
only 1+% and Lown (16) reported only 0.5%
sudden deaths in his series of 650 patients.
Finally, in regard to quinidine, some note of
its efficacy need be made. Bloomfield et al. (7) studied 53 patients with acute myocardial infarction in a
placebo controlled, randomly allocated prospective

ACCVMULATION (FIXED O&ILY COS E)
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I NO DAILY DOSE)
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Fig. 2-The accumulation and disappearance of a drug is
depicted in terms of its half-life.

Fig. 3-Blood quinidine concentrations at various intervals
during five days of prophylactic quinidine ther11py in 27
patients with acute myocardial infarction. (Reproduced by
permission of the New England Journal of Medicine, 285 :
981, 1971, and S.S. Bloomfield).
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trial of oral quinidine ( vide supra). Because of the
lag in achieving therapeutic serum quinidine levels,
there was no difference between the treated and
placebo groups in the first six hours, but thereafter
(see fig. 4), there was a statistically significant reduction in premature ventricular and supraventricular contractions and in "serious ventricular arrhythmias." As has also been true of the studies of other
antiarrhythmics in acute myocardial infarction, there
was no difference in mortality between the treated
and control groups.
Beta Adrenerglc Receptor Blockers. The serum half-life of oral propranolol (Inderal®) is 3-4
hours. Successful management with less frequent
dosing intervals is likely due to the fact that the
large doses used result in blood levels which remain
above the therapeutic level for a longer period of
time.
The major concern in beta-blocker therapy is
the marked cardiovascular depression which these
agents induce. In three separate series of dogs, we
(19) determined the mean doses of three antiarrhythmic drugs required to convert ouabain (a cardiac glycoside)-induced ventricular tachycardia to
normal sinus rhythm. Alprenolol is an effective
beta-blocker, the dose of which (intravenously)
does not differ from propranolol. These doses of the
three antiarrhythmics were then studied in a new

series of paced, open chest dogs, and the electrocardiographic and hemodynamic effects of these drugs
given in "equi-antiarrhythmic" doses are depicted
in figure 5. The beta-blocker significantly prolonged the P-R and Q-T intervals and depressed
blood pressure, cardiac output (aortic flow via an
electromagnetic flow transducer), and left ventricular contractility ( dp/ dt, peak left ventricular
rate of pressure rise) . Directionally similar but less
marked alterations occurred with procainamide, while
diphenylhydantoin did not affect these or any of
the other measured cardiovascular functions. Betablockers are, therefore, the most likely of the antiarrhythmics to induce cardiac depression, and even in
low doses, a worsening of heart failure or the precipitation of pulmonary edema may result. While it
is true that the correction of an arrhythmia by the
beta-blocker may so improve the heart's overall
function as to counteract any direct myocardial depression, such therapy is fraught with the danger that
should the beta-blocker not affect the arrhythmia,
its negative inotropic action will still be manifest.
Except where an arrhythmia is caused by
adrenergic mechanisms, beta-blockers are best
avoided in patients with myocardial disease unless
other therapy has failed and the situation is desperate.
Diphenylhydantoin. Diphenylhydantoin (DPH) is
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Fig. 5-The responses to equi-antiarrhythmic doses of
alprenolol, diphenylhydantoin, and procainamide are shown.
Statistically significant (P < .05) changes from control are
indicated. (Reproduced by permission of Archives Internationales de Pharmacodynamie et de T herapie, 190:354,
1971, and J. D . Proctor) .
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of particular interest. The differences in its electfophysiologic effects have already been noted elsewhere. Also, any consideration of DPH must include
information about its pharmacokinetics and blotransformation.
Diphenylhydantoin is slowly absorbed by
mouth , peak levels not being achieved for hours.
This drug should not be given intramuscularly sirlce
its absorption is erratic. Even intravenously, DPH
effect requires 1-5 minutes, and rapid (bolus) injections must be avoided.
The biotransformation of DPH is shown in figure 6. Diphenylhydantoin is parahydroxylated by
oxidizing enzymes in the liver microsomes, converting DPH to HPPH (hydroxyphenyl, phenylhydantoin or 5 phenyl 5'parahydroxyphenylhydantoin) .
It is this enzyme which is so susceptible to both enzyme inhibition and enzyme induction, accoundng
for the large number of reported DPH drug interactions (see addendum 2). Hydroxyphenyl, phenylhydantoin, the inactive metabolite, is conjugated with
glucuronide, and its excretion in the urine normally
accounts for about 75 % of the elimination of
DPH. Letteri et al. (15) have found that patients
with uremia have lower serum levels of DPH than
do normal subjects receiving the same dose, tlnd
that furthermore, the t 112 in uremia is shorter (mbre
rapid DPH disappearance) . This, of course, is quite
the opposite from most drugs where renal failure
results in higher serum levels and longer t112 . The
mechanism whereby lower DPH levels are seen in
uremia has not been completely elucidated, but
several possible mechanisms have beetl suggested.
It is known that HPPH levels are higher in uremic
patients. It might be that something in the uremic
state induces the parahydroxylating enzyme, hence
more rapidly converting DPH to HPPH, or it may be
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Fig. 6-Major route of metabolism of DPH. (Reproduced
by permission of the New England Journal of Medicine,
285 : 651, and Joseph M. Letteri) .

57

that the renal failure blocks the excretion of HPPH
which competes with DPH for serum protein binding
sites (see fig. 6) . The unbound, free DPH would
be more accessible to enzymatic conversion to
HPPH and also more accessible to its receptor site.
Thus, while total DPH would be reduced, the free
(active) portion might be normal. Finally, it is
known that serum protein binding is altered in uremia and this, too, could account for the lower total
DPH and its more rapid conversion to HPPH due to
more of the serum DPH existing in the free, unbound form.
The clinical role of DPH is receiving more
attention. Lown and Wolf (16) report studies in
which ventricular fibrillation was induced in dogs
by occluding, and if necessary, later releasing the
occlusion, of the anterior descending coronary artery. About 75% of untreated dogs developed ventricular fibrillation, and pretreatment with DPH
had no effect. On the other hand, pretreatment with
procainamide reduced the incidence of ventricular
fibrillation to about 20%; quinidine, lidocaine,
practolol (a beta-blocker), and bretylium tosylate
reduced it to about 3 5 % ; and dextro-propranolol and
ajmaline reduced ventricular fibrillation to about
50%.
Last year an Australian cooperative group reported a clinical trial of DPH prophylaxis in patients
discharged from the hospital after their first acute
myocardial infarction (8). Diphenylhydantoin, 300400 mg per day, was given to 283 patients while the
control group received 3-4 mg per day. Although
the high dose DPH group had less palpitations and
less documented arrhythmias than the control group,
survival was unaffected.
Mercer and Osborne (18) in 1967, noted that
the etiology of the arrhythmia was a significant factor in predicting its response to DPH. Where the
arrhythmia was due to digitalis intoxication, onehalf of the patients were successfully managed with
DPH, but where the arrhythmia was due to coronary heart disease, only about one-fourth responded. (These percentages may not represent
the maximum efficacy of DPH as the dosage schedules suggested below were not employed.)
From these data, it would appear that digitalis
intoxication is the prime indication for DPH and
that its usefulness in coronary heart disease is likely
to be limited.
The effective serum concentration of DPH was

WASSERMAN AND PROCTOR: PHARMACOLOGY OF ANTIARRHYTHMICS

58

establisped by the elegant studies of Bigger and
his colleagues (5) (fig. 7). These data indicate an
effective level of about 6-18 µg per ml, the same
range ~s that established for anti-convulsant efficacy
(10-20 µg per ml).
Diphenylhydantoin does not follow first-order
kinetics as even usual doses approach saturation of
the parahydroxylating enzyme system. Thus, the
"rules" of half-life do not, strictly speaking, apply
to DPH. In the effective serum level range, however, DPH serum levels decline by one-half over
18-24 hours. It is evident then, that without a loading dose, several days will be needed to achieve
equilibrium levels. Kutt and McDowell ( 14) and
Bigger et al. ( 5) have recommended the following
dose schedule for prompt DPH effect :
Day
1
2
3
Thereafter

Dose (mg)
1,000
500-600
500-600
400-500

Where urgent indications exist, DPH may be
given intravenously, 50-100 mg at 5 minute intervals
until a therapeutic effect, a toxic effect, or 1,000 mg
is given (5) . If less than 1,000 mg is given IV, the

NUMBER OF
PATIENTS

PLASMA DPH LEVEL (,ug/ml)

Fig. 7-Plasma levels at which ventricular arrhythmias
were abolished. Plasma DPH concentrations are plotted
on the abscissa. The number of patients whose arrhythmia
was abolished in each range of plasma level is represented
on the ordinate as unfilled bars. The one patient whose
arrhythmia was unaffected by DPH is represented by the
filled bar; this unresponsive arrhythmia was a typical ventricular parasystole. Seventy percent of the conversions occurred at plasma concentrations between 1O and 18
µg/ml. Only one patient required a plasma concentration
above 18 µg / ml before conversion occurred. (Reproduced
by permission of the American Heart Association from
Circulation, 38 :367, 1968, and J . T. Bigger, Jr.).

rest of the loading dose may be given slowly IV
or orally over the next 6-18 hours . Where less
urgency exists, the 1,000 mg should be given orally
over 6-18 hours.
One last point needs to be made in regard to
DPH. This is one of the very few currently available drugs for which generic non-equivalence exists.
(Digoxin is the other important example.) Generic
brands of DPH have been shown to result in higher
serum levels than the first marketed product, Dilantin®. An "epidemic" of DPH toxicity occurred
when the source of supply of DPH was changed to
a generic product and its greater bioavailability resulted in toxic effects in previously stable patients
with convulsive disorders (25). Patients on DPH
should receive a single manufacturer's product.
Bretylium Tosyl;ite. Bretylium tosylate, BT, is
a drug of considerable current interest. It is available only on an investigational basis, viz., it is not
approved for marketing in this country.
Much of the action of bretylium can be understood in light of its effects on the sympathetic neuron. Norepinephrine is present in the terminal sympathetic neurons in two pools, a larger storage pool
and a smaller labile pool. Bretylium tosylate does
not affect the former, but its acute administration
causes a sudden release of norepinephrine from
the latter. This release of norepinephrine accounts
for a number of the early effects of parenterally
administered BT, such as the early transient hypertension, enhanced automaticity, and increased conduction velocity. The initial positive inotropic effect
(increased myocardial contractility) is largely, if not
totally due to this norepinephrine release. Chronic
bretylium therapy does, however, cause a supersensitivity to circulating and infused epinephrine
and norepinephrine since BT blocks the sympathetic neuronal uptake of these catecholamines,
the major route of modulating the catecholaminereceptor action. This same uptake mechanism also
accounts for a number of bretylium drug interactions as BT competes with tyramine, amphetamines,
and metaraminol (Aramine®) for uptake. The tricyclic anti-depressants also block BT uptake and
antagonize its effect, as they do, too, for guanethidine (Ismelin®).
Bretylium is excreted unchanged in the urine.
Its serum half-life is unclear. Kuntzman et al. (13)
studied four normal subjects and found a nonexponential decline of serum levels with the rate of
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disappearance quite rapid early ( t 112 = ± 1 hour)
and somewhat slower later (t1 ; 2 = ± 5 hours). Romhilt and associates (22), using the serum method
established by Kuntzman, studied eight patients.
They found an exponential decline of serum levels
with a tu.2 = 10 hours (fig. 8). There was no apparent
relationship between the t 112 and the levels of
BUN in this latter study, and personal communication failed to resolve this discrepancy. The t 11 2
value for bretylium tosylate may not be critical,
however, since, as shown in figure 8, there is a
temporal disparity between the serum levels and
the antiarrhythmic efficacy. Bretylium tosylate
may, therefore, be one of the so-called "hit-and-run"
drugs (12). On the other hand, there appears to be
an excellent correlation between the hypotensive
effects and the serum levels of this "peripheral
sympathetic blocker." This temporal dispersion of
hypotensive and antiarrhythmic action prompted
these authors (22) to suggest that BT's antiarrhythmic effect may not be related to its action on the
sympathetic neuron.
There are both animal and human data to suggest that other antiarrhythmic drugs antagonize the
effects of bretylium. Bernstein and Koch-Weser (4)
found that patients concurrently receiving other
antiarrhythmic drugs were less likely to respond to
BT, confirming the observations of Bacaner (2) in
experimental animals. Therefore, it would appear
wise to discontinue all other antiarrhythmics when
initiating bretylium therapy.
Bernstein and Koch-Weser (4) noted the following incidence of adverse effects:
Side Effects of Short-Term Bretylium Therapy in
30 Patients
%
Hypo tension
63
Hypertension
17
Initial increase in arrhythmias
13
Nausea or vomiting
10
Involuntary head movements
3
Headache
3
In only one of the 19 patients with hypotension
did the decline in blood pressure exceed 20 mm Hg.
As these patients were recumbent and as the hypotensive effect of BT is largely orthostatic, such results could be anticipated ( vide infra). Transient
hypertension and transient enhanced automaticity
(increase in arrhythmias) were surely related to

the initial release of norepinephrine. Nausea and
vomiting are rare with intramuscular administration, but common if bretylium is given intravenously.
Chronic oral administration commonly produces
severe, persistent parotid pain during mastication.
This pain is of sufficient magnitude to be the major
cause for discontinuing chronic oral therapy. Postural hypotension is a problem early, but tolerance to
this action develops fairly promptly.
The clinical role of bretylium is still unclear, but
the drug may find a place in the management of
recurrent severe ventricular tachyarrhythmias, viz.,
ventricular tachycardia, and ventricular fibrillation.
Bacaner reviewed 250 reported cases of ventricular tachyarrhythmias ( 1). Eighty-five percent re-
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Fig. 8-Comparison of the onset and duration of action
of bretylium, 4 mg/ kg, on PVC frequency and arterial
pressure in relation to blood levels. On the average, hypotensive effect was present in the first hour, when mean
plasma concentration of bretylium was at its peak, and
continued until the ninth hour after administration. By
contrast 50% suppression of mean PVC frequency began
at the sixth hour and continued until the 18th hour. The
mean elimination half-life of bretylium was about 10
hours. N refers to number of patients. ( Reproduced by
permission of the American Heart Association from Circulation, 45 : 804, 1972, and D. W. Romhilt ) .
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sponded favorably. Romhilt et al. (22) continuously
monitored eight patients with frequent premature
ventricular contractions (fig. 9) . The effectiveness
of bretylium tosylate, 4 mg per kg intramuscularly, is
evident after a six-hour lag. Bernstein and KochWeser (4) found an excellent response in 18 of
30 patients with ventricular tachycardia unresponsive to other drugs. Five patients had a partial response and in seven, no response was evident.
Those failing to respond were more often receiving
other antiarrhythmic drugs concurrently and were
more likely to have had the arrhythmia for a longer
period of time. These authors rightly caution against
an over zealous interpretation of these data, noting
that had these patients been first treated with bretylium, the failures could well have responded to
whatever the second drug might have been.
One negative report is noteworthy. Taylor
et al. ( 24) studied 101 patients during acute myocardial infarction. Sixty-three patients received
bretylium, 300 mg IM every 6 hours. In 25 of
the 63, therapy was discontinued because of adverse effects, four due to nausea and vomiting and
21 due to hypotension. In these 21 patients, blood
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Fig. 9-Mean PVC frequency during treatment days compared with control days. There was 50 % supression of
mean PVC frequency in the second and third 6-hour intervals following bretylium 4 mg/ kg (solid bars) , while no
suppression was seen after 2 mg/ kg (shaded bars). Control
days are shown in stippled bars. N refers to number of
patients. On day 1, data were not obtained in one patient
during the first 12 hours due to recording-equipment failure.
(Reproduced by permission of the American Heart Association from Circulation, 45:805, 1972, and D. W. Romhilt).

pressure averaged 65 / 40 mm Hg, a marked degree
of hypotension for patients with acute infarction. It
is likely that the unstable state of the circulation in
such patients and their use of bedside commodes,
thus enhancing orthostasis, accounts for the strikingly
higher incidence of significant degrees of hypotension than those noted in the table above. Furthermore,
among those who continued BT therapy, there was
no decrease in ventricular arrhythmias. Supraventricular arrhythmias, however, were less in the
treated group. Again, one patient died in each of the
treated and control groups.
Finally, the role of bretylium tosylate in the
management of digitalis-induced ventricular tachyarrhythmias should be considered. Our group (20)
infused ouabain in a group of ten dogs. In half, the
ouabain was continued until stable ventricular tachycardia was established. Bretylium was then given in
incremental doses, beginning with 5 mg per kg and
increasing to 40 mg per kg total dose. In every dog,
the ventricular tachycardia not only persisted, but
indeed, the ventricular rate accelerated. Furthermore, when the ouabain infusion was stopped at
the time frequent ventricular premature contractions had occurred, bretylium, in each of the five
dogs, promptly induced ventricular tachycardia (fig.
10). This augmentation of automaticity by BT was
also noted by Kleiger and Shander (11) . They produced ventricular tachycardia in dogs with acetylstrophanthidin (another cardiac glycoside). When
the tachycardia had subsided spontaneously after
cessation of the glycoside, they administered bretylium and a recurrence of the ventricular tachycardia
ensued. Both of these animal studies were completed before the time of maximal antiarrhythmic
efficacy of BT, but they indicate the potential danger during the period of initiation of such therapy.
In conclusion, time and space have not allowed a classical pharmacological discussion of these
four important antiarrhythmic drugs. In order to
use a drug rationally so as to obtain a maximum
efficacy: toxicity ratio, one must understand the
drug's absorption, its route and mechanism of biotransformation, and its effective half-life. Such data
are available for the antiarrhythmic drugs.
Where the achievement of one's therapeutic
goal is so readily measurable, as it is with antiarrhythmic drugs, we must demand of ourselves a
more knowledgeable and rational therapeutic approach.
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PANEL DISCUSSION

Dr. Surawicz: I use quinidine less, and some people
have stopped using it. This is actually the only true
antiarrhythmic drug because it is the only drug that
will reasonably consistently convert atrial fibrillation to sinus rhythm. As Dr. Hoffman pointed out, its

effect on conduction would have predictable effects
on the electrocardiogram in terms of prolongation
of the QRS complex and the P-R interval, and
with increasing concentration of the drug, which is
increasing the dose, we have evidence of increasing

Addendum l
ANTIARRHYTHMIC DRUGS
EFFECT OF DRUG ON HEART

Name of Drug

Automaticity
Atrium
Ventricle

Conduction
Velocity

Quinidine

0

Propranolol
(Inderal®)

Therapeutic
Plasma Levels
µg / ml

3-6

1

i

Vagolytic

4-8

1

0

1

0

0

2-5

1

1

1

H

Beta-adrenergic
Blocking

.05-.15

0

0

6-18

i

Initialj

Autonomic
Effects
Vagolytic

Diphenylhydantoin
(Dilan tin ®l

Bretylium
(Daren thin ®l

Inotropic
State

i

Procainamide
(Pronestyl ®)
Lidocaine
(Xylocaine ®l

Refractory
Period

Initialj
thenl(?)

Initialj
then 0

Initial1
thenj

lnitialj

NE Release
Followed by
Sympath Block
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prolongation of P-R and QRS intervals. This is a
dose related toxicity that we can avoid by keeping
our doses down. Dr. Wasserman discussed the quinidine induced ventricular fibrillation and pointed out
that this is not necessarily a dose related effect.
This occurs when the concentrations are therapeutic
and the QRS interval is not widened and the P-R
is not prolonged. Therefore, we have no warning,
and that is much more frightening because this
cannot be avoided. Now, does that mean that we
should stop using quinidine? I, of course, asked
that question and observed some quinidine syncope,
the same kind of record as was shown from Dr.
Seizer's and Dr. Wray's paper. Then I reviewed all
available data on quinidine toxicity and came to
the conclusion that all published reports that I
have been able to review showed three things:
first, all people had severe heart disease; second,
all people were treated with digitalis; and third, in
spite of quinidine syncope not being dose related,
they all received more than 1.2 g of quinidine per
day. I concluded that I have not had any evidence
that lower doses will induce fibrillation. On that
basis I still use quinidine, and I wonder whether you
would like to comment on that.
Dr. Wasserman: Yes. In some of the cases it is clear
that preceding the fibrillation there was prolongation
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of the Q-T interval; thus, whether or not this is
predictable in the majority of cases, I do not know.
It certainly would be in some, and it is for this
reason that we are monitoring. I can tell you about
a case in which a young lady who had no heart
disease whatsoever was erroneously treated for
VPC's which I am sure in retrospect were due to
alcoholism. In the absence of digitalis and with
standard doses she developed this syndrome. She
was shocked 20 or 30 times with typical findings.
We did not have a quinidine level in her, but her
renal function was normal, her heart was normal,
and we simply stopped the drug. Within the usual
six hour period, actually four hours, she stopped
having ectopic activity and stopped her recurrent
bouts of ventricular fibrillation. Subsequently, we
have found normal and even low levels of serum
quinidine in patients exhibiting quinidine syncope,
including cases where syncope followed a single
usual initial dose of quinidine.
Questioner: Did your alcoholic patient have hypokalemia?
Dr. Wasserman: No, she did not. As a matter of
fact, she came in with pelvic inflammatory disease
but unfortunately was seen by a medical intern who
was certain that he knew how to take care of her
Dosage

Plasma
Half-Life
t I/ 2

p.o.

i.v.

Renal ID-50 3
(lif iurine pH)
Liver

4- 6 hr.

2- 4 hr.

5 min.

0 .4 x 1;
0.2- 0.4q
6 hr.

25 / min. to
1000

"Syncope"; Sho~k ; Hemolysis;
Thrombocytopenia; G-I Sx;
Paralysis; Cinchonism

llenal 60 3
(lif i urine pH)

3- 4 hr.

1 hr.

Stat

1.0 x 1;
0 . 5q 3 hr.

50 / min. to
1-2,000

Lupus; Shock; ? Syncope-;
Agranulocytosis; G-I Sx;
Psychosis; Paralysis

Liver

2 hr.

50-100 Stat
1-4 / min.

Twitching, Seizures;
CNS Depression; Shock

Liver

±3 hr.

few hrs.

10 min.

.04 x 1;
.Ol-.03q
6 hr. ?

0.1/min. to Heart failure; Bronchospasm;
IQ
Hypoglycemic Unresponsiveness;
Rash; G-1 Sx

Liver

18-24hr.
average

1- 2 hr.

5 min.

1.0 first day
0.5 next day
then 0.4 / day

50-lOOmg
5/ min. to
1,000

Renal

±10 hr.

hrs.

15 min.

.3-.6q
8-12 hr.

4-5 mg / Kg Initial Tachycardia;
Postural Hypotension;
Parotid pain;
Vomiting l.V.

Biotransformation

Peak Effect Time
p.o.
(gm)

Stat

I.V.

lmg)

Adverse Effects
(See Heart Effects)

Ataxia ; Sedation; Gums;
Lymphoma: Lupus; Rash;
Folate Def; Hepatitis;
Osteomalacia; Thyroiditis
Nystagmus
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Addendum 2

DIPHENYLHYDANTOIN DRUG INTERACTIONS
J.

DRUGS LEADING TO INCREASED DPH EFFECT AND TOXICITY
MEC HANISM

DRUGS

A. Bishydroxycoumarin (Dicumarol ®)
B. Disulfiram (Antabuse®)
C. Isoniazid
slow-inactivators
D . PAS

Inhibition of liver metabolism
Inhibition of liver metabolism
Not definite- probably inhibition of liver
metabolism
Unknown- Possibly due to its increased
blood levels of concommitant INH
Binding displacement of DPH
Inhibition of liver metabolism
Unknown

E. Phenylbutazone (Butazolidin ®)
F. Phenyramidol (Analexin ®)
G. Sulfaphenazole (Sulfabid ®)
and Sulthiame (Ospolot®)
H . Salicylates
I. Chloramphenicol
J. Benzodiazepines
K . Methylphenidate (Ritalin ®)
II.

Binding displacement of DPH
Inhibition of liver metabolism
Unknown
Not definite- probably inhibition of liver
metabolism

DRUGS LEADING TO DECREASED DPH EFFECT AND TOXICITY

A. Phenobarbital
B. Amphetamines
C. Alcohol
III.

Increased hepatic microsomal metabolism
Decreased absorption of DPH
Increased liver metabolism of DPH

DPH'S EFFECT ON OTHER DRUGS
DRUGS

A.
B.
C.
D.

Coumarin Anticoagulants
Corticosteroids
Methotrexate
Vitamin D

EFFECT

MECHANISM

Enhancement
Inhibition
Enhancement
Inhibition

Not definite-probably binding displacement
Increased microsomal metabolism
Binding displacement
Increased liver metabolism of Vit. D

VPC's. Of course when she developed the first
episode of ventricular fibrillation, he concluded that
he simply had not given her enough. She received
two doses of quinidine, but that was all.
Dr. Dreifus: I too use quinidine. I just want to
mention two things. The first point Dr. Surawicz
already inferred was low potassium, and this seems
to be one of the settings in which I have seen this
repetitive ventricular tachycardia with quinidine
and with other antiarrhythmic drugs that prolong
Q-T intervals. The second point, which is much more
serious, is acute coronary insufficiency with very
long Q-T intervals. It is usually seen on the basis
of sinus bradycardia. These patients do worse with
quinidine or procainamide because you may move
the premature systole into the long Q-T interval.
The VPC will bisect the T wave, and then ventricular fibrillation or runs of ventricular tachycardia
occur. Actually, the only way to deal with such
patients is to pace them. The reason I wanted to
mention this is, if patients at high risk were on a
prophylactic agent and quinidine or a congener
of quinidine was one on these agents, the patients

who were tending to develop long Q-T intervals with
their bouts of coronary insufficiency might be more
vulnerable to sudden death. This is a very serious
problem, and I think when you use quinidine you
have to take all these facts into consideration if
you want to avoid mistakes.
Dr. Dreifus: I would like to ask Dr. Wasserman if
he feels that bretylium has any membrane effects
as an antiarrhythmic agent.
Dr. Wasserman: Yes. The problem of course has
been to forget the initial articles, all of which were
merely reflecting the release norepinephrine. I
think it is quite clear that it does have direct myocardial effects. It certainly does so in the absence
of norepinephrine depleted by pretreatment reserpine or guanethidine, and it has effects which
differ from guanethidine in terms of the ventricular
fibrillation threshold which suggests that it is not
simply the depletion of catecholamines. Thus, I
think it clearly must have some effect. I think
its role is not yet clear, and I think we need to
know more about it before we can use it wisely.
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Both procainamide and lidocaine are useful for
acutely treating cardiac arrhythmias, and procainamide can be useful in chronic antiarrhythmic regimens. Successful management of cardiac arrhythmias
requires knowledge of: 1) the mechanism and natural history of the arrhythmia, 2) the physiologic
state of the patient, and 3) the cardiac effects, pharmacodynamics, and general pharmacology of the
antiarrhythmic drugs.
Although often done, it is foolhardy to undertake treatment of a cardiac arrhythmia without a
precise diagnosis. The rationalization for such an undertaking frequently is that, no matter which of several possible arrhythmias is at hand, the treatment to
be initiated would be beneficial or at least not harmful
for any. This rationalization is often invoked to avoid
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from the National Heart and Lung Institute ( l-K04-HL70204) ; this work was begun during his tenure as Senior
Investigator, New York Heart Association .
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was a National Hea rt and Lung Institute Trainee, Grant
5-T !2-HL-05864.
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the considerable effort which may be required in order to precisely diagnose the nature of the arrhythmia. There are many specific cases where one not
only treats a harmless arrhythmia, or, by not making
a diagnosis, fails to use the correct therapy, but also
employs a therapy which is actually harmful. Figure
1 shows an example of unnecessary therapy on the
basis of an error in diagnosis. This patient had occasional ventricular premature depolarizations (VPD's) .
The VPD's were often followed by an aberrantly
conducted beat of supraventricular origin. These
couplets of wide QRS's were incorrectly considered
to be salvos of VPD's and were treated with lidocaine. In fact, the patient had no indication for antiarrhythmic drug therapy at all. As luck would have
it, lidocaine caused undesirable central nervous system effects in this patient. As mentioned above, therapy may be not only inappropriate but also damaging. For example, patients with atrial flutter with
variable A-V conduction not infrequently show wide
aberrant beats. In intensive care units, these are often
mistakenly called VPD's. The fact that a non-standard bipolar chest lead is used for monitoring may
obscure the fact that the beat has a RBBB configuration, a finding which might lead the physician to
suspect aberrant conduction. Also, treatment may be
initiated on the basis of observation of the rhythm
on the oscilloscope screen. Thus, the physician may
overlook the typical group beating of the Gouaux65
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Fig. 1- Incorrect interpretation of rhythm leading to unnecessary therapy. The upper panel shows lead I of the ECG which was
incorrectly interpreted as salvos of VPD's, and on this basis lidocaine was begun.
The lower panel shows recordings from high right atrium (HRA), the bundle of His (HBE), and lead I of the ECG. Actually,
the rhythm was occasional VPD's with concealed retrograde conduction resulting in aberrant conduction of the subsequent beat
(LBBB configuration).
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Ashman phenomenon which would have been more
obvious in analyzing a paper recording. This combination of errors in the intensive care unit can
cause aberrant beats to be treated with lidocaine.
Lidocaine can slow the atrial rate and enhance A-V
conductivity, leading to a striking increase in ventricular rate. Lidocaine in these circumstances has
caused atrial flutter to conduct with a 1: 1 A-V ratio
and has produced ventricular rates of nearly 300 per
minute. If the heart is hemodynamically impaired,
rapid heart rates caused in this way can be catastrophic. Other examples could be given, but these
two suffice to underscore the importance of obtaining
a correct diagnosis of the arrhythmia before embarking on a therapeutic course.
Even after precise identification, obviously, not
all arrhythmias deserve treatment with suppressant
antiarrhythmic drugs. Many arrhythmias do not deserve any therapy whatsoever. The past decade of
coronary care unit experience has taught us a great
deal about the natural history and indications for
treating arrhythmias which arise between 4 and 72
hours after onset of symptoms in acute myocardial
infarction. A great error which has become a national epidemic has been the unjustifiable extrapolation of the CCU experience to the first two hours of
infarction or of the late postinfarction period. At both
of these times the pattern arrhythmias, their meaning,
or their response to therapy seem to be very different
from arrhythmias encountered in the CCU and, at
present, less well characterized. Even worse, there is
a widespread tendency in recent years to use the same
criteria for treating arrhythmias in other etiologic
forms of heart disease as those used in acute myocardial infarction. In most forms of heart disease, our
knowledge of the meaning and natural history of arrhythmias is even more rudimentary than our knowledge of arrhythmias in various stages of coronary
heart disease. However, in many diseases, it is abundantly clear that arrhythmias do not need treatment
even though the same ECG pattern would dictate
therapy in acute myocardial infarction.
Once an arrhythmia is identified and the need
for treatment established, the regimen of therapy
may or may not require a specific antiarrhythmic
drug. Arrhythmias encountered outside the coronary
care unit very often are caused or seriously aggravated by non-cardiac factors such as electrolyte, acidbase, or blood gas derangements or drug toxicity.
When initially evaluating any cardiac arrhythmia, the
physician should consider the many possible non-
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cardiac causes and institute the appropriate clinical
and laboratory investigations to identify these, even
though temporary emergency therapy is required immediately. Not only will correction of non-cardiac
causes usually control the arrhythmia but also arrhythmias generated by electrolyte imbalance or
blood gas derangement may be highly resistant to
"specific" antiarrhythmic drugs like procainamide or
lidocaine.
When a drug is finally selected to treat an arrhythmia, the goal is to maintain the plasma concentration above the minimum effective concentration
without inadvertently producing toxic concentrations.
To successfully achieve this goal requires a considerable knowledge about the pharmacokinetics, metabolism, and excretion of the drugs utilized.
It is our purpose to discuss briefly the clinically
relevant electrophysiologic properties, clinical usage,
pharmacodynamics, and toxicity of procainamide
and lidocaine.
Electrophysiologic Properties. The following
are a few clinically relevant electrophysiologic effects
of procainamide and lidocaine.
Lidocaine. Lidocaine is a Group II antiarrhythmic drug. It suppresses automaticity in cardiac Purkinje fibers by increasing the potassium conductance
of the sarcolemma but does not significantly alter
threshold voltage. It shortens action potential duration and refractoriness in Purkinje fibers and ventricular muscle but has practically no effect on atrial
tissues. It does not alter conduction velocity or responsiveness very much in either normal atrial or
normal ventricular tissues. Under certain circumstances, lidocaine can improve conduction or reverse
conduction block in ventricular tissues. Lidocaine
depresses sinus node function less than procainamide.
Rarely, it has been reported to suppress sinus function, usually in older patients, particularly with inferior myocardial infarction and/ or preexisting signs
of sinus node dysfunction. Lidocaine has little effect
on atrial arrhythmias as might be predicted from its
lack of effect on atrial tissues from normal animals.
The drug can, but does not always, cause slight slowing of atrial rate in atrial flutter. Also, lidocaine
causes no change or decrease in A-V conduction
time and A-V refractoriness. Since the drug does not
prolong conduction in the ventricular tissues, it does
not prolong the QRS, and since it does not prolong
action potential duration in the ventricles, it does not
prolong the QT. It is still not clear how lidocaine
abolishes reentrant ventricular arrhythmias in man.
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is modified by many other variable factors. Administration of procainamide to treat VPD's caused by
digitalis toxicity may unpredictably produce severe
A-V conduction disturbances. Slowing of conduction
in the His-Purkinje system and in ordinary ventricular muscle caused by this drug is reflected in a widening of the QRS interval. In a given patient, QRS
width changes usually increase linearly as a function
of plasma drug concentration. The changes in repolarization produced by procainamide usually cause
prolongation of the QT interval and alteration in T
wave contour. The rather reliable change in QRS
and QT intervals has proved quite useful in estimating therapeutic and toxic cardiac effects during therapy. The profound changes procainamide causes in
conduction, responsiveness, and refractoriness of ventricular tissues no doubt underly its impressive ability to suppress VPD's or ventricular tachycardia.
Our recent experiments in man suggest that as the
plasma concentration of this drug rises, it causes a
steadily increasing depression of conduction in a ventricular reentrant circuit until conduction fails altogether and the arrhythmia is abolished.
Clinical Use. Lidocaine. Lidocaine is not effective against a wide variety of cardiac arrhythmias,
being most useful in combatting ventricular arrhyth-

Our studies to date suggest that it may do so either
by improving conduction throughout the reentrant
circuit or by blocking conduction in abnormal components of the circuit without affecting normal components.
Procainamide. Procainamide (like quinidine) is
a typical Group I antiarrhythmic drug. It suppresses
automaticity and moves the threshold voltage of heart
muscle toward zero. Also, it lengthens action potential duration and lengthens the refractory period of
atrial and ventricular cell types. It slows conduction
in the atrium, A-V node, and ventricle and decreases
membrane responsiveness of atrial and ventricular
fibers . Many of these actions are reflected in the
ECG. Procainamide does not usually affect the sinoatrial rate in intact man, but it can cause dramatic
slowing of sinus rhythm in patients with derangements of sinus node function. This drug often causes
minimal flattening and widening of the P wave. The
atrial rate is slowed by procainamide in atrial fibrillation and flutter, and high concentrations will convert these rhythms to sinus rhythm. A direct action
of procainamide is to slow A-V conduction and increase the refractoriness of the A-V conducting system; the magnitude of this effect is quite variable
from patient to patient under similar conditions and

TABLE 1.
Effectiveness of Lidocaine and Procainamide Against Cardiac Arrhythmias*
ARRHYTHMIA

LIDOCAINE

PROCAINAMIDE

# of Success /# of Cases

# of Success /# of Cases

SUPRA VENTRICULAR:

Atrial premature depolarizations
Paroxysmal supraventricular tachycardia
Supraventricular tachycardia with A-V block
Atrial flutter
Atrial fibrillation
A-V junctional premature contractions
Non-paroxysmal A-V junctional tachycardia
Unspecified supraventricular tachycardia
Total:

11

(48 %)
(46 %)

8/ 13
28 / 40

(62 %)
(70 %)

0/ 4
0 / 11
3/ 41
4/ 8
0/ 7
3/ 9
30/ 122

( 0%)
( 7%)
(50%)
( 0%)
(33 %)
(25 %)

14 / 53
73 / 215
9/ 13
26 / 33
14/ 23
172 / 390

(26 %)
(34%)
(69 %)
(79 %)
(61 %)
(44%)

389 / 495
48 / 69
437 / 564

(79 %)
(70 %)
(77 %)

210 / 244
98 / 122
308 / 366

(86%)
(80 %)
(84 %)

15 / 31

5/

VENTRICULAR:

Ventricular premature contractions
Ventricular tachycardia
Total:

* A comparison of clinical effectiveness of lidocaine and procainamide against supraventricular and ventricular arrhythmias.
Calculations are based on a review of the literature up to 1972 and include arrhythmias that were completely suppressed or at least
90 % improved after drug therapy. The percentage was not determined where total cases were less than five.
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mias. It is practically worthless against atrial flutter
or fibrillation (Table 1); the rare instances in which
it appears to abolish one of these rhythms may only
be due to coincidence, or to indirect effects. Lidocaine is also, as a rule, ineffective against atrial or
A-V junctional tachycardias unless they are caused
by digitalis excess. Of course, lidocaine is highly effective against ventricular arrhythmias arising in many
circumstances, but it is limited to relatively shortterm use because it must be administered parenterally.
It should be emphasized that there is considerable difference in electrophysiologic action between
procainamide and lidocaine, and it is common to see
an arrhythmia that is resistant to one, submit to the
other.
Procainamide. Procainamide is an antiarrhythmic drug of broad spectrum, effective against a wide
variety of atrial, A-V junctional, and ventricular arrhythmias (Table 1). In general, higher plasma concentrations are required to convert or prevent atrial
fibrillation than those needed to control ventricular
arrhythmias. Early in its use, this fact led to the mistaken impression that the drug was ineffective against
atrial arrhythmias. However, as will be discussed
later, procainamide has a short half-life which means
to continuously maintain plasma concentrations effective against atrial arrhythmias requires large doses
every six hours . Large doses may produce toxic peak
concentrations and necessitate more frequent dosing,
a change which is usually inconvenient for the patient. This drug is a poor choice against ventricular
arrhythmias in patients with severe A-V conduction
disturbances because it may worsen conduction. Although it can be effective against many digitalis-toxic
arrhythmias, its actions in this circumstance are too
unpredictable to warrant its use.
Prophylaxis. In very recent years, studies have
evaluated prophylactic use of procainamide or lidocaine, as well as other antiarrhythmic drugs, in the
CCU. These studies, conducted in first-rate university hospitals, fail to show a decrease in mortality in
the treated versus the control group. This might be
expected since patients with heart failure, shock,
sinus bradycardia, A-V block, or arrhythmias requiring immediate treatment were not admitted to
the studies. Furthermore, these CCU's were all wellstaffed so that sophisticated hospital-based physicians
were almost instantly available to analyze and treat
arrhythmias which developed in either the placebo
or drug-treated group. It would seem that a pa-
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tient in a university hospital CCU has little to
gain from prophylactic therapy. On the other hand,
a patient residing in any one of the many community
hospital CCU's in this country where the staff may
be less plentiful or well-trained and the patient's
physician is based in his office practice, might have
a great deal to gain from routine prophylaxis. Prophylaxis might prevent harmful results where premonitory arrhythmias were overlooked. However,
routine prophylaxis in every case of myocardial infarction might increase the morbidity and mortality
in patients with cardiac failure or shock, or those
with bradyarrhythmias or conduction defects. Thus,
even in community hospitals, the case for routine
prophylaxis in acute myocardial infarction is not entirely clear.
Prophylaxis for arrhythmias in ambulatory, apparently well patients with coronary heart disease is
even less well-grounded than prophylaxis in acute
myocardial infarction. Several pertinent facts are
emerging. First, VPD's are extremely common in
asymptomatic coronary heart disease patients. Second, middle-aged men who have frequent VPD's
( > 10 VPD's per 1,000 beats) or sustained relative
bradycardia have a much higher incidence of sudden death in follow-up periods than their peers without one of these two rhythm disturbances, even
though neither group has clinically evident coronary
heart disease. What is not clear is whether any available drug can significantly and persistently reduce
the incidence of these arrhythmias for long periods
of time without undue undesirable effects. Neither is
it clear that, if one could alter these arrhythmias that
are correlated with sudden death, the incidence of
sudden death would be reduced. Thus, at present,
prophylaxis in such a population is highly experimental and should be controlled since we do not
even know that prophylaxis would do more good
than harm.
Another related area of current interest arises
from the fact that patients who die from arrhythmias
during early stages of acute myocardial infarction
or ischemia probably suffer from either ventricular
fibrillation or bradyarrhythmias. It has been suggested that patients who are known to be at risk to
myocardial ischemia, that is, patients with known
coronary heart disease, carry syringes containing
lidocaine and/or atropine. These patients would be
advised, on experiencing symptoms of myocardial
ischemia, to inject their drug intramuscularly and
come to the hospital. Again, with the evidence avail-
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able at present, we are not certain that such a course
of action would not be more harmful than helpful,
and such therapy cannot be recommended for more
than controlled trials. However, it is reasonable to
urge immediate contact between the patient with coronary heart disease who has a change in symptoms
and the health care system. Analysis of the ECG
either transmitted by telephone or obtained by a
medical team invading the community would allow
early specific treatment on the basis of the arrhythmias encountered in the individual patient. Some
variant of this method would seem greatly preferable to self-injection of drug or drugs initiated on
the basis of symptoms alone without regard for the
presence or type of rhythm disturbance.
Pharmacodynamic Considerations. Particularly
in treatment of acute arrhythmias, one of the most
important aspects of antiarrhythmic drug therapy
is pharmacodynamics. It is necessary to maintain
the plasma drug level above the minimum effective
concentration (MEC) because life-threatening arrhythmias may emerge when plasma concentrations dip below this level. Also, the rate at which
MEC is achieved may be quite important. Knowledge of drug kinetics is even necessary in order to
assess the effectiveness of the drug being used. Lack
of a consummate knowledge of pharmacodynamics
often leads physicians to conclude that a particular
drug is ineffective in combatting a particular arrhythmia. In actuality, this conclusion is often
incorrect because the physician is unaware of the
expected time course of drug action and thus evaluates drug effectiveness at an inappropriate time.
Since many of the arrhythmias treated in emergency
situations, for example, acute myocardial infarction,
are short-lived, the need for antiarrhythmic drug
therapy is brief. Usually, a few days of such therapy
is sufficient. When discontinuing or interrupting the
antiarrhythmic drug therapy under such circumstances, knowledge of the expected course of elimination is vital. This knowledge allows maximum
intensity of observation at appropriate times without
wasting effort on unnecessarily intense vigilance at
inappropriate times.
Lidocaine. Lidocaine is only used parenterally.
This drug is very popular in treating acute ventricular arrhythmias where it is usually given as a
sudden intravenous injection. If the arrhythmia requires treatment for a few days,_ constant-rate IV
infusion is employed. Intramuscular injections of a
special 10% formulation of lidocaine is being studied

by our group and others for possible use against
arrhythmias.
Brief IV injection. Empirical trial has determined that IV lidocaine doses of 0.5 to 1.5 mg per
kg body weight can be repeated every three to five
minutes until a 200 to 300 mg dose is reached.
This method is usually safe. The time course of
plasma lidocaine after an IV injection is shown in
figure 2. Several features of interest can be noted.
First, the lidocaine concentration rapidly drops below the MEC (15-40 minutes), and the arrhythmia
being treated may return. The early rapid drop
(t11 2 = 9 minutes) in concentration is due to distribution of the drug into its large apparent volume of
distribution (V0 = 120 liters). After distribution, the
rate of elimination slows and is accomplished by a
combination of renal excretion and hepatic metabolism. The hepatic metabolism of lidocaine is so rapid
that under ordinary circumstances, less than 5 to
10% of lidocaine is excreted unchanged by the kidney. A note of caution about repeated IV injections
or injections during infusions: the volume of distribution is partially filled with drug under these circumstances, and an unexpectedly large increase in
plasma concentration may occur.
Intravenous constant-rate infusion. This mode
of therapy is commonly used. Figure 2 shows the
time course of the rise in plasma lidocaine when
infusion is begun without prior doses. Because the
MEC for lidocaine is usually so low ( 1 to 2µ.g per
ml) and the elimination t 112 so short ( 1.5 to 2
hours), the plasma concentration usually rises to
MEC within an hour. If elimination of lidocaine
is normal, a simple, empirical rule can be applied
to estimate the plasma lidocaine concentration at
steady state-the infusion rate of lidocaine in µ.g per
minute per kg body weight divided by 10 equals
the plasma concentration of lidocaine in ,µ.g per
ml, for example, an infusion of 30 µ.g per minute
per kg body weight should produce a plasma
concentration of 3.0 µ.g per ml at steady state.
Like any drug with first order kinetics, 90% of
the steady state value is achieved in 3.3 times
the t112 . Most commonly, lidocaine infusions are
given following one or more IV injections as shown
in figure 3. Since the elimination t 112 of lidocaine
is fairly brief, plasma lidocaine changes fairly rapidly
to a new steady state when IV infusion rate is
increased or decreased and falls rapidly when an
infusion is discontinued. Low cardiac output is associated with reduced hepatic blood flow and a
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Fig. 2- Time-plasma concentration course of Iidocaine ahd procainamide produced by sudden 200 mg intravenous injection (left)
and constant-rate intravenous infusion (right).
After IV injection of either drug (left) , the early, rapid fall in plasma drug concentration is due to distribution of drug into its
large apparent volume of distribution (Vn). A slower late phase of disappearance is seen which is due to elimination of the drugs
by a combination of hepatic metabolism and renal excretion. The half-time for elimination (t 112e) is 1.5 hours for Iidocaine and 3.5
hours for procainamide.
At right, the plasma concentration during and after a 12-hoi.tr constant infusion of procainamide and lidocaine into a 70 kg
patient. The infusion rate was selected so that after an infinite amount of time, the plasma concentration of each drug would be
4 µg/ ml. For lidocaine, t112e = 1.5 hours, Vn = 120 liters, and infusion rate = 52.8 µg / min / kg body weight. For procainamide,
t112e = 3.5 hours, Vn = 140 liters, and infusion rate = 26.4 µg / min / kg body weight. Primarily due to its longer elimination half-life,
a much slower rate of procainamide infusion is required to produce a 4 µg / ml steady-state plasma concentration. Because of its
longer t112e, procainamide takes longer to achieve 90% of its steady-state plasma concentration (11.6 hours) than lidocaine (5.0 hours).
Also, the plasma concentration of procainamide falls slower after discontinuing the infusion.
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Fig. 3-Combined li~ oca ine dosage in a 70 kg patient with
an initial IV injection of 100 mg followed immediatel y by
an infusion of 52.8 µg / min/ kg body weight. The thin solid
line shows the minimum effective concentratio11 (MEC)
for antiarrhythmic action. The thick solid line shows the
concentration-time course resulting from combined the rapy.
T he two interrupted lines show the concentration-time
course which would have resulted from either mode of dosing alone. Note that this method maintains the plasma concentration in the effective range.

reduced rate of lidocaine elimination. Also, lidocaine
elimination can be reduced when hepatocellular function is severely impaired. When congestive failure
or another condition reducing metabolism of the
drug is present, infusion rates must be reduced
accordingly-sometimes by as much as two or threefold.
Intramuscular injection. This route of administration is still being studied for its therapeutic usefulness. The plasma concentration achieved after
intramuscular injection seems to depend on the
formulation and concentration injected, the particular muscle used for injection, activity in the muscle
after injection, and general circulatory status. Using
a special 10% solution and a 4 mg per kg body
weight given in the deltoid muscle, we usually
achieve a 1 µ.g per ml plasma concentration by 5
minutes, an average peak level of 3.3 µ.g per ml
at 15 minutes, and the concentration exceeds 1 µ.g
per ml for 90 to 120 minutes (fig. 4).
Oral doses. When lidocaine is given orally, it
is well absorbed, but this route of administration
has at least two disadvantages which severely limit

its usefulness. First, the liver metabolizes an incredible proportion of an oral dose when the drug is
presented to the liver via the portal circulation,
and very low plasma concentrations of lidocaine are
achieved. Second, oral doses tend to produce significant abdominal discomfort and, very frequently,
nausea. There is evidence to suggest that the nausea
may be caused by the central action of a metabolite
rather than local gastrointestinal irritation.
Procainamide. Procainamide is a more versatile drug than lidocaine not only because of its
broader antiarrhythmic spectrum but also because
it can be adminstered by more routes, including the
oral route which permits long-term therapy.
IV injection. There is a great deal of conflicting data in the literature regarding IV injection
of procainamide. Many reports would lead one to
believe that precipitous arterial hypotension is almost
the rule after IV procainamide. T his is true if large
injections are given. We have devised a simple
method of IV injection which allows rapid control
of ventricular rhythms but circumvents hypotension. We give 100 mg IV every five minutes. This
leads to a linear rise in plasma drug concentration and progressive decrease in VPD's until they
finally disappear. This usually takes 4 to 8 doses
and is not accompanied by clinically significant
hypotension (fig. 5). Another advantage is that the
physician knows immediately whether or not a par-
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Fig. 4-Average plasma lidocaine as
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ticular arrhythmia will respond to this agent and
whether high or low concentrations will be required.
Like lidocaine, procainamide plasma concentration
falls rapidly after a single IV injection because of
an initial rapid distribution of the drug into a large
apparent volume (fig. 2). The late phase of decline
in plasma concentration is due to elimination and
has an average t 112 of 3.5 hours. A large proportion of procainamide is excreted unchanged into the
urine (about 60%), but a significant amount is
acetylated, presumably by the liver (25-30 % ).
Intravenous constant-rate infusion. We have
used this method for many years, particularly in
the intensive care unit when a stable plasma concentration is desired . Figure 2 shows the plasma
concentration of procainamide during and after an
IV infusion . Because the MEC of procainamide is
higher than lidocain e and the elimination t 11 2 is
longer ( ± 3.5 hours) , infusions may not yield therapeutic concentrations until about 6 hours have
elapsed, and 90 % of steady-state concentration
is reached at 12 hours (3.3 x 3.5) . Because the
elimination t 11 2 of procainamide is about twice as
long as that of lidocaine, the former drug takes
longer to achieve a new steady state after a change
in infusion rate and falls much slower when an
infusion is stopped. Figure 4 shows the combination
of intermittent IV injection therapy with constantrate infusion .
Intramuscular injection. Procainamide is fairly
well absorbed after IM injection and when given
by this route rapidly produces antiarrhythmic plasma
concentrations which decline as expected from its
elimination t 1 12 . The rate at which a MEC is
achieved is not a great deal faster than after an
oral dose. Therefore, unless the patient is unable
to take the drug by mouth, there is little indication
for IM administration.
Oral doses. Procainamide can be given by
mouth which is a major advantage over lidocaine.
The drug is not well absorbed from the stomach
when the pH is acid, and delay in gastric emptying
can cause a delay in onset of absorption. However,
this drug is quickly absorbed from the alkaline
small intestine; after adequate doses, effective plasma
levels are achieved in 15 minutes or so, and the
peak level is achieved between 45 and 75 minutes
after a dose. Absorption is virtually complete after
90 to 105 minutes, and elimination takes place with
a ti 12 of 3.5 to 4 hours. Renal excretion of procainamide is greatly reduced when the urine is alkaline,
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12
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Fig. 5-Plasma procainamide concentration plotted as a
function of time when drug is given by incremental intravenous dosing and / or constant intravenous infusion. The
minimum effective concentration, MEC, is represented by
the thin solid line . Six 100 mg doses of procainamide are
given every 5 minutes, black dots, until the arrhythmia is
completely suppressed at a plasma drug concentration of
8.2 µg / ml within 30 minutes. The dash-dot line shows the
concentration-time course which would have resulted if incremental doses were stopped and no other mode of dosing
starteq. Without prior injection, when a constant intravenous
procainamide infusion ( 42.8 µg/ min / kg body weight) is
started, dashed curve, the plasma drug concentration would
be above the MEC at 3 hours and is 6.5 µg / ml at stea9y
state. The thick black line represents the pl asma procainamide concentration which would be obtained by initially
giving the six 100 mg injections and, then, immediately beginning a constant IV infusion of 42.8 µg / min / kg body
weight. Note that the procainamide concentration never falls
below the MEC.

and in instances of congestive failure or renal failure .
In these situations, a larger proportion of a given
dose is acetylated by the liver. In congestive failure,
procainamide, like lidocaine, has a smaller apparent
volume of distribution, which means the same
amount of drug in the body will result in a higher
plasma drug concentration. Some years ago we noted
procainamide toxicity occurring during the change
from intravenous constant-rate infusions of procainamide to an oral regimen, even though the total
24-hour doses were identical. Our error is shown
in figure 6 (upper panel). Since an oral dose produces a rapid rise in plasma concentration, an initial
oral dose given immediately on stopping the infusion
causes a high (toxic) plasma concentration. It is
apparent that an oral dose of a rapidly absorbed
drug is tantamount to an IV injection. This unfor-
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Fig. 6-Changing from continuous intravenous infusion to
an oral dose regimen of procainamide Vn
140 liters, ti1,e
4.0 hours.
The upper graph shows the termination of an intravenous infusion which for three days had maintained a
stable plasma procainamide concentration of 8 µg/ ml. At
time = 0, the infusion was discontinued and a regimen of
1,000 mg oral doses every 6 hours was begun. Note that toxic
concentrations are obtained after each of the first four oral
doses although this will ultimately be a satisfactory regimen
at steady state.
The lower graph shows an identical patient, given an
identical infusion and oral dosage regimen with only one
exception- four hours were allowed to elapse between cessation of infusion and peginning the oral drug. Note that the
plasma procainamide concentration never reaches toxic
concentrations.

=

=

tunate sequence can be avoided completely by
waiting for about four hours after discontinuing the
infusion before giving the first oral dose (fig. 6,
lower panel).
Toxicity. While antiarrhythmic drugs have
considerably decreased mortality from arrhythmias
seen following acute myocardial infarction and open
heart surgery, improper use of these agents is as

potentially life-threatening as the presence of the
arrhythmia itself. A considerable incidence of toxicity is still encountered in using these drugs and
impairs their general usefulness. Toxicity usually
results from insufficient attention to the general
physiologic state of the patient, the functional impairment of the organs which metabolize these
drugs, or pharmacodynamic considerations. However, even when errors in judgement are made using
these drugs, a thorough knowledge of their toxic
effects and a continuing careful search for early
toxic signs can often prevent more severe and serious
toxicity.
Lidocaine. Clinical toxicity of lidocaine appears
to be related to size of dose and rate of administration. Ordinary doses, however, may produce undesirable effects when there is severe hepatic disorder,
acidosis, severe congestive heart failure, low cardiac
output, and shock. If lidocaine is infused at usual
rates where these conditions exist, toxicity may
ensue and, in fact, where blood levels have been
measured in these cases, they are frequently two
or three times higher than those needed for effective
therapy.
Lidocaine usually produces signs of central
nervous system (CNS) involvement before any subjective or opjective cardiovascular effects are observed. The early symptoms may be extremely subtle.
Blood levels greater than 6 µ.g per ml have been associated with dizziness, drowsiness, numbness of lips
and tongue, speech disturbances, and psychosis. At
present we suspect that many of the minor CNS
symptoms of lidocaine toxicity go unrecognizeq as
such and are treated with diazepam or a similar agent.
More severe CNS manifestations such as tremor, convulsions, respiratory depression, and fireflexia occur
most commonly when venous blood levels of lidocaine
are higher than 10 µ.g per ml but may be seen at
lower concentrations. Signs of CNS toxicity may
be treated by stopping lidocaine infusion and, as
a rule, symptoms will improve within 15-30 minutes, but may take several hours to completely abate.
LidoGaine-induced convulsions may require treatment with small intravenous doses of short-acting
barbiturates. High doses of barbiturate should be
avoided since their CNS depressant effects may
potentiate those of lidocaine and may result in
respiratory arrest.
The hemodynamic effects of 1 mg per kg of
lidocaine injected intravenously have been measured
by several groups. While hypotension may result
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from larger doses of lidocaine, in therapeutic doses,
there appears to be little effect on systemic arterial
ressure, ventricular contractile force, cardiac out~ut heart rate, or stroke volume in man. Thus, it
wo~ld seem that !idocaine given in this way exerts
remarkably few if any adverse effects of clinical
significance. T he hemodynamic effects of lidocaine
in the shock state or after a constant intravenous
infusion are as yet unknown .
F inally, lidocaine has been suspected of producing cardiovascular toxicity. Clinical observations,
largely unsubstantiated by conclusive evidence, have
implicated lidocaine as the cause of: 1) rapid ventricular response to an atrial arrhythmia, 2) production of ventricular arrhythmia, or increase in number
of ectopic beats, 3 ) heart block, and 4) asystole.
The use of lidocaine is not advised in the presence
of heart block.
Procainamide. Procainamide is more prone to
produce direct cardiac toxicity expressed as alterations in electrical and mechanical behavior of the
heart than lidocaine. As with lidocaine, many of
the toxic reactions seen with procainamide are
related to size of dose and also to the route of
administration. Rapid intravenous administration,
particularly when given faster than 50-75 mg per
minute, has been associated with undesirable electrocardiographic and hemodynamic effects. Because of
this, oral and intramuscular use of procainamide has
been advocated . However, even with these routes
of administration and recommended dose size, toxicity may be encountered in congestive heart failure,
renal disease, or shock.
In our experience, therapeutic effectiveness and
toxicity of procainamide are closely related to
plasma drug concentration. We consider the effective antiarrhythmic plasma drug concentration range
to be 3 or 4-1 0 µ,g per ml and have observed electro~hysiologic and hemodynamic toxicity at concentrations greater than 12 µ,g per ml. Notwithstanding
the bad reputation of intravenously administered
procainamide, we have found that antiarrhythmic
plasma drug concentrations are attained rapidly,
~afely, and predictably when procainamide is given
Int~avenou sly. We recommend 100 mg of procainamide be given intravenously every 5 minutes with
~ectrocardiographic and blood pressure monitoring.
n example of this method is shown in figure 4 ·
the I
.
'
e ectrocard1ogram was continuously monitored
and patient P.B. was given 100 mg of procainamide
every 5 ·
rnmutes until VPD's were abolished. Plasma
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samples taken 4 1/2 minutes after each dose indicate
there is a direct linear relationship between cumulative dose and plasma drug concentration. Moreover,
after each procainamide injection, the number of
VPD's diminishes until the sixth dose when the
arrhythmia is completely abolished and a plasma
drug concentration within the therapeutic range
( 8.3 µ,g per ml) is achieved. Neither untoward
hemodynamic nor electrocardiographic effects were
encountered during the course of treatment.
Even at low plasma drug concentration range,
procainamide produces electrocardiographic changes
resulting from its cardiac electrophysiologic actions.
The P-R, QRS, and QT intervals are all prolonged
at therapeutic plasma concentrations. In addition,
toxic drug concentrations have been associated with
progression of these or appearance of more dramatic
electrophysiologic effects such as: 1) suppression
of cardiac automaticity, including the S-A node, leading to asystole, 2) impairment of A-V conduction,
leading to heart block, and 3) slowing of intraventricular conduction greater than 30%. Another
noteworthy undesirable electrocardiographic change
stems from the fact that toxic concentrations of
procainamide almost invariably cause increased
automaticity and multifocal pacemaker activity in
isolated cardiac Purkinje fibers. Thus, the appearance of ectopic ventricular beats, ventricular tachycardi a, or fibrillation in a patient who presumably
has achieved therapeutic drug concentration may
not represent arrhythmia breakthrough but rather
procainamide toxicity. If the physician is unaware
of this complication, he may continue to administer
procainamide or even increase the dose, not realizing that the drug is responsible for evoking the
arrhythmia. Since therapeutic and toxic drug effects
are so well correlated with electrocardiographic
changes, the electrocardiogram is an excellent way
to monitor procainamide efficacy and, when carefully used, the incidence of toxicity is likely to be
reduced. Because of its depressant effects on A-V
conduction and ventricular automaticity, procainamide is contraindicated in heart block, and cautious
use has been advised in patients with wide QRS
intervals and bundle branch block.
Procainamide may produce hemodynamic
changes by depressing myocardial contractility and
the cardiac output and thereby produce hypotension.
While the severity of these hemodynamic alterations
appears to be related to dose size and rate of administration, they may be further intensified by heart
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disease and congestive heart failure. Although procainamide should be used cautiously in these conditions, they do not preclude therapy. We have noted
that the probability of untoward hemodynamic
effects is minimized by intermittent intravenous injections and by careful monitoring of blood pressure.
If necessary, doses higher than 1000 mg may be
given by this technique without evidence of cardiac
toxicity or hypotension. Procainamide-induced hemodynamic or electrocardiographic toxicity may be
treated by molar sodium lactate and the catecholamines, norepinephrine or isoproterenol.
Extracardiac toxic reactions to procainamide
are most commonly seen during chronic oral
therapy. Gastrointestinal disturbances (nausea, vomiting, diarrhea), and CNS disturbances (mental depression, psychosis, and convulsions) have been
reported. Other toxic effects include skin rash, fever
and chills, and agranulocytosis. Most of these extracardiac reactions subside almost immediately with

discontinuation of the drug, but some may persist
a few days to a few weeks. A syndrome resembling
systemic lupus erythematosis (SLE) characterized
by arthralgia, fever, pleuropneumonic involvement,
and hepatomegaly has occurred frequently in patients on long-term maintenance therapy. Rarely,
adrenal corticosteroids have been required to control unusually tenacious symptoms of SLE. It should
be pointed out that, unlike SLE, the drug induced
SLE-like syndrome produces no permanent damage
in any vital organ system. This and the fact that
aspirin or steroids may control symptoms are important considerations in planning the management
of a patient who has a life-threatening arrhythmia
for which other drugs are ineffective, and who has
developed the SLE-like syndrome. In such a case,
one reasonable course of action is to continue procainamide and control symptoms of the SLE syndrome with salicylates or adrenal corticosteroids.
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The function of the sinoatrial node is complex. In nearly all hearts, this small bit of tissue is
responsible for spontaneously generating the impulse
which will be distributed to the remainder of the
heart, maintaining coordinated electrical and mechanical function. In recent years, it has become
clear that S-A node dysfunction is not rare, can
cause disabling symptoms, and often presents difficult management problems. The challenges presented by the "Sick Sinus Syndromes" have increased our desire to know more about normal
S-A node function and about function in disease
states.
The intimate mechanisms of sinus node function remain a mystery despite the "prying eye" of the
microelectrode and modern anatomical and chemical methods. At least the time-voltage course of
spontaneous activity in the sinus node cells has been
elucidated. After self-excitation, a pacemaking sinus
node cell slowly depolarizes to zero potential differ-
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ence with the extracellular fluid and often shows
some overshoot, that is, the inside of the cell may
become slightly positive relative to the extracellular
potential. After reaching this peak inside-positive
value of transmembrane voltage (Vm), the sinus
node cell slowly repolarizes to a maximum insidenegative value-so-called maximum diastolic voltage. Then, the transmembrane voltage spontaneously
begins to decrease (phase 4 depolarization) until
a critical value of V 111 , threshold voltage, is reached
and self-excitation recurs. The rate of recurring
self-excitation could theoretically be altered by
changes in: 1) maximum diastolic voltage, 2)
threshold voltage, and 3) rate of phase 4 depolarization. Changes in firing of a sinus node cell are
most often mediated by changes in rate of phase 4
depolarization. We still do not know the precise
sequence of membrane permeabilities as a function
of time and voltage which are responsible for the
normal automatic behavior of the S-A node.
Sinus node rate is sensitively adjusted to most
suitably meet the needs of the body as a whole.
These adjustments are usually mediated through
autonomic reflexes which change the rate and pattern
of firing on sympathetic and/ or parasympathetic
nerves terminating at or near the sinus node. R elease of norepinephrine from sympathetic nerve
terminals in the vicinity of a sinus node cell will
accelerate phase 4 depolarization and the spontaneous firing rate of the S-A node while acetylcholine
released from cholinergic terminals has the opposite
effect.
77
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Once the normal automatic mechanism has
generated an impulse in the S-A node itself, the
impulse must be transmitted to the ordinary and
specialized atrial fibers in order to effect atrial and,
ultimately, total cardiac excitation. The action potential of the S-A nodal cell is of a type associated
with slow conduction and vulnerability to block or
fragmentation in transmission, that is, phase 0 is
small in amplitude and extremely slow rising. Also,
the S-A nodal pacemaker cells are small, have
multiple connections with their neighbors, and are
entangled in a dense connective tissue stroma. These
anatomical features undoubtedly contribute to slow
conduction in the sinus node. In addition, the sinus
node is surrounded by a group of cells which are
intermediate in time-voltage course between S-A
nodal cells and atrial specialized cells. These cells,
called "perinodal fibers" are not automatic under
normal circumstances but do have electrophysiologic
properties which promote slow conduction and
block; "perinodal cells" represent a barrier to conduction into the S-A node and a region where
"organization" and amplification of impulses leaving
the S-A node might occur.
All of the events discussed above-impulse
generation in the S-A node and its transmission to
the atrium-are invisible both on the body surface
electrocardiogram and in local extracellular atrial
electrograms. Analysis of the behavior of the S-A
node in man is even more complicated than analysis
of the A-V node. We have been able to study the
A-V node in man by recording local electrograms
from the atrial margin of the A-V node and, on
the other side, the nearby bundle of His. Programmed stimulation of the atria or ventricles and
analysis of the electrical responses allow a rather
complete characterization of the A-V node. The
S-A node is somewhat analogous to the A-V node
in that the impulse generated in the S-A node must
pass through the "perinodal fiber" (analogous to
the A-V node) in order to reach specialized atrial
fibers (analogous to the bundle of His) . However,
this analogy is very incomplete in that the S-A
node itself is an area of slow conduction and, in
addition, spontaneously generates impulses.
Experimental and clinical observations made
in the first decade of the twentieth century established that second degree S-A block could occur in
animal and human hearts. In fact, second degree
sinoatrial block was well established clinically from
analysis of the jugular venous pulse well before this

abnormality was recorded electrocardiographically.
Since that time there has been a great increase in
our knowledge of the electrocardiographic features
of second degree S-A block. More recently, the
use of electrical pacemakers as a therapeutic device
has led to an increased interest in and understanding
of a variety of clinical patterns of S-A nodal dysfunction . These clinical patterns include:
1. severe sinus bradycardia, not induced by
drugs or inappropriately severe for the type
and amount of drug administered.
2. periods of second degree S-A block, inappropriate for drug therapy.
3. long pauses in sinoatrial rhythm caused by
sinus arrest, repetitive concealed sinus exit
block or third degree S-A exit block .
4. chronic atrial fibrillation with a slow ventricular rate in the absence of drugs which
slow A-V conduction, and inability of the
heart to resume stable sinus rhythm after
electrical cardioversion.
5. the tachycardia-bradycardia syndromes.
Several features of these syndromes deserve
comment. The first three listed have been recognized for a long time and if accompanied by heart
failure or central nervous system symptoms are
often treated, and successfully, with implanted electrical pacemakers. For a long time we recognized
that patients with atrial fibrillation who had a slow
ventricular rate without drug treatment were prone
to develop very slow ventricular rates when treated
with digitalis and often had severe sinus bradycardia, sinus pauses and other rhythms of sinus
dysfunction when cardioverted. Recently, we have
learned that this is due to the fact that many patients
with severe S-A node dysfunction also have impaired A-V conduction and sluggish ventricular
pacemakers. The tachycardia-bradycardia syndromes
(fig. I) have been recognized for about twenty
years, but they presented difficult, often insurmountable, management problems until combined treatment with drugs and an electrical pacemaker became
available.
It is easy to recognize S-A nodal dysfunction
when it presents as one of the five syndromes listed
above . However, it can be difficult to know whether
S-A node dysfunction is present. Two examples
which present clinical difficulty are: 1) moderate
sinus bradycardia which may or may not indicate
intrinsic malfunction of the S-A node and portend
a series of difficult rhythm problems and their
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Fig. 1- The tachycardia-bradycardia syndrome. A 67-year-old man referred for evaluation of recurrent syncope, di zz iness, and
weakness. Lead IL of his admission electrocardiogram shows a repeated change in rhythm from atrial flutter to sinus bradycardia.
He was treated with a permanent transvenous pacemaker and digitalis and has been symptom-free for more than a year.

sequelae and 2) drug-induced sinus bradycardia or
S-A block which improves to normal or near-normal
when the inducing drug is removed. We need
clinical applicable tests to evaluate patients who
demonstrate such events. Ideally, these tests would
separate patients with intrinsic S-A nodal dysfunction who require careful follow-up observation and
have a high probability of need for early therapeutic
intervention from those who merely have a slow
sinus rate or those in whom a combination of extrinsic factors caused a temporary impairment in
function of an essentially normal S-A node. Recently, two techniques have been used in the attempt
to evaluate sinus node function in man : 1) rapid
atrial pacing and 2) premature atrial stimulation.
We will discuss briefly the µse of these techniques
in analyzing S-A nodal function.
Rapid Atriaf Pacing. Out of a group of patients with syncopal attacks who presented to the
National Heart Hospital in England, four were
noted to have periods of sinus bradycardia alter-

nating with periods of atrial tachyarrhythmias. In
these patients the sinus rate usually ranged between
22 and 50 per minute. The episodes of atrial tachyarrhythmias were of variable duration, and in one
patient, syncope associated with the termination of
the tachyarrhythmia was documented . The episodes
of syncope in these patients were due to a long
period of cqrdiac standstill that followed the sudden
termination of the atrial tachyarrhythmia (fig. 1).
The extra long pauses that followed the termination of the tachyarrhythmia were a manifestation of
depressed sinus node automaticity. That this was
the case is suggested by the effects of quinidine
hydrochloride on the sinus rate, that is, atrial standstill was observed in all four patients. Recent experimental studies reporting on the sinus node response
to atrial pacing have obtained data that is somewhat analogous to the clinical observations on the
sinus node response following sudden termination
of an atrial tachyarrhythmia. These reports also
have speculated on the ability of this technique to
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determine sinus node automaticity in patients with
and without evidence of sinus node dysfunction.
The technique consists of pacing the atria at rates
ranging between a rate slightly in excess of the
spontaneous sinus rate and 170 per minute. The duration of the pacing peripd has ranged from 15 seconds
to 5 minµtes in different studies. The sinus escape
interval is determined by measuring the interval
between the last paced P wave and the first spontaneously occurring sinus P wave. The sinus escape
interval is dependent upon the rate of atrial pacing
and the spontaneous sinus heart rate prior to pacing.
The longest sinus escape interval usually occurs at
a rate near 130 per minute (fig. 2) and, in general,
the slower the spontaneous heart rate, the longer the
sinus escape interval after atrial pacing is discontinued. Varying the duration of atrial pacing from
15 to 180 seconds has little effect on the sinus esc<1pe
interval, so that pacing for one minute is sufficient
when measuring the sinus escape interval.
Rapid atrial pacing is most useful in evaluating
a patient with syncope and sinus bradycardi<1. If
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Fig. 2-The effect of atrial pacing on sinus escape interval.
The patient's mean spontaneous sinus cycle length was 1050
msec (57 / min). The right atrium was paced at each cycle
length for 60 seconds and the interval between the last
paced P wave and the first sin11s P wave measured (plotted
on the abscissa) . As the paced atrial cycle length shortened,
the sinus escape interval lengthened to a maximum of
1510 msec at a pacing cycle length of 540 msec (110 / min) .
Thereafter, the cycle length of the sinus escape beat paradoxically decreasecj as the pacing rate increased. This finding sµggests that, due to entrance block, the ~inus node is
actually being discharged more slowly at faster atrial pacing
rates so that the decreasing cycle length of the sinµs escape
beat reflects the slower rate of sinus node discharge. The
progressive shortening of the sinus escape interval as the
rate of atrial pacing increases above 1 IO/ min probably reflects increasing degrees of sinoatrial entrance block.

prolonged sinus pauses are demonstrated, this condition suggests that sinus malfunction is responsible
for the patient's syncope and pacemaker therapy
is recommended. Also, one should not cardiovert
patients with atrial fibrill ation who have a history
of either clinical sinus node dysfunction or a prolonged sinus escape interval unless a ventricular
pacemaker is in place.
The normal sinus escape interval is not wellestablished, although values below 1.4 seconds have
been called normal. H owever, the sinus escape interval is dependent on the basic sinus cycle length . Thus,
in a young athlete, neither a heart rate of 43 per minute nor a sinus escape interval greater than 1.4 seconds need necessarily indicate sinus node dysfunction.
Second, as was pointed out earlier, sinus node automaticity is regulated by autonom ic nervous system
tone. Thus, when sympathetic nervous system activity is increased, sinus node automaticity is enhanced.
Since the sinus escape interval is determined largely
by sinus node automaticity, a patient with sinus
node dysfunction might not show a prolonged sinus
node escape interval when his sympathetic nervous
system activity is enhanced.
It must be emphasized that the ability of rapid
atrial pacing to adequately assess sinus node automaticity is dependent upon 1 : 1 conduction from the
atrium to the sinus node without excessive conduction delay between the atrium and sinus node.
Should conduction from the atrium to the sinus
node fail during atrial pacing, then the sinus node
must be depolarized at a rate that is, in fact, much
slower than the rate of atrial pacing. This entrance
block could explain why the sinus node escape
interval at 150 per minute was shorter than the escape interval at 130 per minute (fig. 2).
In patients with diseased sinoatrial nodes and
sinoatrial junctional tissue, conduction from the
sinus node to the atrium and from the atrium to
the sinus node may be prolonged (fig. 6). In this
circumstance, atrial pacing may fail to adequately
assess sinus node automaticity since conduction from
the atrium to the sinus node may become less than
1: 1 even at very low pacing rates.
It is of interest that prolonged second ary sinus
pauses are seen after discontinuing atrial pacing at
170 per minute (fig. 3). Secondary sinus pauses can
recur many times during the first 20 seconds following termination of rapid atrial pacing. The duration
of the secondary sinus pauses can even be greater
than the duration of the sinus escape interval. This
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Fig. 3- Secondary sinus pauses occurring during the measurement of sinus escape interval. A 53-year-old woman with angina
pectoris, and normal coronary arteriograms was referred for evaluation of sinus bradycardia. In this patient, the longest sinus escape
interval was seen after an atrial pacing rate of 130 / min. At a pacing rate of 170 / min, the sinus escape beat interval was shorter than
at 130/ min, and prolonged secondary sinus pauses were noted following termination of rapid atrial pacing. These secondary sinus
pauses may reflect pacemaker malfunction or advanced degrees of sinoatrial exit block. Atropine caused shortening of the sinus
escape interval at all paced rates and abolished secondary sinus pauses. See text for discussion.

pattern of beating is compatible with repeated short
periods of sinoatrial exit block (repetitive concealed exit block) . Secondary sinus pauses seen

after discontinuing atrial pacing are abolished by
atropine, suggesting that they may be encouraged by
cholinergic influences (fig. 3) .
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In patients with classic features of the "Sick
Sinus Syndrome," sinus escape intervals as long as
5 seconds have been seen. Two mechanisms can
be postulated to explain these extraordinarily long
pauses. The first is that in the depressed sinus node,
automaticity is particularly sensitive to overdrive
suppression, and the long escape intervals reflect
an extreme degree of sinus node pacemaker depression. The second possibility is that sinoatrial
exit block is just more pronounced in these cases
of advanced sinus node dysfunction than in milder
forms (fig. 3). It is certainly reasonable that in
cases of "Sick Sinus Syndrome" both mechanisms
might operate together to produce the extremely
long sinus pauses.
The episodes of sinoatrial entrance and exit
block and concealed conduction at the junction
between the sinus node and atrium are analogous
to the better-known phenomena of A-V and V-A
conduction block and concealed conduction in the

A-V junction.
Premature Atrial Stimulation. A second technique which has been employed recently in evaluating S-A node function is that of premature atrial
stimulation (PAS). We have performed PAS to
evaluate S-A node function in the following manner.
Two pairs of catheter electrodes are placed in the
upper right atrium, near the junction of the superior
vena cava and atrium. If A-V conduction is also to
be evaluated, a third pair of electrodes is positioned
over the bundle of H is and used for recording. The
high right atrial electrogram is used to trigger a
counter during spontaneous rhythm so that a premature stimulus (S 2) can be delivered to the atrium
during every seventh or eighth spontaneous cycle.
A programmable stimulator is used so that the
stimulus can be moved throughout the entire atrial
cycle to elicit atrial premature depolarizations (APD
or A 2 ). The following intervals are measured:
1) the spontaneous sinus cycle (A 1Ai), that is, the
interval between the two spontaneous atrial depolarizations immediately preceding A 2 , 2) the test cycle
(A 1A2), the interval between the atrial premature
depolarization (A 2) and the immediately preceding
spontaneous atrial depolarization (Ai), and 3) the
return cycle (A 2 A 3 ), that is, the interval between
A2 and the subsequent spontaneous atrial depolarization (A3 ). In order to check the stability of
atrial cycle length and evaluate the feasibility of
normalizing, we measure the spontaneous atrial cycle
immediately following the return cycle ( A 3 A 1 ) .

In order to compare results from different patients
with a wide variety of different heart rates, we
analyze the response to a series of stimuli which
scan the atrial cycle by plotting the normalized
return cycle (A 2 A 3 per A 1A 1) as a function of the
normalized test cycle (A 1 A 2 per A 1 A 1 ). Figure 4
shows such a plot. For purposes . of discussion a
typical plot can be divided into three zones.
Zone I. A/s elicited late in atrial diastole are
followed by a return cycle which is fully compensatory, that is, the sum of the test and return cycles approximately equals two spontaneous sinus cyclesA 1A2 + A~A 3 = 2 (A 1 Ai). Typically; this response
is seen in the terminal quarter of the spontaneous
sinus cycle (0.75 to 1.00 of the cycle). Our postulated mechanism for this behavior is shown in figure SA. The A 2 elicited by the electrical stimulus
propagates toward the sinus node and collides with
the emerging impulse which has spontaneously arisen
in the sinus node. Sirtce spontaneous activity in the
sinus node has not been disturbed, the next spontaneous impulse arises in the sinus node and activates the atrium at the expected time.
Zone II. Typically, A 2's elicited in the middle
half of atrial diastole (0.25-0.30 to 0.75 of the
cycle) show a very different pattern. Despite the
decreasing A 1A 2 per A 1 Ai, the A 2 A 3 per A 1 A 1
cycle remains approximately constant. The A 2 A 3
interval is less than compensatory but greater than

05

LO

Fig. 4- The three zones of the atrial cycle revealed by premature atriai stimulation. Every seventh spontaneous atrial
cycle, a stimulus (S2) evoked a premature atrial depolarization. Here, the normalized return cycle (A.A,/ A,A,) is
plotted as a function of the normalized test cycle (A,A./
A1A1). The atrial zones are referenced to the electrocardiogram above. See text for detailed explanation.
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Fig. 5- Ladder diagrams depicting the events responsible for the response in Zones l, II, and lll . SAN = sinoatrial node, PNF
peri(sinus)nodal fibers, AT = atrium.
A. Events in Zone l: non-reset of the sinus node
B. Events in Zone 11: reset of the sinus node
C. Events in Zone Ill: non-reset of sinus node- interpolated APD
D. Events in Zone Ill: non-reset of sinus node- interpolated APD with concealed atrial-sinoatrial conduction causing delay
of conduction of the subsequent sinus impulse to the atrium.

the A1 A 1 interval and is constant (fig. 4). Figure SB
shows the mechanism we postulate for this phenomena observed in Zone II. The S2 evokes an A 2
which propagates across the junction between the
S-A node and atrium to discharge the S-A node
pacemaker before it spontaneously excites itself,
that is, the S-A node pacemaker is reset. The pacemaker repolarizes and immediately begins to depolarize spontaneously; when threshold is reached,
another S-A nodal action potential results, and this
impulse propagates to the atrium producing A 3 .
Thus, three events contribute to the duration of the
A 2A 3 interval: 1) the conduction time from atrium
to S-A node pacemaker site (ArSAN 2 ), 2) the
time to the next spontaneous S-A nodal action potential (SANrSAN 3 ) , and 3) the conduction time
from the S-A nodal pacemaker to the atrium (SAN3A3). The A 2A 3 interval remains almost constant
throughout Zone II, indicating that the sum of these
three events remains almost constant. If the spontaneous S-A node cycle following reset (SANr SAN3 )
is equal to the basic sinus cycle length (SAN 1 SAN1), then the difference between A 2 A, and the
spontaneous atrial cycle (A 1Ai) represents the sum
of conduction into and out of the S-A node(A:!A;i )-(A1A1) = (ATSAN:! ) + (SAN 0-A 0 ).

Z one Ill. In some human hearts, the A 2A 3 interval remains constant until S:! becomes so premature that no A:! can be elicited (atrial refractory
period is encountered). In others, a third zone may
be encountered in which several phenomena may occur. The position of this zone varies from about
0.18-0.23 to 0.2S-0.3S of the cycle. When the A 1A 2
interval is shortened to 0.3 of the A 1A 1 interval, the
A:A 3 interval may suddenly shorten from values of
about l.2S to about 0.70 of the A 1 A1 interval. This
would indicate a true interpolated A", entirely analogous to the rarely observed phenomenon of spontaneous interpolated APD. Such an event indicates
(fig. SC) that the A 2 blocks in tissues around the
S-A node; S-A discharge occurs on time and conducts normally to the atrium to produce A 3 . For the
SANa-A 3 conduction time to remain normal, the
perinodal tissues must recover from the refractoriness engendered by the blocked A :! before the SAN3
impulse arrives. If the perisinus node zone is still
refractory when SAN3 propagates through this region on its way to the atrium, SAN3-Ai and A2A3
will be prolonged ; A"A 3 might be 0.8 to 0.9 of A1A1
at A1A" = 0.3 rather than 0.7, the value expected
if SAN:r A 3 remains equal to SAN1-A 1 (fig. SD).
In general, the response in patients with normal
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or near-normal sinoatrial conduction is much like
that shown in figure 4. However, many other patterns are being encountered as sinus node function
is evaluated in this way. It is possible to obtain useful information with premature atrial stimulation
which is not obtainable in any other way. For example, analysis of the response to premature atrial
stimul ation can reveal first degree S-A block in man.
Figure 6 diagrammatically shows normal and two
degrees of conduction impairment between the S-A
node and atrium. T he normal case is illu strated by
line A. The transition between Zones I and II comes
when A~A1 is 1.25 of A 1 A 1 and A 2 A 3 remains constant as A 1Ac is shortened fur ther. As mentioned
above, neglecting changes in spontaneous S-A node
cycle length, the difference between AcA ~ and A 1A 1
represents the sum of conduction into (ArSAN 2 )
and out of (SANa-A1 ) th e S-A node. In th is example
with a cycle length of 1,000 msec, the total conduction time-(Ac-SAN 2 ) + (SAN:i-A3 )-would be
250 msec ( [l. 25 - 1.00] = X 1000). Line Bin figure 6 shows the transition betwee n Zones I and II at
0.4 th e spontaneous atrial cycle length . In thi s instance, total conduction time would be 600 msec-

20

I 5

10

0 5

10

Fig. 6-The di ag no sis of first-degree sinoatrial block in man
by prem ature atrial stimul ation . T he abscissa is the no rm alized test cycle (A1A2/ A1A1), th e ordinate the normalized
return cycle (A,A,,/ A,A, ) . The heavy diagona l lin e represents responses without reset (Zone I ). Line A sho ws the
transition from Zone I to Zone II in the usual portion of
the cycle. Line B shows tran siti on from Zone I to Zone II at
0.4 of the cycle indicating marked sino atrial conduction delay. In C, a transition from Zone I to Zone II was never obtained, indicating either ext reme si no atrial cond uction delay
or, much less likely, unidirection al S-A block throughout the
cycle .

(A 2 A:l - A 1 A 1 ) x 1000 = (1.6 - 1.0) x 1000 =
600 msec. If the conduction tim e in and out were
eq ual then conduction time from sinus node to atrium
would take 300 msec. Even though (SAN 1 -A 1 ) and
(SAN 3 -A 3 ) are very probably not equal under such
circumstances, (SAN 1 -A 1 ) must be prolonged because A 1 Ac had to be shortened to 0.4 of the spontaneous cycle length before reset occurred, that is, before Zone II was encountered. This indicates that
when th e A 1 A~ interval was longer than 0.4, Ac collided with the emerging sinus impulse; the fact that
reset only occurs when A 2 is introduced early in the
cycle surely indicates that first degree sinoatrial block
is prese nt (th at SAN 1 -A 1 is prolonged). Line C of
figure 6 shows an even more extreme case of sinoatrial block. Throughout the entire cycle wh ere responses could be elicited, A 1 A 2 per A 1 A 1 from 1.0 to
0.3, AcA 3 was fully compensatory. This pattern of respo nse indicates that A 2 never reached the S-A node
pacemaker to reset it ; therefore, the conduction time
between the S-A node and atrium must be very long
or unidirectional block must be present. The total
conduction time is 700 msec- (AcA 3 - A 1 A 1 ) X
1000 = ( 1.7 - 1.0) x 1000 = 700 msec. Thus,
premature atrial stimulation can be used to detect
first degree sinoatrial block in man, a feat not possibl e with any other technique.
Also, a variety of behavior has been observed in
the early part of Zon e II. When A 2 is placed early in
Zone II, for example, 0.30-0.40 of A,A 1 , A 2A 3 may
depart from its usual constant value. If the perinodal
tissues are more refractory than usual, an A 2 in this
portion of the cycle may conduct into the S-A node
with great delay (ArSAN 2 greatly prolonged); even
if SAN 2 -SAN 8 is constant, A 2 A 3 will be prolonged
in direct proportion to the increase in ArSAN 2 • If
the S-A node pacemaker is unstable, then the spontaneous cycle length of the sinoatrial node pacemaker may not recover immediately after being reset by Ac, that is, SAN 2 -SAN 3 may prolong. Even
if ArSANc and SANH-Ai are not increased, A 2A 3
will prolong. An increase in A 2 A1 caused either by
changes in conduction or automaticity would cause
early Zone II responses to curve upward and be
readily ap parent in a plot of A 2A 3 vs. A 1 A 2 . Finally,
in Zone III, the effects of concealed conduction can
be so marked as to cause A 2 A 3 to vary from 0.7 to
values exceeding 1.0.
Thus, it is apparent that there is a great deal
that can be learned from analyzing the responses to
atrial pacing or premature atrial stimulation. The
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final role for these techniques in evaluating S-A
node function will not be settled until they have
been applied to a large group of patients and careful follow-up of these patients has been continued
for a period of time sufficient to determine the prognostic value of the tests. However, we have every
reason to hope that these tests which permit new insights into S-A node function will ultimately improve
our ability to predict the course of patients with S-A
node dysfunction. If they do, such tests will greatly
improve our therapeutic management of the "Sick
Sinus Syndromes."
PANEL DISCUSSION

Dr. Baird: Dr. Bigger, is atrial pacing of any value
in stressing ventricular conduction in patients with
bilateral bundle branch block?
Dr. Bigger: Do you mean rapid atrial pacing?
Dr. Baird: Yes.
Dr. Bigger: Very little, I think. In such cases, rapid
atrial pacing usually produces block at the A-V
node. It is more than useful to use premature
atrial stimulation, a technique which often permits
one to demonstrate transmission through the A-V
node but block in the bundle branches, if a His
bundle recording is also made. This is a better
technique for demonstrating bundle branch disease.
In A-V nodal disease, of course, you may get second
degree A-V block at an unduly low rate during
fixed rate atrial pacing.
Dr. Scherlag: As I think most people know, there
are patients who show periods of complete heart
block and then periods of sinus rhythm with normal
conduction. Doctor (Onkar) Narula has alluded to
the fact that these patients, after complete heart
block and subsequent sinus rhythm , sometimes will
show 1 : 1 conduction up to rates of 150 or 180 per
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minute without showing any evidence of fatigue in
A-V conduction. My indication from his data is that
atrial pacing is not a good way of assessing conduction defects in the His-Purkinje system, even
with atropine. Doctor Narula feels that the use of
premature beats might be a useful tool in assessing
critical A-V conduction delays, particularly those
in the His-Purkinje system, but I do not think the
definitive data are as yet available.
Dr. Bigger: Premature atrial stimulation is also a
better test to assess A-V conduction when marked
left axis right bundle branch block is present, since
you can actually measure the functional refractory
period of the posterior division of the left bundle
with premature atrial stimulation. Prediction of
future functional performance is what we all would
like, but I am afraid that is the pot of gold at the
end of the rainbow. As we have emphasized so
many times, the heart under test conditions may not
relate to the heart under conditions not related to
the test or predict the future . Much remains to be
learned about the prognostic significance of functional testing.
Dr. Moe: Years ago I used to demonstrate this
phenomenon to students in the open chest dog as an
attempt, in effect, to estimate refractory period of
the sinus node. If you deliver a premature atrial
stimulus at a time when the S-A node is refractory,
the node will not discharge. Thus, the next expected sinus beat arrives almost on schedule and is,
therefore, an almost interpolated atrial beat. Later
premature beats will, of course, discharge the pacemaker although with a delay attributable to delayed
conduction. The sum of the test cycle plus the
"return" cycle, when plotted against the duration of
the test cycle, will exhibit a sharp break. I wonder
if you ever saw this break in the human heart.
Dr. Bigger: Yes, we have seen that quite often.
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Within recent years an abundance of information has become available concerning the pathology,
electrophysiology, anatomy, and clinical significance
of disturbances of atrioventricular (A-V) conduction.
Interest on this subject apparently began in 1827
with a description by Adams ( 1) of syncope associated with a slow heart rate and subsequent observations by Stokes (27) in 1846. Wenckebach
(36) (1899) and Hay (7) (1906) described atrioventricular conduction block and ushered in the
era of eponyms and synonyms in the classification
of atrioventricular conduction disturbances . The
issue heated up intensely in 1924 when Mobitz (15)
classified A-V block according to rather precise
criteria. In the following years, numerous clinical
and experimental studies appeared in the medical
literature. In 1941, Katz (9) attempted to describe the clinical correlation in the presence of
various types of A-V block. Uhley and Rivkin (28,
29) first described the ECG pattern following the
interruption of the main and peripheral branches of
the canine right (1961) and left (1964) bundle
branch system, and in 1963 , Lenegre ( 11, 12,
13) and Lev (14) initiated the intense anatomical
studies that led to the more recent concepts of
intraventricular conduction disturbances. Precise
experimental studies by Lenegre (11, 12, 13),
Lev (14), Pruitt (22), and Rosenbaum (23) offered a logical classification of block within the
fascicles of the Purkin je system. By the mid-1960's,
Hoffman and Cranefield (8) , Paes de Carvalho (20) ,
Watanabe and Dreifus (30, 31) , and others had

* Prese nted by Dr. Dreifus at the Symposium on Cardiac Arrhythmias, June JO, 1972, at Virginia Beach, Virginia.
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explored the electrophysiologic mechanisms of atrioventricular conduction delay at the cellular level.
Studies in man using His bundle electrograms by
Damato and associates (2) and Narula and coworkers (17, 18, 19) confirmed the findings in
earlier animal experiments . However, the importance of a more precise classification of A-V block
came into sharp focus with the development of
electronic pacing and the dramatic lifesaving results
which followed . Unfortunately, too little is known
about the life expectancy in patients with A-V block,
and the medical literature is often distorted by a
few scattered cases with unusually long survival
or by including cases of A-V block engendered by
an acute myocardial process ( 5). It is our intention
to review the present anatomic, electrophysiologic,
and clinical knowledge in an attempt to define A-V
conduction disturbances. It is probably wise to consider first the classical definitions set forth by
Wenckebach (36) and Mobitz (15, 16).
In his original paper in 1899, Wenckebach
( 36) described a progressive prolongation of the
a-c interval (interval between atrial and ventricular
contractions) until one ventricular contraction
dropped out. Following a pause, the a-c interval
was shortest, which suggests improved conductivity.
Impairment of conductivity as judged from the increment of the a-c interval was most marked in the
second conducted beat and much less in subsequent
beats. This resulted in a quickening of the radial
pulse. However, the increment of a-c interval was
often again greater immediately before the dropped
beat in the presence of higher conduction ratios,
resulting in a slowing of the pulse. When Mobitz ( 15)
for the first time classified incomplete A-V conduction disturbances in 1924, he termed the above
MCV QUARTERLY 9(1): 86-91. 1973
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variety Type I, which subsequently became known
by the name of "Wenckebach periodicity."
In contrast, Mobitz ( 16) called a block Type
II when a ventricular complex dropped out without
any change in the P-R interval of the electrocardiogram in immediately preceding beats. He
also mentioned that, in the Type II variety, often
many successive ventricular beats dropped out
causing prolonged asystole, despite preceding periods
of 1: 1 conduction with a normal P-R interval.
Hence, it must be reemphasized that the original
classification of the two types of "partial heart
block" was based entirely on variation or constancy of the A-V conduction time.
Clinical Findings. First Degree Atrioventricular
Block. First degree block does not itself produce
any symptoms. From a physical standpoint the
presence of this type block may be suspected by
the finding of a soft first heatt sound. Levine and
Harvey ( 1949) provided us with an explanation
of this finding. These workers reported that the
intensity of a first heart sound depended upon the
position of the cusps of the A-V valves at the onset
of systole. If ventricular systole occurs shortly
after atrial systole, the A-V valves are open wide and
will be closed violently and abruptly during systole
producing a loud first sound. When the interval
between atrial and ventricular systole is longer, the
cusps will tend to return to their original position
so that the sound produced at the time df ventricular
systole would be much softer. This suspicion may be
confirmed when inspection of the jugular pulse
discloses a delay between the A and V waves.
Second Degree and High-Grade Atrioventricular Block. Second degree and high-grade atrioventricular block may or may not produce symptoms.
Second degree A-V block with Wenckebach periods
must be differentiated from the pause following an
extrasystole. This can usually be done with
auscultation. In block there is ventricular acceleration before the pause. Difficulty may arise
in diagnosis because occasionally a blocked atrial
premature beat may cause a pause in the sinus
rhythm. If the P wave is hidden in the T wave,
interpretation may be quite difficult. From the
physical standpoint, however, the extrasystole will
produce a cannon wave in the neck. More advanced second degree block with 2: 1 A-V ratio
produces a marked bradycardia.
Electrocardiographic Findings. The traditional
classification of atrioventricular block involves three
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major types. In first degree, there is merely a prolongation of the P-R interval, and every atrial impulse is conducted into the ventricle. Second degree
A-V block has been divided into two sub types:
Mobitz Type I which is equated with the traditional
Wenckebach (15) periodicity, in which the P-R
interval is gradually prolonged and eventually the
QRS complex drops out (figs. 1 and 2), and
Mobitz Type II second degree block; characterized
by the sudden dropping out of a QRS complex
without progressive proiongation of the P-R interval
(figs. 3 and 4) . Complete or third degree A-V
block is identified by independent activation of
atria and ventricles with nd conduction seen when
physiologic P-R intervals are possible. The ventricles
beat independently, each with its own pacemaker.
The difficulty with this traditional classification is
that the site of the A-V block is not specifically
identified. In addition; it cannot be utilized In 2: 1
conduction or in any rhythm othet than sinus
(figs. 5 and 6) . Hence, more precise identification
of the type and site of conduction block is
mandatory, as specific clinical programs must be
organized. There is no problem with first degree
block; however, with second degree block, classification based on the width of the QRS interval will
apply to all conduction ratios including 2: 1, high
grade A-V block, and in certain instances of atrial
fibrillatidn (figs. 3, 4, 5, and 6).

x

Fig. I-Orthogonal leads X, Y, Z. A sinus rhythm is present at a rate of 75/ min. The P-R interval becomes progressively prolonged with 0.22 sec to 0.32 sec before the
6th P wave fused with the T wave is dropped. This is a
Type I block (Wenckebach) associated with an acute inferior wall infarction.
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Fig. 2- Second degree block Type I, produced by atrial stimulation, lead 2 and His bundle electrogram shown. The A-H interval
increases from 150 to 440 msec before the 4th atrial impulse is not conducted to the ventricles.

Confusion occurs when one talks exclusively
of the progressive or sudden increase of the P-R
interval before the dropped beat in attempting to
classify the two types of block, as this criteria can
be applied only in the presence of regular supraventricular rhythm and second degree A-V block
associated with conduction ratios greater than 2: 1
( 3 3) (fig. 7). Furthermore, instances of atrial
fibrillation and higher grades of A-V block cannot
be considered in this classification (fig. 6).
In figure 7, taken from the same patient within
a few seconds, both types of conduction block are
demonstrated. In the upper strip (lead 3) sudden
dropping out of a QRS complex is evident after
beats 1, 6, and 7. The P-R remains constant at
0.20 seconds before the block occurs. This is Type
II conduction block. However, in the lower strip,
the P-R interval increases from 0.20 to 0.32 seconds
before the third and ninth P waves are not conducted. This represents a Type I conduction block.

Fig. 3-Second degree block Type 11 variety. In lead l,
2: 1 cohduction is seen; in lead 2, 3:2 conduction is present. AYR shows 1: 1 conduction.

However, the QRS complexes are narrow, and
block, in both instances, is most likely within the
A-V node.
On the other hand, the QRS duration cannot
always identify the precise site of conduction block.
Type I or the Wenckebach variety can occur in
all excitable tissue, and along the entire A-V
transmission system ( 4). However, the nature of
conduction delay usually localizes the block in
the intra nodal region of the A-V node ( 6). Further
problems may arise when more than one region
of block may be present in the same patient.
From the clinical standpoint, it is the location of
the block that largely determines the significance,
rather than the variation or constancy of the P-R
interval. Mobitz originally described the high incidence of Adams-Stokes attacks as well as complete
heart block in cases of Type II variety. Later
Katz ( 9) and Donoso and associates ( 3) confirmed
the sinister prognosis associated with block and wide
QRS complexes. Similar observations were made
by Lenegre (12) , Scanlon (24, 25), and Haiat (6)
and their co-workers. In the latter study, major
neurologic or cardiac symptoms were present in
86.2 % of patients with A-V block associated with
wide QRS complexes as contrasted to 37.5 % of
those patients with narrow QRS complexes. Futhermore, the incidence of sudden cardiovascular death
was more than twofold in the group with wide
QRS complexes. Second degree and high-grade A-V
block offered a similar prognosis.
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Fig. 4- His bundle electrogram, first two beats are produced by ventricular pacing. P waves are conducted to His bundle but are
blocked below His. This type of conduction block is usually associated with Type II conduction.

With the development of cardiac pacemakers
as well qS the expanding knowledge in precise
localization of the pharmacologic action of antiarrhythmic and cardiotonic agents, the clinician must
acquire a firm understanding of the nature of A-V
transmission. Digitalis, acetylcholine, and ischemia
appear to slow intranodal conduction, while procainamide, quinidine, propranolol, potassiuin salts,
and lidocaine slow conduction above the A-V node
and in the subjunctional region (21, 34, 35). For
practical purposes, the site of block can be identified
by the duration of QRS in most instances, and His
bundle electrocardiography will add little to clinical manageinent. If progressive P-R prolongation

is seen with a wide QRS complex, two levels of
block may be present, but therapy is predicated on
the lowest level of block. Conduction delay of the
Wenckebach variety is most common in the "N"
region of the A-V node but can be seen in the
subjunctional region of the A-V transmission system ( 19) and even between contiguous ventricular
fibers ( 4) , but offers little as a prognostic sign
alone.
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Fig. 5- 0rthogonal leads X, Y, Z. 2: 1 conduction is present and QRS complexes are wide. This type of conduction
cannot be classified, block probably exists in the fascicles
and is subjunctional in location.
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Fig. 6-0rthogonal leads X, Y, Z. QRS complexes are
wide and show a right bundle branch system block configuration with an S wave a ppearipg in lead X. A QRS
complex fai ls to appear following the 6th P wave. P-R
interval had become progressively lo nger from 0. 18 sec to
0.32 sec before dropping out of QRS. Two levels of block
m ay be postulated, the first withiTJ the A-V node, causing
Wenckebach periodicity, and second , a subjunction block in
the fasc icles of the ri ght bundle branch system.
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9. KATZ, L. N . Electrocardiograph y . Philadelphia, Lea &
Febiger, Inc., 1941, p . 729.
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JO. KAUFMAN, J. G. , WACHTEL, F . W ., RoTHFI ELD , E., and
BERNSTEIN, A . The association of complete heart block
and Adams-Stokes syndrome in two cases of Mobitz
type block. Circulation 23: 253 , 196 J.
11. LENEGRE, J. and MOREAU, P . Le block auriculpventriculaires chronique-etude anatomiq ue, cliniqu e et histologique . Arch. Mal . Coeur 51:867 , 1963 .

Fig. 7-Second degree block showing both Type I and
Type II conduction block (see text).

Determination of the varieties of A-V block
is predicated on the precise identification of the
site ( s) of conduction delay as prognosis, and therapy
must follow on this basis. Further electrophysiologic
and pharmacologic studies will undoubtedly reveal
other mechanisms on the nature of A-V transmission.
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Microelectrode and His Bundle Studies on
Type I and II Second Degree A-V Block*
E. NEIL MOORE, D.Y.M., Ph.D., F.AC.C.
Professor of Physiology, The School of Veterinary Medicine,
University of Pennsylvania, and Professor of Physiology in Medicine,
Department of Medicine, Hospital of the University of Pennsylvania,
Philadelphia, Pennsylvania

JOSEPH F. SPEAR, Ph.D.
Assistant Professor of Physiology, The School of Veterinary Medicine,
University of Pennsylvania, Philadelphia, Pennsylvania

Mobitz classified second degree A-V block
into two cateogries. Mobitz type I, or Wenckebach
block, is characterized by a gradual prolongation
of the P-R interval preceding the dropped ventricular beat. In Mobitz type II block, the dropped beat
occurs without preceding prolongation of the P-R
interval. Bundle branch block usually is present in
patients with Mobitz type II block. The importance of
distinguishing between these two types of A-V block
lies in the usual irreversibility and higher mortality
of patients with type II A-V block, as contrasted with
type I or Wenckebach block. Also, Mobitz type
II block frequently progresses to complete A-V block
and Adams-Stokes attacks, thus necessitating a cardiac pacemaker (1, 2, 3).
Using only electrocardiographic recordings, it
is not possible to define the location within the A-V
conduction system where A-V block actually develops. The need to distinguish between conduction failure above or below the bundle of His is important
since dropped beats occurring from block within the

* Presented by Dr. Moore at the Symposium on Cardiac
Arrhythmias, June 10, 1972, at Virginia Beach, Virginia.
These studies were supported in part by grants from the
American Heart Association 71-787 and USPHS (HE-0488513).
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A-V node would not carry as serious a clinical prognosis as would block within the ventricular specialized conduction system (VSCS or His-Purkinje
system). The following figures are presented to demonstrate the use of the microelectrode technique
and His bundle electrogram recording technique to
localize the site of A-V block in type I and II block.
Figure 1 is an example of Wenckebach or
Mobitz type I second degree A-V block. Electrograms were recorded simultaneously from the right
atrial appendage (RA), bundle of His (BH), and
right ventricles along with a lead II electrocardiogram. The bundle of His electrogram contains three
deflections: an atrial deflection, His bundle spike,
and a ventricular septa! complex. Each of the His
bundle depolarization complexes is designated by
a small letter h.
In the lead II ECG, it can be noted that the
first three P-R intervals progressively increase until
the fourth P wave is not followed by a ventricular
response. This 4 : 3 Wenckebach cycle then repeats
again. An approximation of the conduction time
through the A-V node can be determined by the
interval between the atrial deflection in the RA
electrogram to the His bundle spike (h) in the BH
electrogram. The fact that the progressive increase
in the P-R interval in this typical example of Mobitz
MCV QUARTERLY 9(1) : 92-98, 1973
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Fig. 1- Mobitz type I block due to conduction failure within the A-V node of the in vivo dog heart. Bipolar electrograms were recorded from the right atrium (RA), bundle of His (BH), and right ventricle (RV) together with the lead II electrocardiogram (II).
The timing signal (T) denotes 100 msec. The h indicates the His spike in the BH electrogram.

I block is a reflection of a progressive increase in A-V
nodal conduction time is demonstrated by the atrial
to His conduction time between the first and third
beats. The fourth atrial deflection is not followed by
a His bundle spike. Therefore, A-V block of this
atrial beat occurred at a site above the bundle of
His recording site, that is, within the A-V node. Note
that the interval between His bundle depolarization and ventricular depolarization did not change in
any of the conducted beats, thereby indicating that
ventricular conduction in Mobitz type I block is normal. Type I Mobitz block can be a functional type of
A-V block when associated with rapid atrial pacing.
Most normal human hearts will exhibit Wenckebach
type block upon rapid atrial pacing. Again, this
type of second degree A-V block is nearly always
due to conduction delays and block within the
A-V node.
Figure 2 is presented to further demonstrate that
the prolongation and block of A-V conduction
in type I block occurs within the A-V node. Atrial
(RA) and ventricular (RV) electrograms were
recorded simultaneously with transmembrane potentials from two single A-V nodal fibers (N and NH)
during 3: 2 Wenckebach. Ten msec and 100 msec
time dots are indicated in the top trace, T. The first
atrial response was conducted to the upper A-V nodal
fiber (N) with little conduction delay. Conduction
time from the upper nodal fiber (N) to the lower
A-V nodal (or upper bundle of His) fiber, labeled
NH, required 110 msec. Conduction from the NH fiber to the RV extracellular electrode required only
58 msec. The increase in atrial (RA) to ventricular
(RV) conduction time of the second beat resulted

from slowed conduction within the A-V node as demonstrated by the increased time for the excitation
wave to be transmitted from the upper to lower
A-V node, that is, the N-NH interval (A-V conduction time) for the second response is 60 msec
longer than for the first beat. Conduction time
between the NH fiber to RV extracellular electrogram was 12 msec longer than for the first beat.
The third atrial response (RA) failed to be conducted to the ventricles as shown by the absence
of a ventricular depolarization complex in the RV
electrogram. Block of this atrial beat occurred
within the A-V node at a location between the
impaled upper and lower A-V nodal recording sites.
Clearly, this example of 3 : 2 Wenckebach resulted
from block within the A-V node.
In Mobitz type II second degree A-V block,
the P-R interval is usually normal and remains
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Fig. 2-Mobitz type I block due to conduction fai lure within
the A-V node of the in vitro rabbit heart. Bipolar electrograms were recorded from the right atrium (RA) and right
ventricle (RV) together with transmembrane potentials from
the high A-V node (N) and low A-V node (NH). The
timing signal (T) denotes 10 msec and 100 msec intervals.
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constant preceding the dropped beat. Figure 3 is an
example of Mobitz II block in a patient with left
bundle branch block. As mentioned previously, Mobitz type II block is usually accompanied by some
form of bundle branch block. In figure 3, electrograms were recorded from the bundle of His, atrium,
and ventricles together with ECG leads 1, 2 and
V 1 . His bundle depolarization complexes are denoted by "h". The first three beats were conducted
normally to the bundle of His; conduction time
from the His bundle to the ventricles was prolonged
to 70 msec. The fourth atrial response resulted in a
bundle of His depolarization complex, but was not
accompanied by ventricular depolarization. The
atrial to His bundle conduction time for the dropped
ventricular beat was normal. Therefore, in this typical case of Mobitz type II block, conduction failure
occurred within the ventricular specialized conduction system at a site below the A-V node and
bundle of His. The fourth ventricular beat is an
idioventricular escape beat. The P-R intervals before and after the "dropped" beat are identical and
within normal limits. On a routine ECG, the presence of an intraventricular conduction defect accompanying second degree A-V block would be
highly suggestive that block developed below the
A-V node.
Figure 4 demonstrates type II Mobitz block in
the isolated rabbit heart. In this experiment the
heart was paced from the atrium at a constant rate
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Fig. 3-Mobitz type II block in a patient with left bundle
branch block. Catheters were used to record from the
bundle of His (BH) , the right atrium (RA), and right
ventricle (RV) together with three simultaneous electrocardiographic leads (I, II and V,). The h in the BH record
indicates the His spike. (Reproduced with permission from
B. N. Goldreyer and from Annals of Internal Medicine
77: 132, 1972.)
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RV
Fig. 4-Mobitz type II block occurring in the His-Purkinje
system of the in vitro rabbit heart. Bipola r electrograms
were recorded from the right atrium (RA), and right
ventricle (RV) together with transmembrane potentials
from the bundle of His (BH) and right bundle branch
(RBB). The timing signal (T) denotes 100 msec and 1 sec
intervals. (Reproduced by permission of The American
Heart Association, Inc. from J. F. Spear and E . N. Moore,
"Electrophysiologic Studies on Mobitz Type II Second Degree Heart Block," Circulation 44: 1090, 1971.)

of 99 per minute; this rate caused some beats to be
dropped abruptly. Electrograms were recorded from
the right atrium (RA) and right ventricle (RV)
simultaneously with transmembrane action potentials recorded from a bundle of His fiber (BH) and
right bundle branch fiber (RBB). Time marks (T)
denote 100-msec and 10-sec intervals. Notice that
each right atrial electrogram was accompanied by
an action potential recorded from the bundle of
His, and that the atrial-to-His bundle conduction
time (RA-BH) and His-to-right ventricular conduction time (BH-RV) remained constant. The
bundle of His action potential was not accompanied
by a right bundle branch action potential when the
atrial impulse failed to be conducted to the ventricles (fourth, eighth, and tenth RA responses).
Therefore, in this example of Mobitz type II block,
conduction failure occurred below the bundle of
His somewhere above the impaled bundle branch
fiber. Figures 3 and 4 confirm studies completed in
man where the sudden dropped beat in type II
second degree block results from block within the
ventricular specialized conduction system.
Figures 3 and 4 demonstrate the usual site of
conduction failure in Mobitz type II block, that is,
block within the VSCS below the A-V node and
bundle of His. However, in some rare instances a
constant P-R interval with sudden dropped beats
may result from block within the A-V node. These
cases of Mobitz type II block are usually associated
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with a prolonged P-R interval and a normal QRS
complex (4). In these rare cases of Mobitz type
II block where block develops within the A-V node,
one would not expect as grave clinical consequences
as those associated with A-V block below the bundle
of His within the VSCS.
Figure 5 presents an example of a constant
P-R with a sudden ciropped beat developing due to
A-V nodal conduction block. The data was recorded
in an in vivo dog preparation in which electrograms
were recorded from the right atrium (RA), bundle
of His (H), and left endocardial Purkinje fiber
(LPF) simultaneously with the lead II electrocardiogram (II). Time marks denote 100 msec
intervals. The right atrium was paced at a basic cycle length of 258 msec (heart rate of 234 per min).
At this rapid rate, conduction time through the A-V
node was somewhat prolonged, but the P-R interval
of 0.14 sec is still within the normal range in the
dog (0.06 to 0.15 sec). Every fourth atrial beat in
figure 5 was made premature by 20 msec. In the
standard electrocardiographic tracing, this would
mean that every fourth response would have a variation in the P-R interval of 0.5 mm, tpat is, a sinus
arrhythmia was present which would be barely perceptible in the routine ECG tracing. This small variation in the P-R interval resulted in 4: 3 second degree block; it can be observed in the lead II ECG
that the fourth atrial response is blocked. As so commonly occurs in clinical cases of type II block in
man, the P-R interval following the blocked beat was
slightly shorter than that for the responses preceding the blocked beat. The fact that bundle of His
and left Purkinje electrograms were not recorded
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during the dropped response demonstrates that in
this instance of type II Mobitz second degree block,
conduction failure occurred above the bundle of His,
rather than within the VSCS as is the usual case in
man. This finding is important since it points out
that type II block can occur above the bundle of
His as well as within the VSCS, and that small
variations in cycle lengths can determine whether an
atrial response is or is not conducted to the ventricles. Similar findings of type II block above the
His bundle occurred when A-V conduction was depressed by vagal stimulation or digitalis toxicity ( 6).
Recent studies indicate that concealed His bundle extrasystoles or echo beats can cause pseudo-type
II block ( 5, 6) . Such findings have been dependent
upon the chance occurrence of an extrasystole or
echo beat blocking a regularly conducted beat. In
our experiments we were able to demonstrate
pseudo-type II block consistently by evoking extrasystoles in the bundle of His using a technique for
intracellularly stimulating and recording through the
same microelectrode. This technique allows precise
localization of the site of stimulation as well as direct
verification of activation of the same cell.
In figure 6, simultaneous atrial and ventricular
electrograms are shown as well as a transmembrane
potential recording from the bundle of His in an isolated rabbit heart. The ladder diagram is included
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Fig. 5-Mobitz type II block due to conduction failure
within the A-V node of the in vivo dog heart. Bipolar
elec(rograms were recorded from the right atrium (RA),
bu ndle of His (H), and left Purkinje fiber (LPF) together
with a lead II electrocardiogram (II) . The timing signal
(T ) denotes JOO msec interyals. The h in the H electrograrn
indicates the His spike, and the p in the LPF electrogram
indicates the Purkinje spike. (Reproduced by permission of
the American Heart Association, Inc. from J. F. Spear
and E. N. Moore, "Electrophysiologjc Studies on j\fobitz
Type II Second Degree Heart E!lock," Circulation 44: 1091,
1971.)
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Fig. 6-Pseudo-Mobitz type II block due to a premature
concealed impulse arising in the bundle of His . in the in
vitro rabbit heart. Bipolar electrograms were recorded from
the right atrium (RA) and right ventricle (RV) together
with the tninsmembrane potential from the bundle of His
(H) . The timing signal (T) denotes 100 msec in(ervals. The
ladder diagram below demonstrates the conduction sequence
through the right atrium, A-V node (AVN) , His bundle and
right ventricle. (Reproduced by permission of The American
Heart Association, Inc. from J. F. Spear and E. N. Moore,
"Electrophysiologic Studies on Mobitz Type II Second Degree Heart Block," Circulation 44: 1093, 1971.)
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TABLE 1.
DESC::RIPTION

PATTERNS OF MOBITZ TYPE I AND TYPE II HEART BLOCK

CLINICAL APPEARANCE
P-R interval
QRS duration

CAUSE OF CONDUCTION FAILURE
block in A VN
block in VSCS " pseudo-block"

Mobitz I
(increasi_ng P-R interval)

increased
increased

increased
normal

possible
likely

likely
possible

possible
possible

Mobitz II
(constant P-R interval)

normal
increased

increased
normal

possible
likely

likely
possible

possible
possible

below the analog tracings as an orientation to the
sequence of conduction. Notice that after the third
conducted beat a premature action potential is
evoked in the bundle of His by stimulation through
the recording microelectrode. The premature action potential is concealed both antegradely and
retrogradely but has the effect of blocking conduction
of the subsequent atrial activation (fourth atrial response). The electrocardiographic pattern that this
intervention produces is "pseudo" Mobitz type II
block with the site of block occurring within the
A-V node.
Table I summarizes varioµs possibilities for
Mobitz types I and II second degree A-V block.
Mobitz type I, or Wenckebach block, with progressive P-R prolongation is usually associated with a
normal ORS complex and block within the A-V node.
At rapid atrial rates, this can be a functional type
of block without any pathology being present in
the A-V node. Mobitz type I block following myocardial infarction in which block develops within the
A-V node usually is a reversible arrhythmia. When
block occurs below the A-V node within the ventricular specialized conduction system, a graver
prognosis would usually pe given.
Mobitz type II block, in which the P-R interval
is constant preceding the dropped beat, is usually
associated with bundle branch block, prolonged
ORS complex, and a high instance of Adams-Stokes
attacks. In these cases, the site of A-V block is nearly
always below the A-V node within the ventricular
specialized conduction system. In rare instances, a
variation of Mobitz type II block in which the P-R
interval is fixed but prolonged and the ORS complex is normal may be encountered where the site
of block is within the A-V node. Thus, second
degree A-V block is one instance where His bundle electrocardiography may be indicated. This is
true since from the clinical standpoint it is predominantly the site of block rather than the P-R interval

which determines the significance of the block; block
above the bundle of His is usually benign while
block below His bundle is usually malignant.
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PANEL DISCUSSION

Dr. Baird: Dr. Bigger, if a patient presents with a
Mobitz type II block and syncope, although you
have not documented t~at the patient had third
degree block, what woul~ you recommend with
regard to permanent pacemaker therapy, or would
you recommend pacemaker therapy without documentation of third degree A-V block?
Dr, Bigger: With Mobitz type TT block or even
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with left axis deviation, right bundle branch block,
and even one nonconducted beat and the history
of syncope, I think there is sufficient indication for
a pacemaker. I think there is almost unanimous
agreement on that. There are groups now, however,
who would put pacemakers in those patients with
a vague history of dizziness, light-headedness, fatigue,
and marked left axis deviation with right bundle
branch block. I want to tell this audience that this
is a highly experimental approach and not of proven
benefit. People can carry the pattern of marked
left axis right bundle branch block and, if they
have never dropped a beat, they may carry that
pattern for 20 years without experiencing difficulty.
In my view, it has by no means been proven that
you should put in a pacemaker unless you have
seen dropped beats. However, it is very clear in
several prospective studies that once you have seen
one drop beat in a patient with marked left axis
deviation and a right bundle branch block type
pattern on the electrocardiogram, then a very high
percentage of those patients will be in complete
heart block within one year to 18 months.
Dr. Moore: Would you put a pacemaker in a
patient with Mobitz type I block in which a His
bundle electrogram demonstrates that type I block
is due to progressive delay in the His-Purkinje
system?
Dr. Bigger: I have studied only three such patients
myself. All of them had marked left axis with right
bundle branch block and subsequently showed
Wenckebach phenomenon with the H-V getting
longer and longer in the His bundle study. One
characteristic of the body surface electrogram is that
the increments in P-R interval prolongation are
not large. The entire Wenckebach cycle tends to
be just two or three beats; the beat drop is more
abrupt. It is strikingly different to the eye than the
usual type I A-V block. I think these patients do
deserve pacemakers.
Dr. Scherlag: Dr. (Onkar) Narula and Dr. (Philip)
Samet have published a paper on Wenckebach
not only below the His bundle but also within the
His bundle itself. I think one uses the well-accepted
clinical criteria that if one sees a drop beat and one
knows it is in the His-Purkinje system, certainly
that is a strong indication for pacemaker therapy.
The problem, and I think this is an important one
that others have not really dealt with, is that the
natural history of such cases is not well known. I
do not know if any physician would want to chance

97

just following a case of that type because of the
possibility that Stokes-Adams might occur a short
time afterwards. So, in general, most people want to
be safe and would put a pacemaker in under those
circumstances. I believe that is what happened to
those patients who were described by N arula, et al.
Dr. Bigger: I would have to agree with that last
statement except that I think it is possible to follow
natural history such as when using a demand pacemaker. You can see when the pacemaker starts to
stimulate or how often it is active by the usual
ambulatory monitoring techniques. If the pacemaker
activates, you could bring them in and with temporary transvenous catheters inhibit the demand
pacemaker for study. I do not think we completely
lose our opportunity for studying the natural history
of a patient by introducing therapy.
Dr. Moore: I personally would wan.t a pacemaker
just to be sure.
Dr. Bigger: I do not think it is reasonable to implant pacemakers in left axis right bundle branch
block. No such indication is evident in second
degree A-V block. Yet in some places every patient
with that pattern gets a pacemaker. I am not sure
all of those physicians are carefully following the
patients as a study to see what happens in real life.
This is clearly a very experimental type of program
to be carrying on.
Dr. Moore: Recently, in a patient with a right
bundle branch conduction delay, we demonstrated
that slight variations in the P-P interval could result in a sudden dropped beat and a Mobitz type
II electrocardiogram. In this patient we did the same
thing we did in the dog; that is, we drove the atrium
rapidly so that the A-V conduction time was slightly
prolonged, but still giving a normal P-R. The QRS
was abnormal because of the underlying bundle
branch conduction problem. By bringing in one P
wave 20 msec early we were able to have this
atrial response block within the A-V node. Again,
this would look like a Mobitz type II with a sudden
drop beat due to the slight prematurity of the atrial
response. However, the dropped beat was blocked
within the A-V node and, thus, probably should not
require a pacemaker.
Dr. Baird: . Dr. Bigger, how would you manage a
patient with left bundle branch block and syncope
that was presumably a recent onset?
Dr. Bigger: How old is this man?
Dr. Baird: He is sixty-seven.
Dr. Bigger: Well, this electrocardiogram, as I see
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it of course, is left bundle branch block, and the
P-R is probably 19 or 20, clearly prolonged. Did
' the left bundle branch block just come on about the
time of the syncope?
Dr. Baird: It was a persistent left bundle.
Dr. Bigger: Of known duration or just encountered?
Dr. Baird: It was at least two months in duration.
A previous tracing was taken two months before he
had the syncope and, at that time, during his routine
physical examination, the electrocardiogram appeared to be completely within the normal limits.
Dr. Bigger: It is difficult to be sure syncope had
anything to do with his heart. It would require a
work-up involving the extracranial vascular system
and possible CNS causes of syncope.
Dr. Baird: He was lying down one Sunday night
and suddenly developed seizure-iike activity. He
then awoke in about 10 or 15 seconds and resumed
normal activity for the evening. We did just as you
suggested and had the neurology service evaluate
him. They found nothing neurological. We did Holter
monitoring, and there was no evidence of A-V block
or any dropped response. The patient felt, like Dr.
Bigger, that there was possibly no justification for a
pacemaker. The question is, would a His bundle
recording be of any benefit in a patient of this
type in determining whether he deserves consideration for demand pacing, particularly in the presence
of the history of recurring syncope?

Dr. Bigger: This is a question Dr. Ken Rosen has
been particularly interested in, the H-V time in left
bundle branch block. The probability of developing
complete heart block may relate to whether or not
the H-V interval is long when the body surface
cardiogram shows complete left bundle branch block.
I think his hope is that H-V time wili become a
criteria that will be helpful in pointing to those who
should and those who should not have pacemaker
therapy. I have not been entirely convinced, but it
seems a fruitful area for study.
Dr. Scherlag: I can appreciate the perplexity of the
problem, and it is rather important because of the
studies in Miami. There they have done several
hundred cases, and they feel that with an H-V time
of 70 or more and with this kind of history, such
a patient is possibly going to have another seizure.
I thirik that the H-V time would be an important
objective measure to get.
Dr. Baird: Our patient refused pacemaker therapy,
so we taught his wife cardiopulmonary resuscitation.
However, with recurrent attacks he agreed to have
a pacemaker and while waiting in the clinical center,
he again had syncope. On this occasion, his wife
successfully resuscitated him. The following day
during elective pacemaker surgery, he developed
complete A-V block. At this time, he has done
relatively well, but A-V block was finally documented.

Recent Studies in the Pre-Excitation Syndrome*
E. NEIL MOORE, D.V.M., Ph.D., F.A.C.C.
Professor of Physiology, The School of Veterinary Medicine,
University of Pennsylvania, and Professor of Physiology in Medicine,
Department of Medicine, Hospital of the University of Pennsylvania,
Philadelphia, Pennsylvania

The Wolff-Parkinson-White syndrome has
held an unusual fascination for cardiologists ever
since its original description in 1930. Over 60 different theories have been postulated to describe the
mechanism of pre-excitation. The recent development of epicardial mapping techniques to define the
sequence of ventricular activation, and the introduction of His bundle electrocardiography have
provided valuable procedures for studying pre-excitation . This presentation will discuss some of the
insights into the mechanism of pre-excitation that
have been derived from these two electrophysiological procedures.
Epicardial Mapping. Epicardial mapping of
the sequence of ventricular activation is usually
accomplished in the following way. First, a monopolar recording electrode is fixed within the ventricular cavity, or else bipolar electrodes are attached to the ventricular free wall. This permits
recording of a consistent activation time which remains stable at a fixed time during ventricular
activation and the inscription of the QRS complex.
The standard ECG cannot be used as an indication
of onset of ventricular activation due to the variations that result from moving the heart within the
chest cavity to facilitate mapping both the right and
left ventricular free walls. In addition to a fixed
reference electrode, a second bipolar electrode ( roving electrode) is placed at multiple sites on the ventricular epicardium; the time for onset of activation
at each site is measured against the activation time
of the fixed reference electrogram . By determining
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the activation times at many epicardial sites, for
example, 40 sites would be very minimal for constructing an activation map of the right ventricle,
it is possible to construct a map of the sequence of
epicardial activation. Detailed methods for determining the sequence of cardiac activation have been
reported previously (1).
Figure 1 presents an ECG and bipolar electrograms recorded from a dog having spontaneous
WPW. The Lead II ECG has a prominent delta wave
without a visible isoelectric P-R segment. The uppermost electrogram labeled "Bipolar Electrograms
Post. RV" was recorded from the earliest site on
the ventricular epicardium where activation was
recorded. Note that this ventricular electrogram occurs at the end of the P wave and before the initiation of the delta wave. In any normal heart, ventricular activation at the posterior right ventricular
base would occur at least 50 msec later than shown
in figure 1. In addition to the epicardial electrode,
multipolar intramural electrodes were used to record from the right and left ventricular septum, in
this case of spontaneous WPW in a dog. Purkinje
spikes (labeled P) were recorded at the beginning
of both septal electrograms. In a normal heart, septa!
Purkinje activation develops just before, or at the
initiation of the QRS complex. In this WPW heart,
early activation in the right ventricle began before
the end of the P wave and preceded activity in
the right Purkinje system by 10 msec. The right
Purkinje system was activated prematurely by retrograde spread from the adjacent pre-excited myocardium. The impulse that spread over the normal
A-V pathway was recorded in the left Purkinje
network 30 msec after the onset of activity in the
right Purkinje system and occurred 40 msec after
pre-excitation of the posterior right ventricle. Since
99
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Fig. I-The degree of ventricular fusion during activation
in a dog with spontaneous WPW. Bipolar electrograms
recorded from the site of pre-excitation in the posterior
right ventricle and from the right and left septa! surfaces
are shown in relationship to the lead II ECG. P denotes
Purkinje potentials. Pre-excitation begins in the posterior
right ventricle during the P wave and before onset of the
delta wave in the ECG. The pre-excitation wave spreads to
the right septum and activates the right Purkinje system
prematurely. The left Purkinje system is activated normally
over the A-V conduction syste m. (Modified from J. P.
Boineau and E. N. Moore, "Evidence for Propagation of
Activation Across an Accessory Atrioventricular Connection in Types A and B Pre-excitation," Circulation 41 :386,
1970. Reproduced by permission of The American Heart
Association, Inc.)

the QRS duration was 65 msec, 60% of ventricular
activation must have occurred due to activation over
the accessory pathway before the impulse was propagated over the normal A-V conduction system to
the left Purkinje system.
Figure 2 presents th e sequence of ventricular
epicardial excitation and the lead II ECG recorded
at the time of surgery in a patient with type B
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Wolff-Parkinson-White syndrome. It was decided to
perform surgery since this patient had recurrent bouts
of tachycardia and had to be resuscitated from a
bout of ventricular fibrillation while in the hospital
for evaluation. The subject's preoperative ECG
(left tracing labeled "Pre-excitation") shows the
absence of a P-R segment, the presence of a delta
wave, and a marked prolongation of QRS. The initial or delta forces are oriented toward the left,
and the principal QRS forces are directed posteriorly, superiorly, and to the left. The time sequence
key below the maps of the heart indicates the times
in milliseconds that the various areas of the heart
were activated during the inscription of the ECG.
Earliest activity at time 0 was recorded from the region of the sinus node. The atrial activation wave
spread radially to the lateral right ventricular free
wall with earliest activity being recorded at 100
msec at the A-V sulcus. The spread of ventricular
activation then progressively spread radially from
the right lateral A-V sulcus towards the apex. Once
the sequence of ventricular activation was mapped
in this WPW patient, the region of pre-excitation
was sectioned along the right A-V sulcus. Following
sectioning of this region, pre-excitation disappeared .
Postoperatively, the ventricular activation sequence
became completely normal, with activation occurring
first at the medial aspect of the right ventricle near
the anterior descending coronary artery. Activity
then spread toward the A-V groove and into the
pulmonary conus region in a normal manner. The
patient's ECG has remained normal and no further bouts of tachycardia have been recorded since
interruption of the presumed lateral accessory bypass
tract.
The surgical interruption of a region of preexcitation resulting in normalization of the ECG is
strong supportive indirect evidence for the existence
of a lateral accessory bypass tract (bundle of Kent).
However, direct proof that lateral accessory bypass
tracts actually can conduct and pre-excite the ventricles resulting in pre-excitation in the ECG was
obtained in the dog with spontaneous WPW. Rather
than surgically section the region where pre-excitation was demonstrated by electrophysiological activation mapping procedures, the region was removed
for serial histological sectioning. An atrioventricular
accessory bundle was demonstrated histologically
at the precise location where pre-excitation was
found by activation mapping procedures. This study
provided the first direct demonstration that a lateral
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Fig. 2- Ventricular epicardial activation sequence map in a patient with type B WPW syndrome. On the left is the activation map and
lead II ECG recording during pre-excitation, and on the right is the map of epicardial excitation and the ECG following surgical
interruption of the A-V region where pre-excitation was recorded. The sequence key below each map indicates the relative activation
times. During pre-excitation (left map) a focal region at the lateral right A-V sulcus is activated first and closely follows atrial activation of the adjacent atrial muscle. Following surgical interruption earliest activation occurs at the region of the ventricular septum.
(Modified from J. P. Boineau and E. N. Moore, "Evidence for Propagation of Activation Across an Accessory Atrioventricular
Connection in Types A and B Pre-excitation," Circulation 41: 382, 1970. Reproduced by permission of The American Heart Association, Inc.)

accessory bypass tract (bundle of Kent) can produce an electrocardiogram exhibiting the WolffParkinson-White syndrome (1).
Bundle of His Electrograms in Pre-excitation.
The other development in cardiac electrophysiology
that has contributed recently to our better understanding of the pre-excitation syndrome is His bundle electrocardiography. The electrogram recorded
from the bundle of His contains three complexes
recorded from the lower right atrial septum (A), the
H is bundle (H), and the ventricular septum (V). The
atrial-to-His bundle activation time (A-H interval)
is roughly equal to A-V nodal conduction time and
the His-to-ventricular septa! activation time (or to

the earliest ventricular depolarization represented
on an electrocardiogram) reflects conduction time
within the ventricular specialized conduction system
(H-V interval). Sufficient numbers of studies in normal patients and in dogs have provided us with
normal A-H (50-120 msec in man) and H-V (25-55
msec in man) values.
Figure 3 presents electrograms recorded simultaneously from the right atrium (RA), bundle of
His (BH), left Purkinje fiber and left ventricular
muscle (LPF) together with a lead II electrocardiogram ( 3). The tracing labeled S is a recording denoting the time that an electronically simulated lateral accessory A-V bypass pathway pre-excited the
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Fig. 3-Electrograms and electrocardiograms recorded during pre-excitation using electronic circuitry to simulate
an accessory atrioventricular bypass tract. Right atrial (RA) ,
bundle of His (BH), and left Purkinje ventricular muscle
(LPF) electrograms were recorded simultaneously with the
lead II ECG . The upper tracing, S, indicates the time when
the lateral wall of the right ventricular base was pre-excited
by the "electronic A-V bypass" circuitry. Pre-excitation occurred 80 msec after the atrial electrogram in all three
beats. The third beat is a premature atrial beat and the A-V
nodal conduction time increased due to the prematurity.
Since the conduction time rem ained constant over the "electronic accessory bypass" tract, obvious pre-excitation occurred in the third beat as indicated by the inscription of
the QRS complex (ventricular depolarization) before the
depolarization of the bundle of His and Purkinje system.
(Modified from E. N. Moore and J . F . Spear, "Electrophysiological Studies on Pre-excitation in the Dog Using
an Electronically Simulated Atrioventricular Bypass Pathway," Circulation R es. 31: 174, 1972. Reproduced by permission of The American Heart Association, Inc.)

base of the right ventricle at the middle of the right
A-V sulcus. It can be noted that the electronically
simulated accessory bundle excited the right ventricular base at a constant interval following the RA
electrogram in all three beats. The atrial-to-His
bundle interval is normal in the first two beats reflecting normal conduction time through the A-V
node. The His bundle-to-ventricular septa! interval
is short, but within normal limits. Both His bundle
and Purkinje excitation precede the initiation of the
QRS complex in the ECG tracing. Therefore, the
presence of pre-excitation is not suspected, that is,
the P-R interval is normal and a delta wave is not
present. However, there is no question about preexcitation being present since we have electrically
pre-excited the right ventricular base. The amount
of ventricular fusion caused by pre-excitation in the

first two beats is too small to be observed without
additional procedures.
The major criteria for diagnosing WPW is the
presence of a short P-R interval, and a prolonged
QRS duration associated with a delta wave. Both
of these reflect the presence of ventricular fusion
caused by activity being conducted simultaneously
over the accessory A-V pathway and normal A-V
conduction system. The degree of fusion is influenced by the relative conduction times over the two
A-V pathways; as the conduction times over these
two pathways become more out of phase, for example, short accessory conduction and long A-V nodal
conduction, the delta wave and QRS duration prolong. One can alter the phase relationships of conduction in the accessory and normal A-V pathways
in a number of ways including administration of
drugs, vagal stimulation, rapid atrial pacing, and
introduction of premature beats.
Figure 3 is an example, as mentioned previously, where we know that pre-excitation has occurred in the first two beats since we electrically
pre-excited the right ventricular base; yet even with
a His bundle electrogram we cannot diagnose this as
an example of WPW. The third beat is a premature
atrial beat as denoted by the interval between the
third and second RA electrograms having a shorter
cycle length than that between the first two RA electrograms . Premature atrial beats are normally conducted with an increased conduction time through
the A-V node. If the conduction time over the accessory pathway does not increase, or increases less than
that through the A-V nodal conduction system, we
can anticipate a greater degree of ventricular fusion .
The third beat in figure 3 shows marked fusion in the
ECG. The fact that an accessory bundle should be
strongly suspected is also shown by the BH and LPJ
electrograms. Both the His bundle (R) and Purkinje
(P) depolarization complexes occur following the
inscription of ventricular· depolarization in the lead
II ECG. This fact is emphasized by the dotted line
which indicates when the bundle of His was excited
during the third QRS fusion complex. Also, the H-V
interval in the BH electrogram is too short for normal
conduction to have occurred over the ventricular
specialized conduction system. An abbreviation of
the H-V interval and prolongation of the QRS following a premature atrial beat or rapid atrial pacing
suggests that pre-excitation is present.
His bundle electrocardiography and atrial pacing have also demonstrated that the effective refrac-
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tory period of the accessory A-V pathway often is
longer than for the normal A-V pathway, that is, premature conduction over the accessory pathway fails
before conduction fails through the normal A-V node.
Therefore, an even earlier premature atrial beat
than in figure 3 may result in complete normalization of the QRS complex if conduction over the accessory pathway fails, since, in this case the ventricles
are normally activated only through the normal A-V
conduction system and ventricular fusion is absent.
It is indeed fortunate that the accessory pathway
usually has a longer effective refractory period than
the normal A-V transmission systeli1. If this were
not the case, then atrial fibrillation in the presence
of an accessory A-V bypass tract would be expected to cause ventricular fibrillation in many patients with pre-excitation due to rapid activation of
the ventricles over the accessory A-V tract. The fact
that atrial fibrillation in a patient with pre-excitation may cause ventricular fibrillation has been documented in both mari and the dog. Therefore, it is
important in patients with recurrent supraventricular tachycardias in which an atrial pacemaker is
being considered as a treatment to terminate the
dysrhythmia, that atrial pacing studies be undertaken to rule out the possibility of the presence of
an accessory A-V bypass tract.
Summary. In this brief presentation, I have
attempted to point out some of the new electrophysiological techniques used in studying the preexcitation syndrome as well as some of the interesting findings which these techniques have provided.
For more detailed particulars on the newer findings
on the WPW syndrome, the reviews of Durrer et al.
and Wallace et al. can be recommended (2, 4).
The technique for mapping the sequence of
ventricular epicardial activation has provided a
mechanism of defining the anatomical site of preexcitation. Surgical interruption of the atrium and
ventricle at the region where pre-excitation was
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found has permitted normalization of the ECG of
patients having the WPW syndrome. The incapacitating episodes of tachycardia associated with WPW
have likewise been eliminated by sectioning of an accessory A-V bypass tract. This technique, however,
must still be considered experimental and should be
suggested only in WPW patients in whom other
methods of controlling the tachyarrhythmias are unsuccessful. Prior to surgery it should be considered
essential that other studies such as His bundle
electrograms be recorded and suitable electrical
pacing studies undertaken to assure the likelihood
that the patient is a suitable candidate for surgery.
The indications for His bundle electrocardiography
in patients with supraventricular tachycardias in
which an implanted cardiac atriai pacemaker is
being considered should also be emphasized, that
is, if pre-excitation were present and the atria were
rapidly paced, then ventricular fibrillation might
develop due to rapid conduction over an accessory
A-V pathway.
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Workshop
Presiding: WILLIAM A DICKINSON, JR., M.D.
Co-Director of Coronary Care Unit and Electrocardiography, General
Hospital of Virginia Beach, Virginia Beach, Virginia

CASE I

Dr. Dickinson: How would you manage this patient?
Dr. Dreifus: I do not believe that there is much
to discuss in the first lead of ventricular fibrillation,
and I would probably defibrillate the heart. The
second one; however, reveals anteroseptal infarction.
The exact age is not clear, but it is probably recent.
The P-R interval appears to be normal; however,
there is left axis deviation with right bundle branch
block. Thus, I believe that this is sinus rhythm with
bifascicular block and an anteroseptal wall infarction.
Dr. Baird: What are the criteria for the insertion
of temporary pacemakers during an acute myocardial infarction?
Dr. Dreifus: The prognosis in patients with acute
infarction complicated by bifascicular or trifascicular
block is poor. The mortality may approach 60 or
70%, whether or not we utilize pacemakers. There
is considerable work to show that patients who
have two fascicles blocked with an acute process
may eventually involve the third fascicle, and high
grade block develops rapidly. I do not know whether
I would put one in this patient unless there is
associated first degree block. This can be either
intranodal or block in the third fascicle. If it behaved like a basic Wenckebach, I would assume
that it was in the A-V junction, but if the QRS suaderily dropped out, I would believe that the block
is in the distal portion of the third fascicle or
the posterior division. I would certainly put in the
temporary pacemaker under these circumstances.
However, I do not think I would recommend insertion of pacemakers in patients with mono- or
bifascicular block alone in the electrocardiogram,
even though two fascicles are blocked.
Dr. Dickinson: Are there any other comments regarding this?
104

Dr. Surawicz: I would .like to make a comment.
This kind of discussion always breaks down somewhat because we have two groups of people who
manage such a problem, the university or teaching
hospital with a house staff and the private hospital
without house staff, which is quite different. The pf)ysician in a small private hospital knows that he l)as
an hour's time and that later he will be busy. Aware
of this, he will place in a pacemaker earlier, even
though it may not be necessary. That is the situation
frequently found in a small private hospital. To
open the discussion in this case, I would not recommend temporary pacemaker insertion in a patient
with a normal P-R interval, right bundle branch
block, and left anterior hemi-block.
Dr. Bigger: At our hospital , Macken and Stock reviewed a series of cases of acute myocardial infarction with anteroseptal infarction and right
bundle branch block. Nearly half of these cases
developed sudden complete heart block or high
degree A-V block without warning or Wenckebach
periods.
Dr. Scherlag: I can report on studies that were
done in a large series by Dr. Narula and recently
published in the American Journal of Medicine.
The patients with right bundle and left axis deviation, or what people term left anterior hemi-block,
showed a 70% incidence of damage in all the
"fascicles" of bundle branches, that is, the H-V
times were prolonged, indicating bilateral bundle
branch block. Twenty-eight to 30 % showed that
this was truly bifascicular, that is, the posterior
"fascicle" was probably intact, and the H-V time
was normal. The statistics are identical for both the
infarcted as well as the noninfarcted.
Dr. Baird: I think it is interesting to note that the
acute development of right bundle branch block
during acute myocardial infarction has a mortality
MCV QUARTERLY 9(1): 104- 109, 1973
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CASE I:
This 56-year-old white male painter was in excellent health prior to the development of substernal pain, diaphoresis two days prior
to admission. During the ER evaluation, the patient had ventricular fibrillation and asystole. After defibrillation, a complete electrocardiogram demonstrated the following.
What would you recommend?

of close to 50%; therefore, I am sure Dr. Bigger
and I, although we would insert a pacemaker
catheter in this situation, realize the prognosis is
extremely poor. It is possible that in the future,
studies such as selective coronary arteriography
With the consideration of emergency aorto-coronary surgery would be a more appropriate approach
~han the sole management of heart block with the
lllsertion of a standby catheter.

Dr. Scherlag: I would like to make another comment.

I agree that in patients with acute infarction and
bundle branch block, pacemaker therapy does not
appear to aid in terms of survival. However, we
have been involved in studies with Dr. Clyde
Schoenfeld in the intensive care unit utilizing His
bundle recordings. Acute inferior myocardial infarction with Wenckebach phenomena is a situation in which most people do not recommend pace-
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maker catheter insertion, but five of our patients
showing Wenckebach cycles have developed higher
degrees of block. In a given patient I think that Dr.
Bigger was quite correct since these patients may
show a period of nonconduction, and the pacemaker
is the difference between life and death.
Dr. Bigger: In these people with complications
such as hypotension, congestive failure, pulmonary
edema, or emboli, a period of asystole may be
catastrophic. I think that an individu al who has
borderline compensation of pump failure because
one-third of his ventricle is necrotic or nonfunctioning would not survive a minute or two of asystole.
Dr. Dickinson: The audience might be interested
in your recommendations concerning types of
catheters and the use of portable fluoroscopy, Dr.
Bigger.
Dr. Bigger: We often utilize No. 5 Cordis® transvenous bipolar pacemaker catheters or the semi-floating USCI® catheter. We prefer bipolar pacemaker
catheters and insert them using portable fluoroscopy
in our intensive care unit. Up until two and onehalf years ago we utilized a large number of the
Davis and Geck floatable platinum probes with a
teflon coating made popular by Drs. Kimball and
Killip of New York Hospital. We used several hundred of these catheters for various reasons and found
them to be satisfactory. At present we use bipolar
catheters that have good characteristics for torque
manipulation.
Dr. Dickinson: Do you use the brachia! or femoral
vein?
Dr. Bigger: We have used the external jugular,
subclavian, brachia!, and more recently, the femoral
vein. Probably the most convenient place to insert
the catheter, as far as the patient is concerned, is
in the external jugular system because both the
patient's arms and legs are left free. A cut down on
the jugular vein may be difficult for inexperienced
personnel because it is friable.
Dr. Dreifus: Dr. Dickinson, may I make one more
remark before you leave the pacemaker discussion?
We have been using the Swan-Ganz floating balloon
catheter and have found it successful in these situations. I think it is an alternative for fluoroscopy,
particularly if you want to insert one rapidly. It
may be placed through a needle percutaneously. If
you need to put in one on a more permanent basis,
for example, a week to ten days, you may transfer
the patient to a fluoroscopy room and replace it
with a stiff catheter. I would recommend that those

of you who cover coronary care units develop some
facility in using the Swan-Ganz catheters.
Dr. Baird: Dr. Hoffman, what is the mechanism of
ventricular fibrillation observed after temporary occlusion of the coronary artery in the experimental
animal?
Dr. Hoffman: I think that I have some idea what
the mechanism would be in an experimental
animal, and it is very straightforward. If you occlude
a branch of the coronary artery and the ventricle
does not fibrillate during ischemia-let us say you
are fairly far down the anterior descending artery
-you leave the artery occluded long enough for
cells normally nourished by the vessel to become
ischemic and lose a good deal of potassium . Then
when you release the occlusion you suddenly reperfuse this bed and move a fairly large amount
of potassium out of the ischemic area to the adjacent areas of the myocardium. I think for the most
part the so-called "release fibrillation" results from
the flushing out from the ischemic area of potassium, lactic acid, and everything else that comes
out suddently from ischemic cells.
Dr. Scherlag: I certainly agree with Dr. Hoffman
and would like to ask whether the arrhythmia is
on the basis of automaticity or a reentry phenomena.
We have performed studies utilizing the Sidney
Harris preparation with anterior descending artery
tie-offs and reperfusion after several hours. The
resultant arrhythmias appear to be due to enhanced automaticity.
Dr. Bigger: I wonder if you would be more specific
about the term automaticity in this situation. Do
you mean that the arrhythmias do not stop when you
stimulate the vagu~? Even a reentrant arrhythmia
might continue when you stop the atrium.
Dr. Scherlag: I think is is a good point, and it is
difficult to differentiate between reentry and automaticity.
CASE II

Dr. Dickinson: Dr. Surawicz, we would like your
interpretation of this . and any remarks regarding
etiology and treatment.
Dr. Surawicz: I presume that this patient has severe hyperkalemia with the serum potassium above
8 meg/ L because of the absence of P waves. The
presence of chest pain and syncope raises the possibility of fibrillation and a diaphragmic myocardial
infarction with peri-infarction block. I would probably get some clue from the electrocardiogram
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CASE II :
This 67-year-old white male with arteriosclerotic heart disease, angina pectoris, and mild chronic renal disease developed chest pain
and syncope associated with the following electrocardiogram.
How would you manage this patient?

preceding this episode, but if this diagnosis of hyperkalemia is correct, then I would treat it with
glucose, insulin, and bicarbonate.
Dr. Dickinson: The potassium level was 9 meg/ L.
Would you like to be more specific as to how you
would use the dextrose and insulin?
Dr. Surawicz: In a case like this, we can give 50%
glucose and 1 unit of insulin per 2 g of glucose
during a period of electrocardiographic monitoring.
I would then give 1-2 ampoules of bicarbonate
and see what is happening.
Dr. Hoffman: I agree with Dr. Surawicz. In most
mammalian hearts, including the human heart, the
atria seem to be more sensitive to hyperkalemia than
the ventricles. I do not know why the atria are
more sensitive to the potassium than the ventricles
and the ventricular conduction system . Perhaps Dr.
Surawicz can tell us .

Dr. Surawicz: No, but the question is, why does
the rhythm remain regular? Is it an escape pacemaker or is it from the sinus node?
Dr. Hoffman: If I had not read a recent paper by
Dr. Fred Pick, I might have said what you wanted.
I think that in many instances, if you have a ventricular rhythm of this sort in a patient with hyperkalemia, it may be a sinus rhythm where there
is sinoventricular conduction and sinoatrial block.
Dr. Pick is a very careful investigator, and he has
not been able to reproduce some of our studies.
Thus, I have been hedging on it for awhile. To
come back to the question of other electrolytes,
I imagine that one might wonder about changes in
the level of calcium. As the serum calcium is
elevated, the only thing this will do to the heart is
to antagonize the effects of high potassium. For
any given level of potassium, if the serum calcium
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is high, the heart is less sensitive to the depolarizing
depressant effects of potassium. If the serum calcium is low, the heart will be more sensitive to
the same level of serum potassium. Thus, there is
an antagonism, but one can demonstrate this experimentally very easily. However, it does not assume much importance in the usual patient.
Dr. Bigger: Why is the patient hyperkalemic?
Dr. Baird: It was not clear to the clinician why
this patient who had had chronic renal disease
suddenly developed such a problem. It is interesting
to note that a temporary pacemaker catheter was
inserted as the initial therapy since hyperkalemia
was not recognized until later.
Dr. Hoffman: I wonder if I could ask a question
reiterating a comment from the audience concerning the general question of the effect of serum
potassium level on the uptake of the digitalis by
the heart. If the serum potassium is elevated, there
is evidence that the uptake of digitalis by the heart
is retarded, and therefore, digitalization might be
less rapid and less complete. I wonder if Dr. Bigger
or someone else could help my vague memory concerning variation among the digitalis compounds.
Dr. Bigger: The first part, I think, has been shown
in experimental animals; if the hyperkalemia precedes the administration of digitalis, then its uptake
in the myocardium is retarded. Also, I think that
it is correct that there is a difference between compounds; however, I am not certain of this.
Dr. Dreifus: If you add magnesium , you can go
even farther with digitalis, but this is very impractical from the clinical standpoint.
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Dr. Hoffman: It must be remembered that hyperkalemia can result in asystole. If you attempt to
overcome the effects of hyperkalemia with calcium,
it must be done very carefully since you may develop
a completely asystolic heart without atrial activity
as well as no ventricular activity. I merely want to
express some caution in general; although when
interpreting physiologic principles one can reverse
some of the effects of high potassium by giving
calcium, it is not a completely innocuous procedure.
CASE Ill

Dr. Dickinson: Dr. Bigger, what is your interpretation of this electrocardiogram?
Dr. Bigger: From left to right, four complexes of
normal sinus rhythms are seen. The problem arises
with the fifth beat, a tall wide ORS complex with
the T wave in the opposite direction. It is premature
with a shorter cycle length than that in normal
sinus rhythm. Atrial activation is not apparent
within the ORS and T complexes of that first wide
beat. Atrial activation reappears at the extreme right
of the slide. The reason for the depression of sinus
node is not clear.
Dr. Dickinson: Would you treat this, and if so, how?
Dr. Bigger: I would first place an atrial lead to
determine if atrial activation is hidden in those wide
beats. I would not treat until the rhythm was diagnosed and the history, physical, and laboratory examination were satisfactorily completed.
Dr. Moe: In this situation I would like to observe a
simultaneous record of the arterial pressure because
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CASE Ill:
This 60-year-old alcoholic was admitted to the Rehabilitation Center and the routine electrocardiogram demonstrated left axis
deviation with right bundle branch block. There had been several episodes of questionable syncope probably related to his alcoholism.
Is provocative atrial pacing of any value in predicting which patients may be subject to Adams-Stokes seizures?
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it is conceivable that this arrhythmia could be
vagally induced. The last P-R interval in which
the P waves are clearly visible is distinctly longer
than the preceding one.
Dr. Dickinson: Dr. Dreifus, could this be ventricular tachycardia with exit block?
Dr. Dreifus: This is a possible explanation, but in
my experience it is extemely rare. Inhibition of
sinus rhythmicity and vagal influence are probably
major factors in this situation. Acceleration of the
sinus rate by the administration of atropine, or by
raising the foot of the bed, may be an effective
approach. I have observed their disappearance by
the administration of lidocaine as well. In general,
they are benign arrhythmias, and it is rare for them
to develop repetitive ventricular tachycardia.
Dr. Hoffman: The fact that lidocaine was administered and that they disappeared does not mean
anything. I believe that this type of arrhythmia
might be observed off and on again for a few
minl!tes or a half-hour, and then it is questionable
whether lidocaine was effective as a therapeutic
agent.
Questioner: In one of our patients we have observed
that slow ventricular tachycardia was terminated by
premature ventricular contraction. I would like to
know whether you consider this evidence of a reentry
mechanism.
Dr. Moe: This is a very broad question, and therefore, it will receive a very broad answer. Yes, it is
possible, but one would have to have more definitive evidence than that to be able to make a
diagnosis. I am sorry if I disappoint you, but that
is how I feel.
Dr. Hoffman: Dr. Dickinson, I wonder if I might
try to confuse the picture a little more. The temptation which I think confronts everybody is to assume that rate and the duration of the QRS complex
provide an indication as to the site of the impulse
initiation. If you have a normal QRS, it is stated to be
above the bifurcation or in the common bundle. If
you have a broad, bizarre QRS complex, then you assume that it arises distal to the bifurcation, and the
ideal rate would be 40, let us say. I believe this is a
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very imprecise set of guidelines because it is quite
possible to have an impulse arise in the common
bundle, to be conducted aberrantly, that is, to be
delayed in one or another of the other fascicles of the
conducting systems and to give you a wide QRS complex even though it is originating proximal to the
bifurcation. The point is that aberration is usually
associated with rapid rate. Yet, when the automaticity of the conducting system is increased, when
the diastolic depolarization is fairly marked with
long diastolic intervals, the depolarization of the
conducting system proceeds farther. Then, even the
impulse that originates in the common bundle will
be conducted with aberration. In general, it is probably not permissable to use the association of a
particular rate or the appearance of the QRS complex to decide that you have ventricular tachycardia
or a junctional rhythm . I believe that you can have
junctional rhythm with an abnormal QRS, and since
the rate is 62, it cannot be stated that it represents
accelerated activity in the distal portion of the
ventricle. I do not know whether Drs. Bigger,
Surawicz, or Dreifus would disagree with me, but I
hope that one of them might try.
Dr. Moe: I doubt that all of the various antiarrhythmics act by suppressing automatic activity.
All of these examples were from Purkinje fibers, and
I think mainly in dogs. One might have the right
to ask why, if these drugs all suppressed automatic
activity and therefore ectopic automatic activity,
do they not suppress all activity totally and thus
cause cardiac arrest.
Dr. Hoffman: I cannot answer this in terms of
"why." I think that Dr. Moe made a good point and
that there are differences in the sensitivity of
pacemakers in the various parts of the heart. When
you are considering the sinus node, this is a special
case, and it is quite insensitive to the slowing effect
of any of these agents. In order to appreciably
slow a healthy sinus node, you have to use very
high concentrations. I do not have the vaguest idea
why the sinus node is resistant to this effect of
antiarrhythmic drugs, but I am glad that it is resistant.
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Though Talwin® Tablets, brand of
pentazocine (as hydrochloride), can
be compared to codeine in analgesic
efficacy, Talwin is not subject to
narcotic controls. Patients receiving
Talwin Tablets for prolonged periods face
fewer of the consequences you've
come to expect with meperidine or
codeine. And that, in the long run,
can mean a better outlook for your
chronic-pain patient.
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Talwin Tablets are:
•Comparable to codeine in analgesic efficacy:
one 50 mg. Talwin Tablet appears equivalent in analgesic
effect to 60 mg. (1 gr.) of codeine. Onset of significant analgesia usually occurs within 15 to 30 minutes. Analgesia
is usually maintained for 3 hours or longer.
•Tolerance not a problem: tolerance to the analgesic
effect of Talwin Tablets has not been reported, and no
significant changes in clinical laboratory parameters
attributable to the drug have been reported.
• Dependence rarely a problem: during three years of
wide clinical use, only a few cases of dependence have
been reported. In prescribing Talwin for chronic use, the
physician should take precautions to avoid increases in
dose by the patient and to prevent the use of the drug in
anticipation of pain rather than for the relief of pain.
•Not subject to narcotic controls: convenient to
prescribe - day or night- even by phone.
•Generally well tolerated by most patients: infrequently cause decrease in blood pressure or tachycardia;
,rarely cause respiratory depression or urina·r y retention;
seldom cause diarrhea or constipation. If dizziness, lightheadedness, nausea or vomiting are encountered, these
effects tend to be self-limiting and to decrease after the
first few doses. (See last page of this advertisement for
a complete discussion of adverse reactfons and a brief
discussion of other Prescribing Information.)
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Contraindications: Talwin, brand of pentazocine (as hydrochloride),
should not be administered to patients who are hypersensitive to it.
Warnings: Head Injury and Increased Intracranial Pressure. The
respiratory depressant effects of Talwin and its potential for elevating cerebrospinal fluid pressure may be markedly exaggerated in
the presence of head injury, other intracr anial lesions, or a preexisting increase in intracranial pressure. Furthermore, Talwin can
produce effects which may obscure the clinical course of patients
with head injuries. In s uch patients, Talwin must be used with extreme caution and only if· its use is deemed essential.
Usage in Pregnancy. Safe use of Talwin during pregnancy (other
than labor) has not been established. Animal r eproduction s tudies
have not demonstrated teratogenic or embryotoxic effects. However, Talwin should be administered to pregnant patients (other
than labor) only when , in the judgment of the physician, the potential benefits outweig h the possible hazards . Patients r eceiving
Ta lwin during labor have experienced no adverse effects other than
those that occur with commonly used analgesics . Talwin should be
u sed with caution in women delivering premature infants.
Drug Dependence. There have been in stances of psychological and
physical dependence on parenteral Talwin in patients with a history
of drug abuse and, rarely, in patients withou t such a history. Abrupt
discontinuance following the extended use of parenteral Talwin has
resulted in withdrawal symptoms. There have been a few reports of
dependence and of withdrawal symptoms with orally adm inistered
Talwin. Patients with a history of drug dependence should be under
close supervision while r eceiving Talwin orally.
In prescribing Talwin for chronic use, t he physician should take precautions to avoid increases in dose by the patient and to prevent t he
use of the drug in a nticipa tion of pain rather than for the relief of
pain.
Acute CNS Manifestations. Patients receiving therapeutic doses of
Talwin have experienced, in rare instances, hallucinations (usually
visual ), disorientation, and confusion which have cleared spontaneously within a period of hours. The mechanism of this reaction is
not known, Such patients should be very closely observed and vita l
signs checked. If the drug is reins tituted it should be done with caution since the acute CNS manifestations may recur.
Usage in Children. Because clinical experience in children under 12
years of age is limited, administration of Talwin in this age group is
not recommended.
Ambillatory Patients. S ince sedation, dizziness, and occasional euphoria have been noted, ambulatory patients should be warned not
to operate machinery, drive cars, or unnecessarily expose themselves to hazards.
Precautions: Certain Respiratory Conditions. Althoug·h respiratory
depression has rarely been r eported after oral adminis tration of
Talwin, the drug should be a dministered with caution to patients
with respiratory depression from any cause, severe bronchial asthma and other obstructive r espiratory conditions, or cyanosis.
Impaired Renal or He patic Function. Decreased metabolism of the
drug by the liver in extensive liver disease may predispose to accentuation of side effects. Although laboratory t ests have not indicated that Talwin causes or increases renal or hepatic impairment,
the drug should be administered with caution to patients with such
impairment.
Myocardial Infarction. As with a ll dr ugs, Talwin should be used
with caution in patients with myocardial infarction who have nausea or vomiting.
Biliary Surgery. Until further experience is gained with the effects

of Talwin on the sphincter of Oddi, t he drug should be used with
caution in patients about to undergo surger y of the biliary tract.
Patients Receiving Narcotics. Talwin is a mild narcotic antagonist.
Some patients previously receiving narcotics have experienced mild
withdrawal symptoms after receiving Talwin .
CNS Effect. Caution should be used when Talwin is administered
to patients prone to seizures; seizures have occurred in a few such
patients in association with the use of Talwin a lthough no cause and
effect relationship has been establish ed.
Adverse R eactions: Reactions reported after oral administration
of Talwin include gastrointestinal: nausea, vomiting; infrequently
constipation; and rarely abdominal distress, anorexia, diarrhea.
CNS effects: dizziness, lightheadedness, sedation, euphoria, headache; infrequently weakness, disturbed dreams, insomnia, syncope,
visual blurring and foc using difficulty, hallucinations (see Acute
CNS Manifestations under WARNINGS); and r a rely tremor, irritabili ty, excitement, t innitus. Autonomic: sweating ; infrequently
flu shing; and rarely chills. Allergic: infrequently rash; and rarely
urticaria, edema of the face. Cardiovascular: infrequently decrease
in blood pressure, tachycardia. Other: rarely respiratory depression,
urinary retention.
Dosage a nd Administration: Adults. The usual initial adult close is
1 tablet (50 mg.) every three or four hours. This may be increased
to 2 tablets (100 mg.) when needed. Total daily dosage should not
exceed 600 mg.
When a ntiinfl ammatory or antipyretic effects a re desired in addition to analgesia, aspirin can be administered concomitantly with
Talwin.
Children Under 12 Years of Age. Since clinical experience in children under 12 years of age is limited, administration of Talwin in
this age group is not recommended.
Duration of Thernpy. Patients with chronic pain who have received
Talwin orally for prolonged periods have not experienced wit hdrawal symptoms even when administration was abruptly discontinued (see WARNINGS) . No tqlerance to the a n a lgesic effect has
been observed. Laboratory tests of blood and urine and of liver a nd
kidney function have revealed no significant abnormalities after
prolonged administration of Talwin.
Overdosage: Manifestations . Clinical experience with Talwin overdosage has been insufficient to define the signs of this condition.
Treatment. Oxygen, intravenous fluids, vasopressors, and other
supportive measures should be employed as indicated. Assisted or
controlled ventilation s hould also be considered. Although nalorphine and levallorphan are not effective antido tes for respiratory
depression due to overdosage or unusual sensitivity to Talwin, parenteral naloxone (Narcan®, available through E ndo Laboratories) is
a specific a nd effective a ntagonist. If naloxone is not availa ble, parenteral administration of t he a n a leptic, methylphenidate (Ritalin®),
may be of value if r espiratory depression occurs.
Talwin is not s ubject to narcotic controls.
How Supplied: Tablets, peach color, scored. Each tablet con ta ins
Talwin (brand of pentazocine) as hydrochloride equivalent to 50 mg.
base. Bottles of 100.
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Before prescribing, please consult
complete product information, a sum·
mary of which follows:
Indications: Tension and anxiety

states; somatic complaints which are
concomitants of emotional factors; psychoneurotic states manifested by tension,
anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic
re lief of acute agitation, tremor, delirium
tremen s and hallucinosis due to acute
alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to
local pathology, spasticity caused by
upper motor neuron disorders, athetosis,
stiff-man syndrome, convulsive disorders
(not for sole therapy) .
Contraindicated: Known hypersensitivity to the drug. Children under 6
months of age. Acute narrow angle glaucoma; may be used in patients with open
angle glaucoma who are receiving appropriate therapy.
Warnings: Not of value in psychotic
patients . Caution against hazardous
occupations requiring complete mental
alertness . When used adjunctively in convulsive disorders, possibility of increase
in frequency and/ or severity of grand mal
seizures may require increased dosage of
standard anticonvulsant medication;
abrupt withdrawa l may be asso'ciated
with temporary increase in frequency
and/ or severity of seizures. Advise
against simultaneous ingestion of alcohol
and other CNS depressants. Withdrawal
symptoms (similar to those with barbitu·
rates and alcohol) have occurred fol lowing abrupt discontinuance (convulsions,
tremor, abdominal and muscle cramps,
vomiting and sweating). Keep addictionprone indiv iduals under carefu l survei llance because of their predisposition to
habituation and dependence. In pregnancy, lactation or women of childbearing
age, we igh potential benefit against
poss ible hazard .
Precautions: If combined with other
psychot rop ics or anticonvu lsants, consider careful ly pharmacology of agents
emp loyed; drugs such as phenothiazines,
narcotics, barbiturates, MAO inhibitors
and other an tidepressants may potentiate
its acti on. Usua l precautions indicated in
patients severe ly depressed, or with latent
depress ion, or with suicidal tendencies.
Observe usua l precautions in impaired
rena l or hepatic function. Limit dosage to
sma llest effective amount in elderly and
debil itated to preclude ataxia or oversedation.
Side Effects: Drowsiness, confusion,
dip lopia, hypotension, changes in libido,
nausea, fatigue, depression, dysarthria,
jau ndice, skin rash, ataxia, constipation,
headache, incontinence, changes in sa livation, slurred speech, tremor, vertigo,
urinary retention, blurred vision . Paradoxical reactions such as acute hyperexci ted states, anxiety, hallucinations,
increased muscle spasticity, insomnia,
rage, sleep disturbances, stimulation
have been reported; shou ld these occur,
discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts
and liver function tests advisable during
long-term therapy.
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If there's
good reason to
prescribe for
psychic tension ...

When, for example,
reassurance and counseling
on repeated visits
are not enough

Effectiveness is
a good reason to
consider Valium
(diazepam)
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10-mg tablets

